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ABSTRACT
The human Duffy “negative” phenotype is a result of the common polymorphism of
the DARC (Duffy antigen receptor for chemokines) gene abolishing its transcription in
erythroid haematopoietic lineage only, designated FYB(ES). This polymorphism is
highly prevalent in individuals of African ancestry and is associated with “benign
ethnic” neutropenia. I investigated the impact of DARC expression in the bone marrow
(BM) on haematopoiesis using DARC-deficient (DD) mice and newly developed
humanised transgenic DARC models expressing the FYB(ES) and FYB human genes.
Firstly, I developed murine irradiation chimeras with differential DARC expression on
either the endothelium or erythroid cells or both, and showed that the absence of
erythroid DARC but continued DARC endothelial expression was associated with
reduced peripheral blood neutrophil counts. To study underlying mechanisms, I
developed two transgenic (TG) murine strains expressing DARC as encoded by
FYB(ES) or FYB. FYB(ES)TG mice showed reduced peripheral neutrophil counts and
expansion of myelopoiesis in the BM, and reduced lymphopoiesis and erythropoiesis,
compared to FYBTG mice. FYB(ES)TG and also DD mice had reduced granulocyte-
macrophage progenitor (GMP) cells and lineage negative, cKit+, Sca1+ (LSK) cells,
and proliferation and apoptosis of these cells were reduced. Microarray analysis of
differentially expressed genes showed increased myeloid gene expression in GMP and
LSK cells. Mixed irradiation chimeras showed that DDBM (DARC deficient BM)
retained these changes, suggesting an intrinsic cell effect. In wild-type BM DARC is
expressed in erythroid cells only but not in other BM cells, including progenitors and
LSK cells. Analysis of BM and serum showed a significant increase in G-CSF and
eotaxin. Immunofluorescent analysis of myeloid cells in frozen femur sections
revealed increased myeloid cell clustering in DD and FYB(ES)TG mice. These data
suggest that neutrophils are preferentially retained in the DDBM, possibly as a result
of loss of optimal chemokine gradients created by erythroblast DARC which may
favour neutrophil egress and thereby leading to peripheral neutropenia.
The impact of carrying FYB(ES) polymorphism on the overall survival following AML
treatment was also studied in a large UK cohort but revealed no statistically significant
effect. However, individuals of African ancestry had improved survival as compared to
Caucasians.
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1Introduction
1.1 The role of the immune system
1.1.1 Introduction
The immune system has developed in order to protect the individual organism from
external pathogens. Primary mechanisms of defence include both chemical and
physical barriers. Once breached, both specialised cells and effector molecules are
activated in order to limit tissue damage, eliminate infecting pathogens and
subsequently achieve tissue repair.
The immune system is divided in two main components, the innate and the adaptive
arms. Innate immunity is a non- or broadly-specific response to counter a wide range
of pathogens, characterised by a typically immediate response, with the purpose of
limiting peripheral tissue infiltration by a broad range of organisms. The skin and the
epithelia of the gut and pulmonary systems provide an initial barrier to pathogen
entry. Once this is breached, cells of the innate immune response limit further tissue
infiltration. The key cellular players of the innate immune system are granulocytes
(neutrophils, eosinophils, and basophils), monocytes and macrophages, these share in
common the ability to phagocytose pathogens, and mast cells.
2Conversely, adaptive immunity is exquisitely specific for individual pathogens, and
can provide immune ‘memory’ leading to a quicker and stronger response on re-
exposure.
Antigen presenting cells (APC) such as dendritic cells (DCs) link innate and adaptive
immunity while lymphocytes are central to the effector responses of the adaptive
immune system (Janeway, 2001). The majority of the leukocyte subsets orchestrating
the immune response are derived from bone marrow precursors whose origin is the
haematopoietic stem cell. However, some specific tissue macrophages develop in the
yolk sac independently of the haematopoietic stem cell (Schulz et al., 2012).
1.1.2 The innate immune system
Innate immune cells respond to infiltrating microorganisms through the recognition of
highly conserved molecular structures known as Pathogen Associated Molecular
Patterns (PAMPs), facilitated by Pattern Recognition Receptors (PRR) such as Toll-like
receptors (TLR) and NOD-like receptors (NLR) (Janeway and Medzhitov, 2002).
Interaction between TLR and PAMP induces NFκB signalling and subsequent secretion
of pro-inflammatory and co-stimulatory molecules. PRR such as retinoic acid inducible
protein 1 and melanoma differentiation associated protein-5 are involved in responses
against viruses whereas other bacterial molecules are recognised by the NLR family.
Secreted PRR such as mannose-binding lectin, bind via sugar groups, phospholipids,
nucleic acids and various proteins to a broad range of micro-organisms, including
bacteria, protozoa and fungi. Opsonins, which may be antibodies or proteins involved
in the complement cascade, coat the surface of the pathogens to enhance
3internalisation. Subsequent triggering of the complement cascade results in the
recruitment of phagocytes to sites of infection, and direct killing of micro-organisms.
‘Danger signals’ provided by endogenous molecules which are associated with tissue
damage or stress, such as high mobility group box 1, heat shock proteins and
hyaluronic acid, can also help induce an immune response (Tsan, 2011).
An acute inflammatory response is characterised by the infiltration of leukocytes in
which neutrophils dominate. Neutrophils are the most abundant leukocyte in human
blood and in common with other cells of the innate immune system play a major role
in the primary defence against invading pathogens by utilising several mechanisms:
(i) phagocytosis and killing of microorganisms, (ii) the release from cytoplasmic
granules of pre-formed soluble anti-microbial products such as defensins,
myeloperoxidase, elastase, proteinase-3 and cathepsin G and properdin, and (iii)
release of neutrophil extracellular traps (NETs), structures that comprise of de-
condensed chromatin and antimicrobial proteins which prevent spreading of
microorganisms extracellularly (Brinkmann et al., 2004).
Present in less abundance than neutrophils, eosinophils and basophils also contain
granules incorporating enzymes and toxic proteins which are released on activation.
These two cell groups are thought to be primarily important in the defence against
parasites too large to be ingested by neutrophils or macrophages, and participate in
allergic inflammatory responses. Effector function by eosinophils is firstly by the
release of toxic cytoplasmic granule proteins and free oxygen radicals, and secondly
by the production of prostaglandins, leukotrienes and cytokines which activate
epithelial cells and recruit other leukocytes, amplifying the immune response. By the
4release of major basic protein, eosinophils induce the degranulation of mast cells and
basophils. Basophils contain IgE bound on the cell surface, and upon activation by
antigen binding to IgE or by cytokines, histamine is released from basophilic granules,
leading to immediate allergic reactions.
Following the arrival of neutrophils, monocytes migrate into the tissue from the blood
across the vascular endothelium. Some monocytes differentiate into tissue
macrophages. Macrophages are polarised functionally in response to cytokines to
mount specific functional actions. The two main macrophage classes are termed M1
(classically activated macrophages) if induced by IFN-γ, TNF-α and LPS; and M2
(alternatively activated) if induced by IL-4 or IL-10 (Martinez et al., 2008).
Macrophages phagocytose pathogens, and produce cytokines which activate
endothelial cells of local blood vessels leading to leukocyte transmigration into the
inflamed tissue. In addition, macrophages produce lipid mediators of inflammation
such as prostaglandins, leukotrienes and platelet-activating factor.
Mast cells differentiate in peripheral tissues and play an important role in
orchestrating allergic responses. Mast cells are located near surfaces exposed to
allergens and pathogens, including connective tissues surrounding blood vessels and
mucosal tissues. This cell type is involved in the immune response to parasitic worms,
and upon activation releases large cytoplasmic granules containing histamine,
heparin, serine esterases and proteases which lead to local vasodilation and increased
vascular permeability.
51.1.3 The adaptive immune response
The adaptive immune response is activated by production of inflammatory cytokines
during the innate immune response. Contrary to innate immunity, the adaptive
immune response is characterised by specificity and memory. After the initial
encounter with an invading pathogen, the adaptive immune response begins after 5-7
days post-infection. Subsequent exposure to the antigen requires only 24-48 hours for
an effective response to occur. The major cell subsets of the adaptive immune
response are (i) B and T lymphocytes, (ii) the natural killer (NK) cells, initially
considered to be innate immune cells but recently shown to contribute to adaptive
immune responses (Vivier et al., 2011), and (iii) the antigen presenting cells (APCs),
primarily DCs but also macrophages and B cells, are able to capture, process and
present antigens. DCs become activated once they encounter a pathogen and migrate
via the lymphatics to the lymph nodes and antigen presentation occur. If the antigen
is of viral origin, it is presented to naïve CD8+ lymphocytes within the major complex
histocompatibility complex, class I. Thereafter the CD8+ lymphocytes are activated
and differentiated to cytotoxic cells or to memory CD8+ cells (Dempsey et al., 2003,
Radtke et al., 2013)). APCs presenting an antigen in combination with MHC class II
molecules, activate CD4+ cells to secrete cytokines such interleukin 2 (IL-2) that
trigger the proliferation of other CD4+ and CD8+ T cells. T cells become activated
upon binding of specific antigen presented by APCs within the MHC to the T-cell
receptor (TCR). In addition to the interaction of the T-cell TCR and an antigen
embedded in the MHC on the APC membrane, a second co-stimulatory signal is
provided to the T-cell through the interaction of its CD28 with B7 molecules of the
6APCs (Sharpe and Freeman, 2002). Activated CD4+ cells release IL-4, leading to B cell
antigen class switching.
B and T cells are derived from common progenitor cells in foetal liver and in adult life
from the bone marrow. B cells originate and develop in the bone marrow (Hirose et
al., 2002). In contrast, T cell precursors migrate from the bone marrow to the thymus
where they mature and undergo a selection for functional TCRs and a deletion of self-
reactive clones (Kyewski and Klein, 2006). T-cells then migrate to the lymph nodes
and other secondary lymphoid organs where they undertake immune surveillance
(Masopust and Schenkel, 2013). B cells are responsible for the humoral response,
undergoing clonal expansion following the ligation of an antigen presented on a
professional APC. These then differentiate into plasma cells which subsequently
secrete large amounts of immunoglobulins specific to that antigen. T cells are
important for efficient humoral responses, as co-stimulatory factors (such as IL-2, IL-4
and IL-5) derived from antigen stimulated T-cells are essential for B-cell maturation
(Meffre et al., 2000).
Five isotypes of immunoglobulins are produced by plasma cells: the IgA, IgD, IgE, IgG
and IgM. Each isotype performs a different function; IgA is present in secretions (e.g.
mucus) and in epithelia, IgM is the first to be secreted in the primary immune
response via activation of the complement system, IgE is involved in mast cell
degranulation and allergic and anti-parasite responses, IgG is the major isotype in the
blood involved in the opsonisation of pathogens. IgD however is not well understood,
and is present mainly in the intravascular pool. B-cells perform class switching when
7activated and secrete different isoforms of the antibody specialised to the different
phases of the immune response (Rosenthal and Tan, 2011).
81.2 Haematopoiesis
1.2.1 Haematopoietic stem cells
Haematopoiesis is organised in a hierarchy of cell types that differ in their capacity for
self-renewal, proliferation and differentiation. The top of the hierarchy is represented
by haematopoietic stem cells (HSC), which generate mature cells committed along
specific lineages of the blood, bone marrow, spleen and thymus (Orkin, 2000).
Since the existence of a HSC was demonstrated by Till and McCulloch in 1961, this
cell type has undergone extensive investigation to understand how it differentiates
into mature blood cells and also retains the essential capacity to reproduce, termed
self-renewal. Through this process, one or both daughter cells retain the exact
developmental potential of the parent stem cell and ensure the maintenance of a
lifelong pool of stem cells, named symmetrical division. Conversely, asymmetric
division results in the generation of two distinct daughter cells, one with an identical
parental form, and another with more differentiated characteristics. Alterations in this
balance provide the ability to support a rapid response to haematological stress and
return to homeostasis.
Self-renewal is tightly regulated, since sustained commitment of stem cells without
replacement would lead to depletion of the stem cell pool; alternatively self-renewal is
a primary feature of leukaemia. Self-renewal is regulated and modulated at the so-
called stem cell niche by altering the decision of stem cells to enter symmetric or
9asymmetric division (Till and McCulloch, 1961, Becker et al., 1963, Siminovitch et al.,
1963) .
During physiological conditions the HSC and many progenitors are quiescent in the
G0 phase of the cell cycle (Cheshier et al., 1999). Haematological stressors such as
infection or haemorrhage induce the quiescent HSCs to enter the cell cycle and
complete asymmetrical division, thereby generating committed progenitors in
response to demand for a specific lineage. Upon restoration of normal physiological
conditions, the stem cell pool returns to its normal turnover rate, with HSCs
undergoing asymmetrical division in order to maintain blood homeostasis. Should the
number of HSC in the bone marrow stem cell pool exceed an intrinsic limit, excess
HSC enter into an apoptotic sequence (Opferman, 2007).
The complex process of haematopoiesis occurs in different sites during vertebrate
development according to the differing demands of the developing organism. Initially
haematopoiesis takes place in the primitive yolk sac, before transferring to the foetal
liver. Finally the bone marrow and spleen become the major sites of haematopoiesis in
late foetal development, with the bone marrow being the exclusive site for
haematopoiesis in humans under physiological conditions, whereas in the mouse the
spleen remains a minor compartment for erythropoiesis (Durand and Dzierzak, 2005).
Both endothelial and haematopoietic cells develop from the yolk sac, and may share a
common parental cell. Haematopoietic stem and progenitor cells (HSPC) do not
resemble endothelial cells in morphological appearance, however they have several
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transcription factors and surface markers in common, including stem cell ligand,
GATA-2, CD34, C-kit, Flt-3 ligand, Sca-1, VEGFR-1 and -2 (Zhu and Emerson, 2002).
1.2.2 Haematopoietic differentiation
HSC lose self-renewal potential during differentiation towards the multipotent
progenitor (MPP). These MPP cells lack self-renewal capacity (Adolfsson et al., 2001)
but are able to undergo multilineage differentiation, giving rise to the common
myeloid progenitors (CMP) (Akashi et al., 2000) and the common lymphoid
progenitors (CLP) (Serwold et al., 2009, Kondo et al., 1997). CLPs further
differentiate, giving rise to B and T lymphocytes and NK cells. CMPs instead
differentiate into the major components of the myeloid compartment:
megakaryocytes/platelets, erythrocytes, monocytes/macrophages basophils and mast
cells, eosinophils and neutrophils. DC can arise from both CMP (Traver et al., 2000)
and CLP (Manz et al., 2001) in response to specific stimuli, or alternatively can bypass
both these progenitor stages (del Hoyo et al., 2002). Under physiological conditions,
haematopoietic stem cells are required to give rise to approximately 1 million cells per
second (Ogawa, 1993), and rapidly undergo an increase in activity in response to
haematopoietic stress, particularly when a specific mature blood component requires
replenishment. Upon restoration of physiological conditions, stem cells will then
return to their steady states.
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1.2.3 Phenotypic characterisation of HSC and committed
progenitors
The bone marrow stem cell compartment consists of a heterogeneous population of
rare cells that can be organised into three subpopulations depending on the ability to
re-form the haematopoietic system of lethally irradiated mice. The most
undifferentiated fraction of the HSC is the long-term stem cell (LT-HSC), which has
the greatest capacity for self-renewal as evidenced by the ability to repopulate the
haematopoietic system of lethally irradiated mice for more than six months. LT-HSC
can be subsequently be re-isolated and serially transplanted into secondary irradiated
recipients (Morrison and Weissman, 1994). LT-HSC generate their immediate
progeny, the short-term stem cells (ST-HSC), which are capable of multilineage
commitment but have reduced self-renewal potential, as they are able to repopulate
irradiated mice for only 6-8 weeks and cannot be serially transplanted (Christensen
and Weissman, 2001). The third sub-population of the bone marrow stem cell
compartment consists of the multipotent progenitors (MPP) (Adolfsson et al., 2001).
This group of cells has no reconstitution potential and gives rise to the CMP and the
CLP, which are lineage-restricted.
Despite their presence at a very low level in the bone marrow, the HSC can be isolated
based on immunophenotypic characteristics. HSCs are lineage negative (Lin-) as they
do not express mature haematopoietic markers such as those of granulocytes,
monocytes and macrophages (CD11b and Gr-1), erythrocytes (Ter119), B cells
(B220), T cells (CD3, CD5) and natural killer cells (CD8a). Lin- cells are further
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characterised in the murine bone marrow by their expression of the stem cell antigen
Sca-1 (Ly6A/E) and of the tyrosine kinase receptor cKit (CD117). The HSC population
described as Lin- Sca1+ cKit+, termed ‘LSK’, entails the LT-HSC, ST-HSC and MPP.
These populations were originally discriminated based on the differential expression
of the adhesion molecule CD34 and the tyrosine kinase receptor Flt3. The staining for
Flt3 allowed for the separation of the self-renewing HSC (Flt3low) from the non-self-
renewing Flt3high MPP (Christensen and Weissman, 2001). While these initial reports
indicated that MPP have similar differentiation potentials as HSC, more recent
evidence has suggested MPP may have reduced erythrocyte and megakaryocyte
potential (Adolfsson et al., 2005). The expression of the Flt3 receptor may therefore
function to direct MPP toward lymphoid development, and is then down-regulated on
myeloid commitment. While it is clear that MPP are able to generate erythrocytes and
megakaryocytes upon transplantation (Forsberg et al., 2006), the level of functional
heterogeneity and lineage bias within the MPP is unclear (Lai and Kondo, 2006).
Further data suggest that a step-wise progression is not necessary as it appears that
HSC may skip the MPP stage (Takano et al., 2004) at times of haematopoietic stress.
Following the MPP stage in the differentiation pathway, the common myeloid
progenitors (CMP) were found to give rise in vitro to erythrocytes, platelets and
granulocytes. After the CMP stage, progenitors restricted to megakaryocyte/erythroid
lineages (MEP: Lin- Sca1- cKit+ CD34- CD16/CD32-) or granulocyte/myelomonocytic
lineages (GMP: Lin- Sca1- cKit+ CD34+ CD16/CD32+) develop. The MEP are thought
to give rise to two unipotent progenitors, either erythroid progenitors or
megakaryocytic progenitors (Akashi et al., 2000).
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In addition to the generally accepted ‘classical’ model of progenitor maturation
described above, an alternative pathway is thought to exist (see Figure 1.1). With the
reduction in MEP potential, a granulocytic/monocytic/lymphocytic progenitor (GMLP)
(Adolfsson et al., 2005) develops within the MPP sub-population of LSK. Those
expressing the highest levels of Flt3 are termed lymphoid-primed multipotent
progenitors (LMPP), with the Lin- Sca1+ cKit+ CD62L+ VCAM- Flt3Hi
immunophenotype. These LMPP may then form CLP (Lin- Sca1low cKitlow IL7RAHi
Flt3Hi). The subpopulation with granulocytic-monocytic potential, the GM-primed MPP
(GMPP) characterised by the Lin- Sca1+ cKit+ CD62L+ VCAM+ Flt3lo
immunophenotype may differentiate into GMP (Lai et al., 2005). Evidence exists for
the ability of lineage commitment switches at this stage to occur from LMPP to GMP,
potentially as a rapid mechanism for coping with haematopoietic stressors.
Furthermore T-lineage development has been described from the CMP population,
further underpinning the concept that haematopoietic development is both fluid and
dynamically able to respond to acute changes in requirements for mature cells (Chi et
al., 2011). Work in myeloid leukaemia has suggested that the LMPP sub-population
and consequently more mature GMP of LMPP derivation may account for the
abnormal progenitors detected in up to 80% of primary acute myeloid leukaemia
(Goardon et al., 2011, Mead et al., 2013).
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Figure 1.1 Diagram representing haematopoietic stem and progenitor cell differentiation in murine and human
haematopoiesis with phenotypic description. From Doulatov et al., 2012
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1.2.4 Localisation of haematopoietic stem and progenitor cells: the
haematopoietic stem cell niche
HSC are located in trabecular cavities predominantly within long and flat bones,
although the precise topological localisation remains controversial. HSC have been
identified adjacent to the endosteum immediately proximate to osteoblasts (OB), and
near the sinusoidal endothelium, suggesting the existence of two niches within the
bone marrow: the endosteal niche and the perivascular niche, respectively. (Ehninger
and Trumpp, 2011). Recent work has shown that HSCs occupy primarily the
perivascular niche and early lymphoid progenitors preferentially occupy the endosteal
niche (Ding and Morrison, 2013).
HSC are found in intimate association with stromal cells, namely OB, mesenchymal
stromal cells (MSC) and CXCL12 abundant reticular cells (CAR cells), and these cells
are critical to maintenance, self-renewal and quiescence of HSC. Depletion of OB
leads to HSC mobilisation (Mendez-Ferrer et al., 2010). Vascular cell adhesion
molecule 1 (VCAM-1) and stem cell factor (SCF) are amongst several cell surface
proteins expressed by OB, in addition to secreted factors such as thrombopoietin
(TPO), angiopoietin-1 (Ang-1), CXCL12 and osteopontin (OPN), keeping HSC
quiescent and metabolically inactive.
Most nestin+ MSC are localised near blood vessels, and fewer numbers are near the
endosteum. These cells are associated with HSC and adrenergic nerve fibres.
(Mendez-Ferrer et al., 2010). MSC express high levels of SCF, Ang-1, IL7, VCAM-1
and OPN, all HSC maintenance factors, in comparison to other stromal cells (Ehninger
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and Trumpp, 2011). Depletion of MSC leads to loss of bone marrow HSC, whereas
parathyroid hormone leads to increased numbers of MSC and directs them to
osteoblastic differentiation (Mendez-Ferrer et al., 2010). CAR cells resemble MSC in
that they are mesenchymal progenitor cells, but are more abundant. CAR cells support
B-cell progenitors, and function to retain haematopoietic progenitors in the bone
marrow via high expression of CXCL12 (Greenbaum et al., 2013). Loss of both of
these cell types interferes with HSC maintenance (Ehninger and Trumpp, 2011).
1.2.5 Key regulators of haematopoiesis
HSC are controlled by cellular extrinsic and intrinsic factors, such as secreted cyto-
and chemokines, and the interaction with bone marrow stromal cells. Signalling
pathways, transcription factors and cell cycle regulators are all necessary for HSC
maintenance.
1.2.5.1 Haematopoietic cytokines and factors
Several factors are important in maintenance of HSC, or are able to expand HSC,
including Flt3-ligand, SCF, TPO and interleukin 3 (IL-3) (Zhu and Emerson, 2002).
SCF is the ligand for cKit, the tyrosine receptor expressed on all HSC, and has been
shown to prevent HSC apoptosis. TPO primarily regulates megakaryocytic and
consequently platelet development, but this cytokine and its receptor Mpl have critical
effects on HSC. Mpl is expressed in all HSC and TPO enhances the survival of HSC, in
addition to promoting expansion of HSC (Zhang and Lodish, 2008). IL-3 promotes
proliferation and differentiation of HSC although it reduces their repopulation ability
(Nitsche et al., 2003).
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Angiopoietin interacts with its receptor Tie2 on HSC to maintain their long term re-
populating ability and in vivo enhance their quiescence and bone adhesion (Arai et
al., 2004).
1.2.5.2 Signalling pathways
Notch signalling pathways originally described in embryonic development are crucial
for the maintenance of HSC, and in cell fate decisions. Constitutive activation of notch
signalling enhances HSC self-renewal; however, deletion of notch ligands does not
affect HSC maintenance underlining the complexity in HSC biology and implying that
other ligands may have a role here (Mancini et al., 2005).
Wnt signalling pathway is a key regulator in several stem cell types, however deletion
of Wnt family members (β or γ catenin) has no effect on HSC maintenance. Inhibition
of Wnt signalling in OB leads to loss of HSC quiescence and reduced engraftment
upon transplantation (Fleming et al., 2008), suggesting an indirect role for Wnt
signalling on HSC through the osteoblastic stem cell niche.
Transforming growth factor β (TGF-β) and bone morphogenic proteins (BMP)
regulate several processes both in embryogenesis and in adult HSC. TGF-β1 inhibits
expansion of HSC in vitro and induces cell cycle arrest, although TGF-β1 receptor
deficient mice demonstrate no HSC-related deficiencies (Scandura et al., 2004). BMP4
deficient bone marrow has a micro-environment defect which leads to reduced HSC
and diminishes repopulating by wild-type HSC in a BMP4-deficient environment
(Goldman et al., 2009).
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Taken together, these multiple signalling pathways are critical regulators of HSC, and
there is likely significant redundancy among them, with potential for cross-talk in the
regulation of HSC maintenance and of the stem cell niche environment.
1.2.5.3 Transcriptional regulation of haematopoiesis
Haematopoietic development from the HSC through to mature cells is critically
dependent on regulation of gene expression. Transcription factors influence HSC and
progenitor lineage commitment depends on both the recognition of specific DNA
elements and the recruitment of co-activators or co-repressors to target gene promoter
and enhancer regions. Specific proteins mediating chromatin changes may recruit
transcription factors leading to either gene activation or silencing. Diverse
transcription factors are critical regulators of haematopoietic development and
through specific interactions establish the lineage and stage specific patterns of gene
expression, ultimately defining cellular identity (Laiosa et al., 2006). It is clear that
positive and antagonistic roles exist for major transcription factors, permitting
efficient determination of lineage choices. Examples include GATA-1 and PU.1
promoting MEP or myeloid development by opposing effects (Orkin and Zon, 2008).
For the purposes of this thesis, transcription factors regulating myelopoiesis and
subsequent granulopoiesis will be examined in further detail in that section.
Transcription factors may be divided between those required for HSC development
and homeostasis, and those directing differentiation towards a particular lineage.
However, this distinction may be arbitrary since factors affecting HSC may also be
expressed later in differentiation, and others considered to have lineage-restricted
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roles (e.g. C/EBPα), are active in HSC. Both the chronological and appropriate lineage
restricted inactivation of transcription factors may be required for the resultant
observed phenotype within individual lineages.
Haematopoietic stem cells
In the HSC compartment, several transcription factors are active in maintaining HSC
homeostasis. These include Runx1, SCL, Lmo-2, MLL, Tel, BMI-1, GFI-1 and GATA-2
(Orkin and Zon, 2008).
Multipotent progenitors
The correct scheduling of transcription factor expression is essential for normal HSPC
differentiation. Within the LSK population, there are phenotypically distinct
populations with skewed lineage potential. Transcription factors such as GATA-1 and
PU.1 direct HSC to either erythroid or myeloid differentiation (Arinobu et al., 2007).
Ikaros and PU.1 are necessary for the development of myeloid and lymphoid
progenitors, and direct further differentiation in a lymphoid direction, with disruption
of either transcription factor leading to B cell differentiation. Ikaros promotes
lymphoid differentiation by activating Flt3 expression, and repressing the GM-CSF
gene. As described in more detail later, PU.1 loss leads to profound inhibition of B cell
and myelomonocytic production (Laiosa et al., 2006).
Lymphoid Lineage
PU.1, Ikaros, EBF, E2A and Pax5 are all critical transcription factors in B cell
development. Progenitors are committed to a B cell fate by Pax5, whereas E2A and
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EBP activate genes appropriate for this lineage. In T cell development GATA-3 and
Notch-1 are essential at the earliest developmental stage. Notch signalling serves a
more focused role committing progenitors by inhibiting factors which lead to other
lineage fates. On the other hand, GATA-3 promotes T cell development only in the
context of Notch signalling (Laiosa et al., 2006).
Erythroid and megakaryocytic lineage
The direction of haematopoiesis towards the production of erythroid cells depends on
the integration of numerous transcription factors. SCL, c-Myb, LMO2 and GATA-2 are
important broad-spectrum factors, whereas in erythropoiesis GATA-1, FOG, EKLF,
PU.1, Stat5 and Herf1 are required for the formation of normal mature erythrocytes
(Perry and Soreq, 2002). In earlier precursors PU.1 directs haematopoiesis towards a
myeloid fate. GATA-2 is critical for early haematopoiesis and GATA-2 down-regulation
is necessary for the initiation of differentiation. GATA-2 is expressed in erythroid and
megakaryocytic progenitors but is down regulated as GATA-1 replaces it at the B gene
locus to induce haemoglobin gene expression. Both GATA-1 and GATA-2 deficient
embryos succumb to a lethal anaemia. GATA-1 is also required in megakaryocytic
maturation, and GATA-1 interacts with FOG-1 during erythroid differentiation and, is
also essential for megakaryopoiesis (Laiosa et al., 2006). There is also evidence for an
interaction between the pro-lymphoid transcription factor Ikaros, regulating the
signalling of Notch and GATA-1 to inhibit megakaryopoiesis. (Malinge et al., 2013)
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Granulopoiesis
Important transcription factors in granulopoiesis will be examined in detail in section
“1.2.7.1 Transcription factors regulating granulopoiesis”
Figure 1.2 Diagram representing important transcription factors in haematopoietic development. Red bars
represent stages at which development is blocked in the absence of the relevant transcription factor. From
Orkin and Zon, 2008.
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1.2.5.4 Other regulators of haematopoiesis
Flt3 and FLt3 ligand
Flt3 or FMS-like tyrosine kinase 3 (CD135) is a membrane-bound tyrosine kinase
receptor expressed in HSPC, where it has an important role in development, and in
the immune system. Ligation of Flt3 leads to phosphorylation of Stat3 and Stat5
associated with JAK pathway, and mTOR (mammalian target of rapamycin) pathway
activation. Flt3 ligand (FL) is part of the family of cytokines which includes SCF and
M-CSF (Stirewalt and Radich, 2003). FL mRNA is expressed in most haematopoietic
and non-haematopoietic tissues, although the FL protein is detectable only in T
lymphocytes and stromal fibroblasts in the bone marrow. FL is able to induce
proliferation in the stem cell compartment not on its own but in synergy with
haematopoietic growth factors and cytokines, such as IL3, SCF, granulocyte colony
stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor
(GM-CSF). FL is highly expressed in progenitors with lymphoid and myeloid potential,
and to a lesser extent in B cells and DC precursors (Gilliland and Griffin, 2002). Flt3
deficient mice develop apparently normal haematopoiesis yet exhibit deficiencies in
primitive B lymphoid progenitors (Mackarehtschian et al., 1995). Flt3 deficient stem
cells fail to contribute to both B cells and myeloid cells upon transplantation, and
targeted disruption of FL results in significant reductions in the number of B cell
progenitors, DC and NK cells.
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Key differences between human and murine Flt3 are the absence of Flt3 expression in
murine CMP and GMP, yet Flt3 is required for the promotion of these same
populations in human haematopoiesis (Kikushige et al., 2008).
1.2.5.5 Haematopoietic stem and progenitor cell mobilisation
HSPC are retained within their own niche as described above by a number of
mechanisms regulating their localisation and quiescence. HSPC can leave the bone
marrow to be detected in the peripheral blood, as well other organs such as heart and
brain, serving to aid in the repair of damaged tissues, and be a part of host immunity
(Massberg et al., 2007). HSPC leave the bone marrow in several conditions of stress,
such as exercise, inflammation, bleeding and the administration of cytotoxic agents
(To et al., 1984, Kroepfl et al., 2012, Cline et al., 1977). A number of mechanisms
have been shown to mobilise HSPC, and are discussed below.
G-CSF induced HSPC mobilisation
The G-CSF receptor (G-CSFR, see in section 1.2.7.2, subsection “G-CSF induced
neutrophil mobilisation”) is present on HSPC and ligation of this receptor by the
cytokine G-CSF, and subsequent receptor signalling is associated with mobilisation of
HSPC. As discussed in the section on granulopoiesis, the G-CSFR is expressed also on
neutrophils, monocytes, myeloid progenitors and other cells. G-CSF is produced in the
context of inflammation and infection, when emergency granulopoiesis is required,
and at lower levels in steady-state in the homeostatic maintenance of neutrophil levels
in the peripheral blood (see in section 1.2.7.2, subsection “Regulation of G-CSF
levels”). G-CSF induces HSPC mobilisation via a number of mechanisms, in part by
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effects on a number of other factors which serve to maintain HSPC in their niche and
regulate their quiescence. HSPC mobilisation by repetitive G-CSF stimulation over
days leads to accelerated myelopoiesis and increases in HSPC motility and egress into
the circulation (Greenbaum and Link, 2011). Evidence suggests that an intermediary
is required for mobilisation of HSPC by G-CSF, since mixed chimeric mice
reconstituted with both wild-type and G-CSFR deficient bone marrow mobilised
HSPCs from both types of cells equally well in response to G-CSF (Liu et al., 2000),
yet G-CSFR deficient mice failed to mobilise in response to this cytokine. G-CSFR
expression by HSPC is therefore not necessary for their mobilisation by G-CSF,
implying that such mobilisation occurs indirectly by various mechanism, as discussed
further below The mediator of HSPC mobilisation by G-CSF has not been defined,
although it has been shown that monocyte-lineage cells may be involved (Christopher
et al., 2011).
The CXCR4 and CXCL12 axis
CXCL12 is produced in bone marrow by stromal cells (Ponomaryov et al., 2000)
including OB and endothelial cells, and it is the sole ligand for CXCR4, as well as a
ligand for the atypical chemokine receptor CXCR7. As described above, CXCL12 has
important roles in HSPC homing, retention, survival and quiescence. CXCL12 is
expressed constitutively at high levels in the bone marrow and within the stem cell
niche, and is a potent chemoattractant for HSPC (Wright et al., 2002). It can activate
matrix metallopeptidases (MMP) and is short-lived in the blood owing to degradation
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by proteases such as CD26, dipeptidyl peptidase -4 (DPPIV) (Christopherson et al.,
2003).
CXCL12 ligation of CXCR4 leading to downstream signalling is critical for
maintenance of HSPC homeostasis. CXCR4 and CXCL12 knockout (KO) mice die at
the time of birth with a hypocellular bone marrow (Eash et al., 2009) and conditional
knock-out of CXCR4 or CXCL12 in the adult murine bone marrow leads to a
hypocellular bone marrow, increased numbers of HSC in cell cycle and increased
HSPC in the peripheral blood (Sugiyama et al., 2006). The CXCR4 antagonist
AMD3100 (Plerixafor) will induce mobilisation of HSPC within hours in mice and
humans alone or in combination with G-CSF (Broxmeyer et al., 2005b) and is used for
this purpose for the mobilisation of stem cell donors. Furthermore, plasma CXCL12
elevation induces mobilisation of haematopoietic precursors and mature cells, possibly
by attracting HSPC to the blood and inducing other indirect mechanisms of
mobilisation (Hattori et al., 2001), and suggesting that CXCL12 in the blood has
opposing effects to that of CXCL12 secreted locally in the stem cell niche.
G-CSF induced HSPC mobilisation is associated with reduction in bone marrow
CXCL12 after a transient upregulation (Petit et al., 2002). Furthermore blocking
CXCR4 or CXCL12 reduces or abolishes G-CSF-induced mobilisation. OB are a source
of CXCL12, and G-CSF treatment leads to marked decrease in expression of this
chemokine by OB (Semerad et al., 2005), and suppresses their number and function
(Christopher and Link, 2008). In addition, G-CSF treatment of mice leads to a
reduction in bone marrow macrophages and is associated with reduced CXCL12
expression in nestin+ MSC within the stem cell niche (Christopher et al., 2011),
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contributing to the reduction in retention signalling via CXCR4 and leading to HSPC
mobilisation (Christopher et al., 2011).
The VCAM-1 and VLA-4 axis and other adhesion molecules
HSPC express VLA-4 (very late antigen-4)/α4β1 integrin and this tethers them to
VCAM-1 expressed on sinusoidal endothelial cells, stromal reticular cells and
fibronectin (Jacobsen et al., 1996). This axis contributes to the regulation of HSPC
trafficking between the bone marrow and peripheral sites (Papayannopoulou et al.,
1995). Blocking of either VCAM-1 or VLA-4 with antibodies leads to HSPC
mobilisation, and a molecule inhibitor of VLA-4 has shown potent mobilisation in
mice (Ramirez et al., 2009). Under physiological conditions, G-CSF induced MMP-8
release cleaves VCAM-1 and leads to HSPC mobilisation (Steinl et al., 2013).
CD44 is an adhesion molecule expressed on HSPC and interacts with the extra-cellular
matrix, binding to hyaluronan. Loss of this adhesion is an important mechanism for
HSPC release from the bone marrow (Vermeulen et al., 1998), and its expression is
essential for re-engraftment of HSPC in the bone marrow. Neutrophil proteases
induced by G-CSF cause CD44 shedding and extra-cellular matrix degradation,
leading to HSPC mobilisation. Conversely bone marrow endothelial expression of
CXCL12 leads to upregulation of CD44 for retention of HSPC within the bone marrow
(Avigdor et al., 2004).
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Other mediators of HSPC mobilisation
The cKit receptor together with SCF play another important role in regulating HSPC,
with crucial roles in maintaining HSC quiescence (Thoren et al., 2008). Although
controversies exist, G-CSF is thought to lead to HSPC mobilisation by inducing
proteases which cleave cKit and SCF (Levesque et al., 2003b, Heissig et al., 2002).
Administration of kit ligand by stimulating cKit signalling will induce significant HSPC
mobilisation (Molineux et al., 1991), and in contrast cKit-deficient mice have reduced
mobilisation of HSPC in response to G-CSF (Papayannopoulou et al., 1998).
FL, which is also required for the regulation of early haematopoiesis, can induce HSPC
mobilisation upon administration alone or with G-CSF (Papayannopoulou et al.,
1997).
In addition to effects on neutrophils, CXCL2 can rapidly mobilise HSPC which have
improved engraftment characteristics on re-transplantation, by inducing MMP (Pelus
and Fukuda, 2006, Fukuda et al., 2007). Several other chemokines can induce
mobilisation in minutes, and mobilisation with chemokines and G-CSF is synergistic
(see section 1.7 Chemokines and chemokine receptors in haematopoiesis).
Under physiological conditions, circulating HSPC are released in a circadian rhythm,
in opposite manner to the expression of CXCL12 regulated by genes responding to
noradrenaline secretion by the sympathetic nervous system via nerves in the bone
marrow (Mendez-Ferrer et al., 2008). It has been shown that one mechanism by
which chemotherapy leads to impaired HSPC mobilisation is by injury to sympathetic
nerves in the bone marrow (Lucas et al., 2013).
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A mechanism for the release of HSPC in the context of tissue injury or fibrinolysis has
been shown for plasminogen activation in haematopoiesis. Upon activation by tPA of
plasminogen (tissue-type plasminogen activator) to plasmin, this enzyme increases
steady-state egress of HSPC from bone marrow, and enhances the mobilisation
response to G-CSF as shown in mice, by inducing MMP-9 activity which
downregulates CXCL12 in the bone marrow and modulates CXCR4 expression on
HSPC (Tjwa et al., 2008, Gong et al., 2011). A membrane plasminogen activator
receptor (MuPAR) is expressed by HSPC and is involved in cell-cycle regulation,
preventing abnormal HSPC proliferation. This may be a further mechanism of HSPC
egress, whereby plasmin may cleave MuPAR during mobilisation (Tjwa et al., 2009).
Other mechanisms for mobilisation such as lipid rafts have been shown to contribute
to HSPC mobilisation by modulating CXCL12-CXCR4 signalling (Wysoczynski et al.,
2005), and enhancing extra-cellular matrix degradation by MMP (Shirvaikar et al.,
2010). Bioactive lipid molecules such as sphingosine-1-phosphate receptor 1 (S1P1)
have been shown to be important mediators of HSPC mobilisation. Receptors for S1P1
are present on HSPC, and these interact with CXCL12-CXCR4 signalling. S1P1
deficient mice or those treated with S1P1 inhibitors show a reduced capacity to
mobilise HSPC in response to AMD3100 or G-CSF. S1P1 induces the secretion of
CXCL12 by nestin+ MSC into the blood leading to HSPC egress (Golan et al., 2012).
Inducers of S1P1 production include the sympathetic nervous system (Mendez-Ferrer
et al., 2008)
29
Various elements of the innate immune system modulate the responsiveness of HSPC
to a CXCL12 gradient and are involved in the regulation of HSPC release from the
bone marrow, such as cationic antimicrobial peptides (Karapetyan et al., 2013),
prostaglandin E2 (Hoggatt et al., 2009) and the complement system (Ratajczak et al.,
2004).
Proteases
Neutrophils themselves have been implicated in HSPC mobilisation as they are a
major source of neutrophil elastase, cathepsin G and matrix metallopeptidase-9
(MMP-9), all implicated in mobilisation of haematopoietic precursors (Borregaard and
Cowland, 1997). These proteases may degrade and inactivate several proteins
required for retaining HSC and progenitor cells in the bone marrow, such as VCAM-1,
CXCL12, CXCR4 and cKit (Winkler and Levesque, 2006). The implication of this is
unclear since mice lacking neutrophil MMP-9, neutrophil elastase or cathepsin G
mobilise HSPC normally (Levesque et al., 2004), although more recently other
investigators have shown that MMP-8 from neutrophils performs an essential role in
HSPC mobilisation by cleaving CXCL12 (Steinl et al., 2013).
1.2.6 Erythropoiesis
The generation of mature erythrocytes is an important and therefore tightly controlled
process since the number of these cells should remain constant (approximately 45% of
blood volume) to ensure adequate tissue oxygenation. The average lifespan of an
erythrocyte in mice is 60 days (Walker et al., 1984) and human 120 days (Greer and
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Wintrobe, 2004), requiring 2.4 x 106 cells to be produced every second in an average
human to support this turnover (Bessis, 1973).
Following the differentiation of HSC into CMP and subsequently MEP, the Burst-
Forming Unit-Erythroid (BFU-E) is the most primitive erythroid-restricted progenitor,
identifiable exclusively by functional assays (see Figure 1.3). In the presence of
erythropoietin, FL, IL-3, GM-CSF, TPO and SCF, this cell can give rise to colonies
containing over 500 haemoglobinised erythroblasts after 5-7 days of methylcellulose
supported culture (mouse) or 10-14 days (human). The BFU-E further differentiates
into the Colony Forming Unit-Erythroid (CFU-E), composed of more mature erythroid
progenitors with close similarity to the pro-erythroblast. In the presence of low
concentrations of EPO, CFU-Es give rise to small colonies, containing 8 to 64
haemoglobinised erythroblasts after 2-4 days of culture (mouse) or 5-8 days (human)
(Dzierzak and Philipsen, 2013). The earliest morphologically identifiable erythroid
progenitor is the proerythroblast, derived from the CFU-E. This is a large cell
characterised by a substantial nucleus with visible nucleoli surrounded by a basophilic
Figure 1.3 Schematic diagram representing erythroid differentiation from HSC (left) sequentially to mature
erythrocyte (right), with significant expression of surface markers represented in the bars below. From
Dzierzak and Philipsen, 2013
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cytoplasm. Basophilic erythroblasts are slightly smaller cells, harbouring a nucleus
with a granular appearance, as nuclear condensation begins, and the basophilic aspect
of the cytoplasm is due to the presence of large numbers of ribosomes. Haemoglobin
can be detectable for the first time at the next polychromatophilic erythroblast stage.
These cells and their nuclei are smaller. Full haemoglobinisation occurs at the
subsequent orthochromatic erythroblast stage. These cells are the smallest nucleated
erythrocyte precursors and their nuclei undergo pycnotic degeneration with chromatin
condensation and nuclear shrinkage. Subsequently the nucleus is extruded from what
is now a reticulocyte, which is larger than mature erythrocytes and has an irregular
form with a stippled appearance due to presence of scanty remaining cytoplasmic
organelles. Terminal differentiation from proerythroblast to reticulocyte occurs in 48
to 72 hours, and reticulocyte maturation occurs for a further 48 hours until the
remaining organelles are eliminated and the cell develops the discoid shape of the
mature erythrocyte (Dzierzak and Philipsen, 2013).
Terminal erythroid differentiation occurs in the erythroid or erythroblastic island, an
anatomic unit which provides an exclusive environment for maturing erythroid
precursors (Manwani and Bieker, 2008). This consists of a central macrophage
surrounded by erythroid precursors at different stages of maturation (Figure 1.4).
More immature precursors are located at the centre, moving away distally as they
mature and maintaining close contact with cytoplasmic extensions of the macrophage
until the occurrence of erythroid enucleation. A function of the macrophage is
phagocytosis of the ejected nucleus, but this is unlikely to be the only function. It is
known that the presence of the macrophage is not essential for the amplification or
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maturation of the erythroblasts in different culture systems but these are not
representative of the in vivo environment. It is likely that the macrophage affects the
local concentration of growth factors and nutrients, considering both the proximity of
the erythroblasts and the presence of gap junction-like structures between the
macrophages and erythroblasts.
Adhesion molecules help to maintain the proximity of the maturing erythroblast to the
macrophage. A molecule named erythroblast-macrophage protein is expressed on both
the macrophage and the erythroblast and its expression is necessary for normal
erythoid development (Soni et al., 2006). The role of other adhesion molecules is less
clear. It is known that the immature erythroid cells to the reticulocyte stage express
VLA-4, whereas the macrophages express the counterpart VCAM-1. In addition,
ICAM4 (LW blood group) and CD51 (αv integrin) are also expressed by erythroblast
and macrophage respectively, and recent work supports a critical role for ICAM4 in
erythoid island development (Lee et al., 2006a).
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a
b
Figure 1.4 The erythroblastic island (a) Schematic diagram (Dzierzak and Philipsen, 2013) (b) Photograph
(Bain, 1999)
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1.2.7 Myelo- and granulopoiesis
Neutrophils and monocytes/macrophages all derive from a common progenitor and
the production of neutrophils is extensive in steady state with 1-2x1011 cells being
produced per 24 hours in a normal adult human. Differentiation of myeloid cells
occurs over 10-14 days, and is followed by the release of mature myeloid cells into the
peripheral blood. Myelopoiesis occurs from the GMP, as evidenced by cell-sorted and
plated GMP in semi-solid medium which give rise to three distinct colony forming unit
types; CFU-G (granulocyte), CFU-M (monocyte) and CFU-GM (granulocyte-
monocyte), (Akashi et al., 2000). Histological staining of bone marrow cells has
identified several intermediate states of myeloid differentiation, where the
promyelocyte is the most undifferentiated progenitor, which sequentially
differentiates into either basophilic, neutrophil or eosinophilic myelocytes, and then
metamyelocytes which mature into their terminally differentiated counter parts,
basophils, neutrophils and eosinophils respectively (Bain et al., 2010). Cytokines
required for coordinated myeloid maturation are G-CSF, GM-CSF, M-CSF and IL3 (Liu
et al., 1996, Ward et al., 2000). These cytokines maintain survival and stimulate
proliferation, leading to maturation and functional activation of the target cells and
subsequently influencing the activity of transcription factors important for myeloid
lineage commitment.
The mature blood neutrophils, also called polymorphonuclear neutrophils (PMN),
contain several granules types which form over the sequential differentiation steps.
The earliest appearing granules are formed at the promyelocyte stage and are named
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azurophilic or primary, followed subsequently by the specific/secondary and
gelatinase/tertiary granules. Finally secretory vesicles develop, which importantly
have a membrane with high expression of receptors which include CD11b, CD14 and
FcγRII (CD32) (Borregaard and Cowland, 1997). Primary granules exclusively contain
the protein myeloperoxidase (MPO), and are further divided into subgroups
dependent not only on size, shape and protein content, but also their appearance
during myelopoiesis. Alpha-defensins form together with MPO in azurophilic granules,
but also proteins such as bactericidal/permeability-increasing protein (BPI) and
neutrophil elastase, proteinase 3, azurocidin and cathepsin G. Secondary and tertiary
granules do not contain MPO, and can be divided into subgroups according to
lactoferrin and gelatinase content. The expression of these MPO-negative granules
occurs as a continuum in myelocytes, metamyelocytes, and PMN, and in addition to
lactoferrin and gelatinase, these granules contain HCAP-18, lipocalin, lysozyme and
collagenase. (Borregaard and Cowland, 1997)
1.2.7.1 Transcription factors regulating granulopoiesis
PU.1
The PU.1 transcription factor is a member of the ETS (E26 transformation-specific)
family of transcription factors and is crucial in the specification of haematopoietic
lineages. It is required for the development of early MPP and plays a further critical
role in the differentiation of monocytes/macrophages in later stages (DeKoter et al.,
1998). PU.1 expression is high in B-cells and myelomonocytic cells, with lower
expression in HSCs and CMPs. The loss of PU.1 leads to late embryonic or early
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neonatal death due to the lack of B-cells and myelomonocytic development
(McKercher et al., 1996). In addition, the HSC formed in PU.1 conditionally deficient
mice have a reduced repopulation potential (Iwasaki et al., 2005). Loss of C/EBPα
expression however has the opposite effect by enhancing the repopulation potential
(Zhang et al., 2004).
C/EBP family
The C/EBP family of transcription factors includes C/EBPα, -β, -γ, -δ and -ε, which are
similar in their C-terminal leucine-zipper domains and DNA-binding domains, but
differ in the N-terminal transactivation domains (Ramji and Foka, 2002, Lekstrom-
Himes and Xanthopoulos, 1998). The C/EBP proteins are able to form homodimers
with themselves or heterodimers with all the other proteins of this family owing to the
high degree of conservation of the leucine zipper domain (Williams et al., 1991).
The precise mechanisms of further differentiation from committed MPP into either
neutrophils or the monocytic lineage are not completely understood. It is thought that
the continued expression of PU.1 leads differentiation of myeloid cells into the
monocytic lineage. Conversely, C/EBPα can inhibit the function of PU.1 and
upregulation of C/EBPα results in the induction of granulocytic development and
inhibition of monocytic development (Reddy et al., 2002). C/EBPα and PU.1 interact
to regulate genes encoding myeloid-specific growth factor receptors G-CSF-receptor
(CSF3), M-CSF-receptor and GM-CSF-receptor (Hohaus et al., 1995, Smith et al.,
1996). Differentiation into monocytic lineage depends on the expression of the M-CSF
receptor and this will only occur if the cells respond to this specific growth factor
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(Anderson et al., 1999). PU.1 deficient cells can commit into the granulocytic and
monocytic lineages, but cannot fully support maturation along these lineages. Mice
deficient in C/EBPα lack mature PMN as myeloid cells fail to differentiate past the
myeloblast stage, but show no monocytic deficiencies (Zhang et al., 1997). As
opposed to PU.1 deficiency, loss of C/EBPα downregulates G-CSFR mRNA expression
but mRNA of GM-CSF and M-CSF receptors are not affected (Iwama et al., 1998).
Furthermore it appears to block the transition from CMP to GMP, leading to a
profound loss of granulocytic potential and accumulation of myeloblasts (Zhang et al.,
2004) Therefore C/EBPα effects in myeloid differentiation include the activation of
genes which encode for the G-CSFR (Hohaus et al., 1995, Smith et al., 1996),
myeloperoxidase (Wang et al., 2001) and the inhibition of proliferation (Theilgaard-
Monch et al., 2005) by interacting with the E2F cell cycle regulator. During terminal
neutrophil differentiation, the expression of C/EBPα is progressively reduced from the
myeloblast stage, whereas C/EBPε expression is maximal at the myelocyte stage.
C/EBPε is up-regulated by C/EBPα and G-CSF through the CSF3 signalling pathway
(Nakajima and Ihle, 2001). Mice with a targeted disruption of C/EBPε fail to produce
mature neutrophils and to express the late-appearing secondary and tertiary granule
proteins (Yamanaka et al., 1997). Other transcription factors such as PU.1, C/EBPβ,
C/EBPδ and C/EBPγ increase continuously through differentiation to the
metamyelocyte stage (Figure 1.5). Mice deficient in C/EBPβ or C/EBPδ demonstrated
no haematopoietic defects in relation to terminal granulopoiesis. However there is an
essential role for C/EBPβ in emergency granulopoiesis, but C/EBPα or C/EBPε were
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not induced under the conditions of cytokine treatment or fungal infection (Hirai et
al., 2006).
Hence, C/EBPα is essential for the commitment of HSCs toward promyelocytes,
whereas C/EBPϵ, which acts downstream of C/EBPα, regulates the transition from
promyelocytes to mature neutrophils.
GATA-2
As stated above, GATA-2 is essential for early haematopoiesis: it is critical for
production of mature erythrocytes at the embryonic stage, it is important at later
stages of myeloid and lymphoid development, and has a central function in
maintaining the proliferation and survival of developing HSC (Tsai et al., 1994) . Mice
Figure 1.5 Representative diagram illustrating terminal granulopoiesis, which is characterised by the sequential
formation of granules and maturation with segmentation of the nucleus. Transcription factors indicated above
the figure are critical for the regulation of granule protein maturation and appearance of granule proteins.
From Fiedler and Brunner, 2012.
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haploinsufficient for GATA-2 have low numbers of HSC associated with increased
apoptosis and a reduced level of granulocyte progenitors (specifically reduced GMP)
with poor performance of mature neutrophil forms in functional assays and no effect
on other progenitors (CMP, CLP) (Rodrigues et al., 2008).
GFI1
GFI1 is part of a network of intrinsic factors that control HSC fate, and regulates the
quiescence of HSC (Hock et al., 2004). In GFI1 deficient mice, there is a lack of
mature neutrophils, and the myeloid cells produced harbour only primary granules
and demonstrate increased monocytic gene expression. It appears that GFI1 silences
monocytic genes and directs myelopoiesis toward granulocytic maturation (Hock et
al., 2003). In humans, rare inherited mutations of GFI1 are the cause of some forms of
severe congenital neutropaenia (Person et al., 2003).
In this compartment, GFI1 and PU.1 inhibit each other's function by competing for
DNA binding in promoters of target genes (Spooner et al., 2009). However, GFI1 also
inhibits PU.1 by direct repression of the PU.1 gene and by counteracting PU.1 function
through a protein–protein interaction (Dahl et al., 2007). PU.1 promotes monocytic
differentiation, whereas GFI1 enhances granulocytic differentiation.
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1.2.7.2 Neutrophil mobilisation and clearance
Neutrophil circulation and clearance
Ex-vivo labelling and re-infusion of neutrophils to measure their clearance have
suggested that the circulating lifespan of murine and human neutrophils is
approximately 8 hours (Dancey et al., 1976). However more recent work confirms
such short lifespan for murine neutrophils but suggest a longer lifespan of over 5 days
for human neutrophils (Pillay et al., 2010). It is likely that ex-vivo manipulation of
neutrophils in early studies accelerated their clearance from the blood. Only a small
part of total neutrophils is present in the circulation, and a substantial proportion (c.
20%) is marginating in the vessels of the lungs, present mainly within the capillaries
(Semerad et al., 2002, Doerschuk et al., 1994). Beta agonists such as epinephrine
(adrenaline) can lead to rapid demargination of neutrophils and their return to the
circulation (Bierman et al., 1952)
Neutrophil clearance occurs via macrophage phagocytosis in several locations,
primarily the spleen, the bone marrow and the liver in roughly equal proportions
(Suratt et al., 2001). Depending on the method of stimulation, neutrophils may
preferentially home to a specific organ, e.g. in a model of thioglycollate induced
peritonitis, peritoneal exudate neutrophils re-infused into untreated recipient mice
homed to the liver, whereas those harvested from bone marrow of the thioglycollate
treated mice, home to the bone marrow of untreated recipients (Suratt et al., 2001).
Aging of neutrophils correlates with cell surface expression of CXCR4, with increased
expression resulting in greater response to CXCL12, thus directing aged neutrophils to
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the bone marrow for clearance (Martin et al., 2003). Blocking antibodies to CXCR4
impede this process, but this is a non-critical mechanism as CXCR4 deficient
neutrophils show comparable clearance to those expressing CXCR4 (Eash et al.,
2009).
Neutrophil release
Neutrophils develop from precursors in bone marrow sinusoids and as they mature,
accumulate away from the bone marrow trabeculae. The bone marrow is a large
reservoir of mature cells, and a wide range of mediators is capable of triggering
release. These include chemokines (CXCL1, CXCL2, CXCL5, CXCL8, CXCL6, CXCL12),
cytokines (G-CSF, IL-6, GM-CSF, SCF) (Seymour et al., 1997, Liu et al., 1997, Lapidot
and Petit, 2002, Hattori et al., 2001), bacterial products, (N-formyl-methionyl-leucyl-
phenylalanine, fMLP), complement fragments such as C5a (Jagels et al., 1995) and
Flt3 ligand (Molineux et al., 1997).
To enter the blood, neutrophils migrate through the diaphragmatic fenestrae of
endothelial cells lining the sinusoids, wherein abluminal and luminal endothelial cell
membranes are fused (Burdon et al., 2008).
The CXCR4 and CXCL12 axis
CXCL12 and its receptor CXCR4 are important regulators of neutrophil release from
the bone marrow. HSPC express CXCR4 at high levels, whereas neutrophils express
low amounts of CXCR4 on the cell surface, with higher intracellular levels of this
receptor. CXCR4 is required for the retention of myeloid precursors within the bone
42
marrow, as evidenced by the premature release of granulocytic precursors in mice
lacking haematopoietic CXCR4 (Ma et al., 1999).
In addition, mice with myeloid only CXCR4 or CXCL12 deletions exhibit constitutive
neutrophilia and impaired mobilisation from the bone marrow (Eash et al., 2009).
CXCL12 expression is significantly decreased following G-CSF treatment (Levesque et
al., 2003a). G-CSF induces a transient increase in CXCR4 expression subsequently
leading to its downregulation, which correlates with HSPC mobilisation (Semerad et
al., 2002). CXCL12 is degraded by elastase from neutrophils (Petit et al., 2002), but
production of CXCL12 may also be reduced due to suppression by G-CSF of bone
marrow OB, the primary bone marrow source of CXCL12 (Semerad et al., 2005,
Katayama et al., 2006). This suggests that CXCL12 is a retention factor for bone
marrow neutrophils, supported by work demonstrating that following the
administration of the CXCR4-antagonist AMD3100 (Plerixafor) there is a rapid
increase in circulating neutrophils due to the egress of neutrophils from the bone
marrow (Martin et al., 2003).
More recent work suggests different roles for CXCR4 and G-CSF in neutrophil
mobilisation. G-CSF increases neutrophil mobilisation within the bone marrow,
leading to their localisation near vessels for entry into the circulation (Devi et al.,
2013), whereas CXCR4 antagonism reduces neutrophil bone marrow retention (Eash
et al., 2010), with G-CSF contributing to the reduction in CXCR4 signalling by its
effects on OB and CXCL12 production. The combination of these and other signals
leads to neutrophil egress from the bone marrow.
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A gain-of-function mutation in CXCR4 leading to constitutive signalling of CXCR4 has
been described to be the cause of WHIM syndrome (Warts, Hyper-
gammaglobulinemia, Immunodeficiency and Myelokathexis). WHIM is characterised
by bone marrow accumulation of neutrophils associated with peripheral neutropaenia
and an inability to effectively mobilise neutrophils, leading to recurrent infections and
virally induced warts (Hernandez et al., 2003).
The clinical importance of the CXCR4-CXCL12 axis is demonstrated by the widespread
use of the CXCR4 antagonist Plerixafor (AMD3100) to mobilise HSC and progenitor
cells (Broxmeyer et al., 2007). Plerixafor is also clinically effective in the treatment of
WHIM syndrome (McDermott et al., 2011)
G-CSF induced neutrophil mobilisation
G-CSF is the principle cytokine controlling granulopoiesis. The effects of G-CSF are
mediated via the G-CSFR and mice lacking either G-CSF or G-CSFR have profound
neutropaenia (Lieschke et al., 1994, Liu et al., 1996). Some patients with severe
congenital neutropaenia have also molecular defects in G-CSF pathway as underlining
causes (Dong et al., 1994). G-CSFR is expressed primarily in neutrophils and their
precursors but also monocytes, platelets, haematopoietic progenitor cells, NK cells and
endothelial cells. The expression of G-CSF-R in several cells is induced by the
transcription factor C/EBPα (Barreda et al., 2004). G-CSFR is a tyrosine kinase type
receptor, with signal transduction involving the JAK-STAT pathway (Barreda et al.,
2004). Following binding to G-CSFR, G-CSF is removed from the circulation and bone
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marrow by internalisation in granulocytes and is subsequently degraded, permitting a
negative feedback mechanism by effector cells. (Sarkar and Lauffenburger, 2003).
Ligation of G-CSF to neutrophil G-CSFR leads to a rapid increase in their motility
within the bone marrow, leading to their emigration through blood vessels (Kohler et
al., 2011). G-CSF also contributes to neutrophil mobilisation by disrupting
CXCR4/CXCL12 mediated bone marrow retention signals (Wengner et al., 2008,
Semerad et al., 2002). In addition to inducing bone marrow neutrophil release, G-CSF
leads to increased neutrophil phagocytic and migratory activity (Platzer et al., 1985).
G-CSF induced neutrophil mobilisation occurs rapidly but chronic treatment of mice
with G-CSF stimulates not only mobilisation but also leads to prolonged increases in
granulopoiesis (Welte et al., 1987).
G-CSF leads to neutrophil mobilisation via indirect mechanisms. G-CSF is also
produced by osteocytes allowing these cells to regulate myelopoiesis independently of
OB in response to G protein-coupled receptor signalling pathways that act through the
heterotrimeric G protein Gsα, through yet-to-be-determined mediators (Fulzele et al.,
2013).
Inhibition of G-CSFR occurs through SOCS3 and Stat3 activation, which are activated
by G-CSFR signalling; deficiency of either leads to neutrophilia and increases in
mature neutrophils in the bone marrow (Barreda et al., 2004).
G-CSF is a well-established treatment for individuals with various forms of acquired or
congenital neutropaenias (Lieschke and Burgess, 1992).
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CXCR1-2 and ELR+ CXCL chemokines
Classical chemokine receptors CXCR1 and 2 and CCR1 are present on neutrophil cell
membranes, as well as the atypical chemokine receptor D6 (ACKR2) (Fan et al., 2007,
Cacalano et al., 1994, Bachelerie et al., 2014). CXCL1-3 and CXCL5-8, cumulatively
called ELR+ chemokines due to the conserved ELR, glutamic acid-leucine-arginine,
motif in their N-termini, are ligands for CXCR2 and CXCR1. Mice deficient in CXCR2
have severe defects in neutrophil emigration to sites of inflammation (Cacalano et al.,
1994), and in normal mice exogenous administration of ELR+ chemokines leads to
neutrophil mobilisation (Burdon et al., 2008), which is independent of G-CSF
(Semerad et al., 2002). CXCR2 ligands CXCL1 and CXCL2 are constitutively expressed
in bone marrow endothelial cells, and the expression of CXCL2 is upregulated by G-
CSF. G-CSF and ELR+ chemokines can work synergistically in order to enhance the
mobilisation of neutrophils (Wengner et al., 2008). CXCR4 and CXCR2 play opposite
regulatory roles as the ELR+/CXCR2 pathway antagonises CXCR4 in the release of
neutrophils from the bone marrow (Eash et al., 2010). The precise mechanism for this
is unclear. However more recent work has shown that the administration of G-CSF
leads to a CXCL1 spike in blood, which is released by bone marrow megakaryocytes. A
similar CXCL1 spike is detected on thrombopoietin administration, and G-CSF
increases systemic levels of thrombopoietin. Thus, G-CSF may act in part indirectly via
megakaryocyte production of CXCL1, which, in turn, leads to neutrophil mobilisation
(Kohler et al., 2011). In particular, the localisation of megakaryocytes and OB close to
bone marrow vasculature, may allow for the rapid production of CXCR2 ligands and
highlights a role for these cells as gatekeepers in emergency neutrophil mobilisation.
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The G-CSF target leading to thrombopoietin release remains unclear. Nevertheless this
is consistent with previous data that G-CSFR on neutrophils is dispensable for their
mobilisation from bone marrow (Semerad et al., 2002).
Adhesion molecules
Selectin and integrins expressed on neutrophils and the vascular endothelium are
critical for the emigration of neutrophils from the circulation into tissues. Loss of
selectins leads to neutrophilia, and integrin deficient mice exhibit an increase in
neutrophil blood numbers and their reduction in the tissues (Stark et al., 2005,
Robinson et al., 1999, Frenette et al., 1996). The neutrophilia which develops appears
to be due to elevated G-CSF levels, produced as a result of reduced neutrophil
phagocytosis by macrophages consequent from the reduction in neutrophil migration
into tissues (Stark et al., 2005). This mechanism is described in detail below.
Regulation of G-CSF levels
Neutrophils exert their effect in host defence through the release of reactive oxygen
species, phagocytosis, degranulation and the release of nuclear material as NETs
(Brinkmann et al., 2004). Apoptotic neutrophils are cleared through phagocytosis by
macrophages. Recent work suggests that blood granulocyte levels are controlled by a
feedback system from the periphery ‘sensing’ neutrophil numbers as they are cleared
by macrophages. IL-23 is produced in macrophages and its production is inhibited by
neutrophil phagocytosis. IL-23 is an inducer of IL-17 production by CD4+ T-cells, and
IL-17 production stimulates G-CSF release. IL-23 production is reduced by neutrophil
phagocytosis, and IL-17 deficient mice show decreased neutrophil counts.
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Furthermore, neutrophil adhesion molecule deficient mice (lacking either CD18,
LFA-1, Core2-glucosaminyltransferase or E-selectin and P-selectin) have elevated IL-
17 levels and neutrophilia, with resolution upon IL-17 blockade (Stark et al., 2005).
Thus G-CSF production depends on peripheral clearance of neutrophils by
macrophages and a feedback to bone marrow production via IL-23 and IL-17. The
baseline function of macrophages is to produce IL-23 with down-stream effects, and
this is negatively regulated on neutrophil phagocytosis. (Stark et al., 2005, Forlow et
al., 2001). More recent work has further supported the role of this axis and suggested
a critical role for commensal bacteria in its regulation (Deshmukh et al., 2014).
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1.3 The vascular endothelium
Inflammation is a fundamental mechanism essential for containing pathogens and the
repair of tissue after injury, and consists of a series of vascular and cellular reactions.
These lead to the removal of damaged tissue and culminate in the completion of
tissue repair. The acute inflammatory process is characterised by the classical signs of
swelling, redness, pain heat and loss of function. It consists of a cascade of events
which include the increased permeability of the small vessels, the adherence of
circulating cells to the blood vessel near the site of injury, the migration of several
immune cell types, controlled cell death and removal of tissue debris, and the growth
of new vessels and tissues. The recruitment and migration of blood leukocytes from
the vasculature to the site of injury is a fundamental event in the process of
inflammation, leading to tissue dysfunction and damage (Janeway, 2001).
The vascular endothelium is lined by a single layer of cells in direct contact with
blood, and acts a barrier regulating the transfer of leukocytes, metabolites and gas.
The barrier function is affected by the type of junctions between endothelial cells, and
the underlying extracellular matrix and basement membrane secreted by these cells as
a point of attachment. Depending on localisation there are variations in the phenotype
of endothelial cells, underlying the requirements of the tissues. For example, within
the spleen, sinusoid capillaries lack tight junctions and a basement membrane,
allowing the slow movement of blood for erythrocyte and other cell “examination” by
macrophages. Endothelial cells in post-capillary venules are most significantly
involved in the tissue migration of leukocytes during inflammation. These respond to
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inflammatory cytokines and express chemo-attractants and adhesion molecules
(Janeway, 2001).
Independent of any inflammatory activation of the vasculature, normal blood flow
leads to the direction of leukocytes towards the blood vessel wall, termed
margination, allowing leukocytes to be in close contact with post-capillary venular
endothelial cells. Inflammation leads to the release of inflammatory mediators which
induce the high expression of adhesion molecules on the endothelium. Of these,
selectins are an important group, comprising E (endothelial)-selectin and P (platelet)-
selectin expressed by endothelial cells, and L(leukocyte)-selectin expressed by
leukocytes (Ley et al., 2007). Selectin ligands are glycoproteins and glycolipids with
sialyl Lewis X motifs contained in the structure with bonds formed between selectins
being calcium dependent. The bonds formed are short lived yet strong, and a
continuous process of bond formation and breakage leads to a slowing and rolling of
cells along the vascular wall (Zarbock et al., 2011, Kansas, 1996).
L-selectin is expressed on leukocyte microvilli and is cleaved soon after leukocyte
activation. It is important for leukocyte recruitment in post capillary venules and
homing to the lymph node. L-selectin counter-ligands are P-selectin glycoprotein
ligand-1, CD34 and glycosylated cell adhesion molecule-1 (Ley et al., 2007, Zarbock
et al., 2011).
P-selectin is contained both in platelets and endothelial cell Weibel-Palade bodies,
translocating to the membrane following stimulation with histamine, oxygen radicals
or thrombin (Kansas, 1996). This molecule is important in early inflammation,
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interacting with P-selectin glycoprotein ligand 1, facilitating tethering of leukocytes.
Neutrophils may adhere to P-selectin on endothelial cells and activated platelets in
situation of high shear stress (Kansas, 1996, Ley, 2003).
E-selectin is expressed on endothelial cells following exposure to IL-1, TNF-α and
bacterial lipopolysaccharide, and ligands comprise P-selectin glycoprotein ligand 1,
CD44 and E-selectin ligand-1 (Ley et al., 2007, Kansas, 1996).
In addition to selectins, some integrins are also important for rolling. Leukocytes roll
on immobilised mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1)
and VCAM-1 via the leukocyte VLA-4. Monocytes and lymphocytes typically engage in
VLA-4-dependent rolling (Ley et al., 2007).
Intercellular adhesion molecule-1 (ICAM-1) is a β2-integrin, which in conjunction with
E-selectin engenders a conformation of intermediate affinity of lymphocyte function-
associated antigen-1 (LFA-1; also known as α1β2-integrin), leading to transient binding
to its ligand ICAM-1. LFA-1 can alter its conformation to increase ligand bind affinity
under high shear stress (Ley et al., 2007).
The induction of inflammation leads to increase of endothelial E-selectin and ICAM-1,
and the slowing down of leukocyte rolling, which requires LFA-1 on lymphocytes or
Mac1 (CD11b/CD18 or α4β2-integrin) on myeloid cells as counter-ligands (Ley et al.,
2007).
The arrest of leukocytes on the endothelium is initiated by chemoattractants such as
chemokines and is mediated via activation of leukocyte integrins, their conformational
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changes and subsequent binding to ICAM-1 and VCAM-1 on endothelial cells (Ley et
al., 2007). These molecules may be produced by endothelial cells, released by
activated platelets or delivered by circulating erythrocytes and microvesicles.
Chemokines are the most effective physiological triggers of integrin-mediated
leukocyte adhesion, rapidly increasing both integrin affinity and valency for individual
cells, and their ligation of cognate GPCRs leads through intracellular pathways to
activation of integrins in less than a second (Ley et al., 2007).
52
1.4 Chemokines
Chemokines (chemotactic cytokines or chemoattractant cytokines) are a superfamily
of 7-12kDa glycoproteins. These are present in a monomeric form, and are also able to
oligomerise, forming dimers or multimers. Chemokines have essential roles in various
functions including angiogenesis, organogenesis and haematopoiesis. In addition
there are roles in both homeostasis and disease, particularly relating to leukocyte
maturation, trafficking and tissue repair. Almost 50 human chemokines have been
described, grouped into four families, CXC, CC, CX3C and XC (see Figure 1.6),
centred on the relative arrangement of cysteine residues which form disulphide bonds.
In the CXC family, an amino acid residue is present between the first two cysteines,
whereas in the CC family the two cysteine residues are next to each other. Similarly,
in the CX3C family, represented by one molecule only, fractalkine, there are 3 amino
acids between the first two cysteines, and in the XC chemokines the first and third
cysteine residues are absent, possessing only one disulphide bond. All vertebrates
have varying numbers of chemokine genes, with the two major human chemokine
gene clusters located on chromosome 4q (CXC) and 17q (CC).
Chemokines may also be classified according to their function and expression.
Following from this, inflammatory chemokines are up-regulated during inflammation,
with important roles in recruitment of leukocytes to sites of inflammation. Conversely
homeostatic chemokines are more typically expressed constitutively and are involved
in homing under physiological conditions. The third group of chemokines have both
inflammatory and homeostatic functions (Blanchet et al., 2012).
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Figure 1.6 Chemokines and respective chemokine receptors.
Abbreviations: I, inflammatory chemokines; H, homeostatic chemokines; D, dual chemokines; P, plasma or
platelet chemokines that are activated by cleavage; Pt, platelet chemokines; U, unknown. H4, histamine
receptor type 4; PITPNM3, phosphatidylinositole transfer protein membrane associated 3; FPRL-1, formyl
peptide receptor like-1.
aGenes in parentheses are not expressed.
bMouse gene whose human counterpart was reassigned after syntenic analysis.
Adapted from Zlotnik and Yoshie, 2012
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1.5 Chemokine receptors
Chemokines exert their effects by binding to cognate receptors present on the cell
surface, and are grouped into the four families based on the chemokine that they
bind. All the classical chemokine receptors are 7 transmembrane domain G-protein-
coupled receptors, which couple the receptor to the G-protein subunit. Eighteen
human chemokine receptors are described, having first appeared in the earliest
vertebrates. Approximately half of the described human chemokine receptors are
located on chromosome 13 (Blanchet et al., 2012). In addition to the classical
receptors, several alternative chemokine receptors, termed atypical chemokine
receptors (ACKR), bind numerous chemokines without signal transduction via G-
proteins. ACKRs comprise the Duffy antigen receptor for chemokines (DARC, ACKR1),
D6 (CCBP2, ACKR2), CXCR7 (ACKR3), CCRL1 (CCX-CKR, ACKR4) and CCRL2
(tentatively ACKR5) (Nibbs and Graham, 2013), see Figure 1.7.
The chemokine receptors of inflammatory chemokines tend to have large numbers of
chemokine ligands, with some ligands shared by multiple receptors. It was suggested
that significant promiscuity in the interaction between chemokines and their receptors
meant redundancy of their function and permits robustness within the system
allowing leukocyte recruitment to occur despite the loss of function of one particular
chemokine (Mantovani, 1999). Investigators have however shown that neutralisation
of a particular chemokine may rapidly suppress chronic inflammation, suggesting that
different ligands binding the same GPCR induce different biological activities. On the
other hand, a single ligand binding to its receptor may lead to different signalling
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cascades, although the mechanisms of this action are still under investigation (Zohar
et al., 2014). The implication is that there is no redundancy of chemokines, in that
unique recognition of each chemokine by the system of receptors, with differential
affinity and nature of responses after ligation of the same receptor by different
chemokines, leads to opposite outcomes.
Figure 1.7 Chemokine receptors and their known ligands.
Abbreviations: acPGP, N-acetyl Pro-Gly-Pro; MIF, macrophage migration inhibitory factor
From Zlotnik and Yoshie, 2012
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1.6 Chemokines in leukocyte trafficking
Leukocyte migration is a central component in immune responses and inflammatory
conditions. Chemokines lead to intravascular adhesion of leukocytes to endothelial
cells, and direct interstitial leukocyte migration as well as assisting location of
leukocytes in healthy and inflamed tissues. The diversity of chemokines, their tissue
location, patterns of expression and the timing of appearance allows exquisite fine
tuning of cellular immune responses (Luster et al., 2005). The switch from leukocyte
rolling to firm adhesion and activation is initiated by inflammatory chemokines such
as CXCL1, leading to an increase in integrin affinity. Other chemokines such as CCL2
promote transmigration of leukocytes (Blanchet et al., 2012).
Chemokines are produced by a wide variety of cells, from mesenchymal stem cells,
circulating leukocytes and platelets, to endothelial cells. Cognate ligand chemokines
bind chemokine receptors expressed on leukocytes to induce activation. Pro-
inflammatory chemokines circulate in plasma or are limited only to inflamed tissue. In
order to support transendothelial migration inflammatory chemokines are transported
in a luminal direction across endothelial cells by DARC (Pruenster et al., 2009). A
further mechanism recently proposed that lymphocytes can cross inflamed
endothelium through uptake of chemokines stored in intraendothelial vesicles and
released within synapses formed between endothelial cells and lymphocytes, without
the presence of surface-bound chemokines or chemokine gradients (Shulman et al.,
2012). In addition, most chemokines can bind extracellular matrix components,
including glycosaminoglycans (GAGs), being immobilised and presented to
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leukocytes. This avoids chemokines being swept away under flow conditions from the
cell surface. This co-immobilization with adhesion molecules will promote leukocyte
activation, adhesion, and migration.
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1.7 Chemokines and chemokine receptors in haematopoiesis
Chemokines and their receptors have critical roles in the maintenance of normal
haematopoiesis, and in the mobilisation of leukocytes during periods of acute need. As
discussed above, the CXCL12/CXCR4 axis has an indispensable role in retaining HSCs
in the stem cell niche, and in maintaining their quiescence. The
ELR+chemokines/CXCR2 axis in contrast is required for acute leukocyte mobilisation
from the bone marrow reserve, as detailed above. Given the clinical importance in
mobilisation of haematopoietic progenitors for transplantation, this aspect of
chemokine biology in haematopoiesis has received considerable attention in the
literature.
A number of mechanisms for regulating availability of CXCL12 have been described.
The primary receptor for CXCL12, CXCR4, is highly expressed on the HSCs. It has
been known for some time that the atypical chemokine receptor CXCR7 binds CXCL12
and degrades it, acting as a sink for CXCL12 (Luker et al., 2010). Despite evidence
that CXCR7 is expressed on endothelial cells, and has roles in embryonic
development, the function of CXCR7 in the bone marrow has not been explored until
recently. Initial studies in CXCR7 deficient mice have shown a crucial role for this
receptor in B cell, endothelial and cardiac development but these mice have no
obvious haematopoietic phenotype (Sierro et al., 2007). CXCR7 is present in low
levels on the cell surface of monocytes and lymphocytes (Balabanian et al., 2005,
Sanchez-Martin et al., 2011). In HSCs it is abundant intracellularly (Hartmann et al.,
2008), but only recently has its presence on bone marrow CD34+ HSCs cell surface
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been confirmed (Torossian et al., 2014). CXCR7 binds CXCL12, and together with
CXCR4, promotes the effects of CXCL12. This occurs via β-arrestin which is considered
to function as a scaffold protein for modulating signal transduction. Both CXCR4 and
CXCR7 activation were necessary for β-arrestin to phosphorylate Akt, leading to
activation of the PI3k/Akt pathway (Torossian et al., 2014).
Several chemokine receptors are used by pathogens to infect haematopoietic cells.
CXCR4 is utilised by HIV-1 to infect HSC and it is suggested that this would provide a
source of long-term reservoir of latent virus (Carter et al., 2011).
Roles for several chemokines leading to HSC mobilisation have been described. The
first chemokine studied in respect of HSC mobilisation was human CCL3 (MIP-1α),
which stimulated the mobilisation of HSCs in mice, but subsequent clinical trials
showed modest mobilisation with a genetically engineered variant of human CCL3
(Lord et al., 1995, Broxmeyer et al., 1998). CXCL8 can induce stem cell mobilisation
in mice and rhesus monkeys in hours by activating MMP-9 and LFA-1, although the
role of MMP-9 as stated above may be redundant since CXCL8 induces mobilisation in
MMP-9 deficient mice (Laterveer et al., 1995, Robinson et al., 2003). An additional
feature of mobilisation by chemokines is that the mobilisation effect is greater when
combined with G-CSF, compared to mobilisation with either chemokine or G-CSF
alone (Broxmeyer et al., 1999a).
Chemokines also have roles apart from retaining or mobilising HSCs and leukocytes.
One of the first described roles for chemokines in haematopoiesis related to
suppression of myelopoiesis by CCL3, a ligand for CCR1 and CCR5, manifest as
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reduced myeloid proliferation both in vitro (Graham et al., 1990) and following
injection of recombinant murine CCL3 into normal mice (Maze et al., 1992). CCL3
also gives protection to primitive cells from chemotherapeutic agents (Lord, 1995). An
example of malignant cells harnessing this effect has been shown in a murine model
of chronic myeloid leukaemia where high CCL3 levels produced by leukaemic cells
help to maintain and promote leukaemic cell growth in the bone marrow while
mobilising normal HSC from the bone marrow (Baba et al., 2013).
Several other chemokines have been shown in vitro and in vivo to have suppressive
effects on bone marrow myeloid cells (see Table 1.1)
It is not clear why such a large number of chemokines should have this suppressive
effect, although it has been suggested that this may reflect the different cell origins of
these chemokines, and the need to control cell proliferation in the different sites of
action (Youn et al., 2000). CXCL12 has been shown to protect HSC from the effects of
these chemokines, but not against other haematopoietic suppressing cytokines such as
TNF-α, IFN-γ, TGF-β or lactoferrin (Broxmeyer et al., 2005a). In addition to the
mobilising effects of ELR+chemokines/CXCR2 axis, other researchers have confirmed
the proliferation suppressing effects of CXCL8 and CXCL1 (Sanchez et al., 1998). In
contrast, in addition to myelo-suppressive effects, CCL2 binding to CCR2 promotes the
survival of myeloid progenitor cells (Reid et al., 1999).
More recent work has shown that some of the chemokines listed in Table 1.1 have
functions which might not be discerned by in vitro co-culture of bone marrow with
chemokines or their injection into mice. For example, rather than having no effect on
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haematopoiesis, CCL5 has been shown to be more highly expressed in the aged
murine bone marrow, and forced over-expression of CCL5 leads to pro-myeloid HSC
differentiation possibly through increased mTOR signalling in LSK cells (Ergen et al.,
2012).
Utilising CCL3 as an example chemokine, it is clear that chemokines have diverse
actions leading to inhibition or promotion of proliferation of different subpopulations
of myeloid progenitor cells, inhibition of stem cells and mobilisation of stem cells. It
binds to both CCR1 and CCR5, but it remains unclear which of these receptors
mediates the different CCL3 responses (de Wynter et al., 2001), particularly since
both receptors are present in CD34+ bone marrow derived cells (de Wynter et al.,
1998).
Suppressive effects on myelopoiesis No effect
CCL1 CCL20 CCL4
CCL2 CCL21 CCL5
CCL3 CCL23 CCL7
CCL6 CCL24 CCL8
CCL9 CCL25 CCL17
CCL10 CXCL2 CCL22
CCL11 CXCL4 CXCL1
CCL12 CXCL5 CXCL3
CCL13 CXCL6 CXCL7
CCL15 CXCL8 CXCL12
CCL16 CXCL9 CX3CL1
CCL18 CXCL10
CCL19 XCL1
Table 1.1 Documented chemokine effects on myelopoiesis, in vitro or in vivo.
Adapted from (Broxmeyer and Kim, 1999, Broxmeyer et al., 1999b)
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1.8 The atypical chemokine receptors (ACKR)
The ACKR have recently been assigned a new nomenclature numbering them in the
sequence of their discovery: the Duffy Antigen Receptor for Chemokines (DARC),
ACKR1; D6, ACKR2; CXCR7, ACKR3; and CCRL1, also known as CCR11 and CCX-
CKR, ACKR4 (Bachelerie et al., 2014); however, because a large part of the thesis was
written and figures produced before the introduction of the new nomenclature, within
this text and in the figures the old previous naming convention will be used.
Whilst DARC binds up to 20 CXC and CC chemokines, D6 is also promiscuous, binding
at least 12 CC human chemokines. The affinity of chemokines for DARC or D6 vary,
and both receptors modulate the availability of inflammatory chemokines and thus
affect leukocyte trafficking. CCRL1 binds the homeostatic CCL19, CCL21 and CCL25,
and CCRL2 binds chimerin, although affinity for other ligands remains controversial.
CXCR7 binds CXCL11 and CXCL12, the latter with higher affinity. CXCL12 has a
higher affinity for CXCR7 than for CXCR4, its sole signalling receptor.
A common aspect across ACKRs is their serpentine structure with seven
transmembrane domains, akin to that of classical chemokine receptors, but absence of
critical sequence determinants, the DRYLAIV motif, required for coupling to G-
proteins and downstream calcium-fluxed based signalling (Nibbs and Graham, 2013).
Three members of the ACKR family (D6, CCRL1 and CXCR7) will be examined briefly,
and in a separate section, DARC will be reviewed in greater detail.
64
1.8.1 D6 (ACKR2)
D6 is expressed in leukocytes such as B cells, of the spleen and those residing in body
cavities. It has also been shown to be expressed on some DCs, monocytes, T cells and
neutrophils. In addition, D6 is expressed on lymphatic endothelial cells lining the
lymphatics of the skin, gut, lungs and lymph nodes. Interestingly, the highest
expression in human is within the placental trophoblasts, in contact with maternal
blood. Hepatocytes express this receptor, and it is upregulated in skin keratinocytes in
psoriasis.
D6 constitutively traffics from the intracellular stores to the cell surface, where it
captures chemokines, internalises them to target the chemokine cargo for lysosomal
degradation, after which D6 is returned to the surface of the cell.
Overall the main function of D6 is clearing inflammatory CC chemokines as for
example from lymphatic endothelial cell surfaces during inflammation, suppressing
the interaction of these cells with immature DCs which have been recruited and are
expressing inflammatory CC chemokine receptors (Nibbs and Graham, 2013).
1.8.2 CXCR7 (ACKR3)
CXCR7 is activated by its ligands CXCL11 and CXCL12 and induces β-arrestin
mediated intracellular signalling in the absence of G-protein-mediated Ca2+ associated
signalling (Zabel et al., 2009). Moreover CXCR7 regulates the localisation and
signalling of CXCR4, and a scavenging function for CXCR7 akin to that of D6 has been
put forward (Naumann et al., 2010). CXCR7 expression is present on vascular
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endothelial cells in the brain, tumours, during inflammation and in embryonic life
(Sierro et al., 2007, Goguet-Surmenian et al., 2013). Lymphatic endothelial cells may
express CXCR7 in the tonsils or kidneys in acute allograft rejection (Neusser et al.,
2010).
CXCR7 has been detected in the inflamed synovia of rheumatoid arthritis patients,
and in murine arthritis models. CXCR7-antagonist treated animals with experimental
arthritis developed less neovascularisation, implying a role for this ACKR in
angiogenesis. Within the CNS CXCR7 enhances the movement of leukocytes into the
brain parenchyma (Nibbs and Graham, 2013).
1.8.3 CCRL1 (ACKR4)
CCRL1 internalises its ligands CCL19, CCL21 and CCL25, a process leading to their
lysosomal degradation. It is expressed on lymphatic endothelial cells but is restricted
to those lining the ceiling of the subcapsular sinus of resting lymph nodes (Ulvmar et
al., 2014). Furthermore CCRL1 is expressed by cortical thymic epithelial cells and
keratinocytes (Nibbs and Graham, 2013). CCRL1 within the skin controls the
distribution of its ligands and hence aids DC migration, while in the lymph node it
modulates the distribution of its ligands to pattern functional chemokine gradients to
preserve receptor responsiveness to chemokine signals for peak CCR7-directed
migration into the lymph node (Ulvmar et al., 2014). Its role in the thymus appears to
be that of controlling lymphocyte maturation and selection process, as CCRL1-
deficient mice spontaneously develop autoimmunity (Nibbs and Graham, 2013).
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1.9 The Duffy Antigen Receptor for Chemokines (ACKR1)
The content of this section has been reviewed in part by the author previously in
Novitzky-Basso and Rot, 2012, and others (Ulvmar et al., 2011, Pruenster and Rot,
2006).
1.9.1 The Duffy blood group
The Duffy antigen / receptor for chemokines (DARC) was first described as a blood
group determinant in 1950 (Cutbush and Mollison, 1950, Cutbush et al., 1950) in the
investigation of a multiply transfused eponymous haemophiliac (Mr Duffy) who had
developed a delayed haemolytic transfusion reaction due to a previously unknown
antibody, termed anti-Fya, detectable only by the indirect anti-globulin test (IAT). In
the following year, an antibody to the second antithetical antigen of the new blood
group, Fyb, was found in a multigravida having presumably been exposed to foetal Fyb
erythrocytes (Ikin et al., 1951). None of her children had shown any features of
haemolytic disease of the foetus or new-born (HDFN). In due course, three
phenotypes were described: Fy(a+b–), Fy(a–b+) and Fy(a+b+), sometimes referred
to as ‘Duffy-positive’, arising from combinations of the antithetical co-dominant FYA
and FYB genes which have frequencies of 0.425 and 0.557 (Klein and Anstee, 2005).
In several human populations neither Fya nor Fyb antigens are expressed, with the
phenotypic designation Fy(a–b–) (or ‘Duffy-negative’). This results from a
polymorphic form of the FYB gene, termed FYB(ES), or “erythroid silent”, present in
up to 99% of West Africans and the majority of African Americans (68%) (Mourant et
al., 1976).
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1.9.2 The DARC gene and gene expression
The Duffy gene, termed DARC, is located on chromosome 1, position 1922 and
segregates with Un locus, and was the first gene in humans allocated to an autosome
(Donahue RP, 1968). Initial sequencing of the corresponding cDNA revealed a
glycoprotein of 338 amino acids (Chaudhuri et al., 1993) and was considered to be
encoded by a single exon (Chaudhuri et al., 1993, Chaudhuri et al., 1995, Iwamoto et
al., 1995, Tournamille et al., 1995); subsequently it became clear that in all examined
tissues the principal transcript of the Fy gene represented two exons interleaved with
a 479 base pair intron, and that the protein consisted of 336 amino acids (Iwamoto et
al., 1996). The first exon encodes a methionine codon initiating translation, and the
seven N-terminal amino acids, giving the sequence MGNCLHRAEL for the major
transcript (Iwamoto et al., 1996). The minor transcript encodes MASSGYVLQAEL
which is two amino acids longer (Chaudhuri et al., 1993), as the sequence which
encodes the 9 N-terminal amino acids is in fact part of the intron of the major
transcript (Iwamoto et al., 1996). As there is more than one transcript, in this thesis,
nucleotides and amino acids will be numbered from the methionine residue of the
first transcript where translation is initiated, unless otherwise stated (as in Chapter 8,
‘Duffy blood group system’, in Daniels, 2002).
Following the first exon of the DARC gene, there is a consensus splice donor sequence,
the intron and subsequently the second exon containing the majority of the open
reading frame (Iwamoto et al., 1996). The two principle alleles FYA and FYB differ in
one base substitution (125 G to A) in codon 42 in the NH2 extracellular domain,
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encoding glycine in Fya and aspartic acid in Fyb (Chaudhuri et al., 1995, Iwamoto et
al., 1995), while the FYB(ES) allele has a single T to C substitution at nucleotide -67,
33bp upstream from the erythroid transcription starting point and 46bp upstream
from the start of the major transcript translation codon, within the erythroid GATA-1
promoter region of the FYB allele, terminating transcription in erythroid cells only
(Tournamille et al., 1995). This mutation (SNP rs2814778) will henceforth be termed
T-46C as it is used frequently in the literature (Tournamille et al., 1995). The major
erythroid transcription starting point was identified at 33 base pairs upstream from
the first ATG. In RNA from kidney and lung tissue, the transcription is initiated 82
base pairs upstream from the ATG (Iwamoto et al., 1996). This may explain in part
the different transcription patterns seen in erythroid tissues compared with other
tissues, possibly allowing differential regulation in response to inflammation.
Confirming this, RNA blot analysis detects 1267bp mRNA in the bone marrow of
Duffy-positive but not Fy(a–b–) individuals (Chaudhuri et al., 1995). The same size
mRNA is identified in most extra-erythroid tissues (Chaudhuri et al., 1993, Neote et
al., 1994); however in brain, a prominent 7.5kb and minor 1.35kb mRNA were
detected (Chaudhuri et al., 1993). In the cerebellum the 7.5kb transcript is highly
expressed, whereas the 1.35kb transcript was prominent in the spinal cord; in other
parts of the brain both transcripts are poorly expressed (Le Van Kim et al., 1997).
However, the DARC glycoprotein expressed in the cerebellum is identical to forms in
other tissues encoded by the 1.35kb transcript. Here it is likely a different promoter
leads to a larger transcript in the 5’ untranslated sequence although the final protein
is the same (Le Van Kim et al., 1997). Finally, tissue localisation and degree of extra-
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erythroid DARC expression is similar across FYA, FYB and FYB(ES) genotypes
(Chaudhuri et al., 1995, Chaudhuri et al., 1997). FYB(ES) Fy(a–b–) individuals still
express DARC at non-erythroid sites, particularly on post-capillary venules of all
tissues, and other sites such as Purkinje cells, and renal and alveolar epithelium
(Peiper et al., 1995, Horuk et al., 1997, Chaudhuri et al., 1997). The importance of
this site-specific loss of DARC expression was demonstrated when Miller and
colleagues revealed in 1976 that volunteers with Fy(a–b–) phenotype exposed to the
bites of Plasmodium vivax-infected mosquitoes did not develop malaria (Miller et al.,
1976), in contrast to their Duffy positive counterparts, thus confirming the long
standing clinical observation that African populations appeared resistant to this form
of malaria, noted particularly during the treatment of neurosyphilis by therapeutic P.
vivax inoculation (Boyd and Stratman-Thomas, 1933, O’Leary, 1927). Further work
showed that this parasite requires DARC for entry into the erythrocytes (Horuk et al.,
1993a, Miller et al., 1975), leading to the hypothesis that the Fy(a–b–) phenotype
evolved as a result of selective pressure to protect its carriers from vivax but not
falciparum malaria (see Figure 1.8).
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Recent geostatistical modelling maps demonstrating Fy(a–b–) populations (Howes et
al., 2011) where the prevalence of this phenotype approaches 1 in West Africa, have
approximate overlap with areas of expected but absent P. vivax infection (Guerra et
al., 2010). However it appears that this resistance is not complete, as some Fy(a–b–)
a
b
Figure 1.8 Global DARC allele and malaria distribution. a) Global frequencies of DARC alleles. Areas a single
allele is dominant are represented by a colour gradient (blue, FYA, green, FYB, red/yellow, FYB(ES)). Areas in
which no allele predominates, and 2 or more alleles each have frequencies >20% are in grey-scale. From King
et al., 2011.
b) The global distribution of P. vivax malaria transmission in 2009. Risk areas: pale pink, low risk; dark
pink/red, high risk; and hatched area, predicted Duffy negativity >90%. From Guerra et al., 2010.
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populations in Madagascar (Menard et al., 2010), both carry parasites
asymptomatically and experience symptomatic vivax malaria. Researchers in the
Brazilian state of Pará found that P. vivax resistance between Duffy-positive and –
negative individuals was not different, although the power to detect this was low
owing to only 4.3% individuals harbouring FYB(ES). Other researchers have noted
similar findings, (Ryan et al., 2006, Cavasini et al., 2007b), while a larger PCR-based
study examining 9 African countries with over 2500 samples reported only one
positive individual, who was also Duffy-positive (Culleton et al., 2008). However P.
vivax remains transmissible in these areas given the reports of European individuals
contracting P. vivax malaria on returning from travel in these areas (Phillips-Howard
et al., 1990, Mendis et al., 2001). Therefore the study in Madagascar is of particular
interest since greater lengths were taken to validate PCR-positivity of P. vivax also by
microscopy. Indeed, the first observation confirming Duffy-independent P. vivax blood
infection and development was reported in this study. In addition, analysis of the
DARC gene DNA sequence confirmed that the Duffy-negative allele isolated in
Madagascar was identical to the FYB(ES) allele present in West African subjects.
Finally, other Duffy-negative people in Ethiopia (Woldearegai et al., 2013) Mauritania
(Wurtz et al., 2011), Equatorial Guinea and Gabon (Mendes et al., 2011) have been
found to be P. vivax positive by PCR analysis.
Remarkably an FYA polymorphism with the T-46C change, identical to that in
FYB(ES), has been observed in Papua New Guinea, in an area endemic for P. vivax.
This mutation leads to reduced Fya expression and consequent resistance to vivax
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malaria infection (Zimmerman et al., 1999, Shimizu et al., 2000, Kasehagen et al.,
2007).
The susceptibility of individuals to P. vivax based on common DARC genotypes has
been examined more recently. When compared to the FYA/FYB genotype, individuals
with the FYA/FYB(ES) and FYA/FYA genotypes have 80% and 29% reduced risk of
clinical disease due to vivax malaria, respectively. In keeping with the stronger affinity
between the FyB variant of DARC and P. vivax Duffy binding protein, subjects with
the FYB/FYB(ES) and FYB/FYB genotypes had a 220–270% increased risk of clinically
apparent vivax malaria when compared to FYA/FYB and FYB/FYB (King et al., 2011),
and no association between DARC genotype and susceptibility for P. falciparum was
detected. Supporting these data, Cavasini et al., 2007a noted the FYA/FYB(ES)
genotype was found to be less frequent among patients with P. vivax than among 330
healthy blood donors. It appears that like the FYB(ES) allele, FYA has increased in
frequency in P. vivax endemic regions (leading to very high frequency in some
populations) possibly selected by the higher resistance against P. vivax malaria (King
et al., 2011).
Other genes described altering Fy expression include a C265T mutation in FYB
leading to the FYX allele and resulting in the “Fyb weak” phenotype, with a 90%
reduction in the expression of Fy protein on erythrocytes (Tournamille et al., 1998),
and associated with a gene frequency of approximately 2.5% in Caucasians (Olsson et
al., 1998). The G298A mutation leading to the Ala100Thr polymorphism has been
noted to have a relatively high allelic frequency of 16.5% amongst Caucasian donors,
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although it does not affect antigenic expression. This was not detected amongst any
samples from black South Africans (Olsson et al., 1998).
As indicated above, Fya and Fyb antigen frequencies amongst human populations vary.
In the Far East, Fya is approximately 90% prevalent, whereas Fyb prevalence is less
than 10% (Lewis et al., 1957, Shimizu et al., 2000). In contrast Fyb is more common
in Europeans than Fya (Chown et al., 1965, Lewis et al., 1972). Due to racial
admixture, after the Fy(a–b–) phenotype, Fyb is also expressed in African, African
American and African European populations although clearly much less frequently
than among Europeans.
1.9.3 The nature of Fy antigens and DARC structure
DARC is modelled as a hepta-spanning transmembrane glycoprotein (Neote et al.,
1994) consisting of 336 amino acids with a total molecular weight of 35733
(Chaudhuri et al., 1993) (See Figure 1.9). DARC was originally predicted to have 9
trans-membrane domains (Chaudhuri et al., 1993), but it became clear that like other
chemokine receptors there are seven α-helices as transmembrane domains (Neote et
al., 1994). An amino-terminal extracellular domain of 65 amino acids harbours 3
potential N-glycosylation sites at residues 16, 27 and 33 (Czerwinski et al., 2007), as
well as epitopes Fya, Fyb and Fy6 (Tournamille et al., 2003). Fya and Fyb epitopes are
destroyed by enzyme treatment with papain but not trypsin (Morton, 1962, Klein and
Anstee, 2005), and Fya is inactivated by neuramidase (Hadley et al., 1986). Fy
antigens appear to elute from red cells during their storage (Williams et al., 1981),
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possibly consistent with observations detecting red cell microparticles with Fy
expression in blood (Oreskovic et al., 1992, Xiong et al., 2010). The number of Fya
antigens is approximately 13300 per Fy(a+b–) erythrocyte, whilst on each Fy(a+b+)
erythrocyte there are an estimated 6900 Fya antigens (Masouredis et al., 1980).
Reticulocytes have up to 49% higher Fy antigen expression compared with mature red
cells (Woolley et al., 2000). Fy(a–b–) cells lack complete expression of both Fya and
Fyb, as well as of Fy3 and Fy6, having initially been defined by sera of sensitised
Fy(a-b-) humans and a mouse monoclonal antibody (Nichols et al., 1987),
respectively. Proteolytic enzyme treatment of red cells enhances the reactivity of Fy3,
whereas Fy6, like Fya and Fyb, is susceptible to degradation by this process (Klein and
Anstee, 2005).
The Fy6 antigen is present within the region of residues Q19 and W26, where the P.
vivax Duffy binding protein (cystein-rich region II) has been demonstrated to bind;
hence anti-Fy6 antibodies have been shown to inhibit the invasion of human
erythrocytes by P. vivax (Tournamille et al., 2005).
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Figure 1.9 Schematic representation of DARC showing the amino acid (aa) residues that are crucial for anti-Fy
antibody and chemokine binding. Function of aa residues contained in the extracellular domains: black, critical
for CXCL8 binding; grey, not involved in CXCL8 binding. AA residues required for Fya and Fy6 epitopes, and
recognised by the 655 and 2c3 monoclonal antibodies respectively, depicted. Stars emphasise the aa residues
participating in the Fy3 epitope recognised by the CRC-512 anti-Fy3 antibody. Suggested disulphide bridges
are indicated by broken arrows. Adapted from Tournamille et al., 2003
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1.9.4 Clinically significant antibodies of the Duffy blood group
system
Most anti-Fya and anti-Fyb are predominantly IgG1 (Hardman and Beck, 1981,
Szymanski et al., 1982), and in about half of those cases studied both antibodies were
able to activate complement. Anti-Fya is very rarely naturally occurring, and typically
follows transfusion and much less commonly after pregnancy. Anti-Fya is often only
detected by indirect antiglobulin testing (IAT) with agglutinating activity developing
following antigenic stimulation, similar to anti-D and anti-K. Fya has been shown to be
significantly more immunogenic in Fy(a–b+) subjects than in those Fy(a–b–). Four
and eleven patients were Fy(a–b–) in two series of 25 and 130 patients with anti-Fya ,
respectively (Kosanke, 1983, Vengelen-Tyler, 1983). Fy(a+b–) red cells suspended in
saline will be agglutinated by anti-Fya, and may react with these cells more strongly
than Fy(a+b+) cells (Race et al., 1953). Anti-Fyb is 20 times less frequent than anti-
Fya, and is typically identified with other allo-antibodies. Both antibodies have been
shown to cause both immediate and delayed haemolytic transfusion reactions (Klein
and Anstee, 2005).
Anti-Fy3 reacts with all human red cells apart from Fy(a–b–) cells, and was initially
described in a Caucasian female transfused following her second delivery, then
pregnant with her third child (Albrey et al., 1971), with subsequent mild HDFN. The
newly detected antibody reacted with Fy(a+b–), Fy(a–b+) and Fy(a+b+) cells but
not Fy(a–b–) cells, and could not be separated into Fya or Fyb specificities. Surprisingly
despite the overwhelmingly higher frequency of Fy(a–b–) in persons of African origin,
77
relatively few examples of this antibody are reported in the literature (Oberdorfer et
al., 1974, Oakes et al., 1978). This is likely to be due to ongoing expression of Fyb on
non-erythroid tissues in these individuals. Nevertheless, as some individuals do
develop antibodies, anti-Fy3 may develop as a result of a different genetic cause for
the Fy(a–b–) phenotype, or alternatively as a result of post-translational differences
between erythrocyte Fy and endothelial Fy protein. (Notably anti-Fy3 taken from
African persons reacted weakly with cord cell samples (Oakes et al., 1978, Kosinski
KS, 1984), whereas anti-Fy3 from those of other ethnic origins reacted clearly with
red cells from adults and neonates (Buchanan et al., 1976)
Anti-Fy4 reacts with Fy(a–b–) cells, some Fy(a+b–) or Fy(a–b+) but no Fy(a+b+)
erythrocytes. Owing to inconsistent results between laboratories, there is even doubt
as to its existence (Behzad et al., 1973), particularly as it is singularly described in the
literature.
Anti-Fy5 was reported in an a black child of Fy(a–b–) phenotype with leukaemia
(Colledge et al., 1973), and this antibody reacts with most red cells except Fy(a–b–)
Rhnull phenotype or those carrying variant forms of the Rh ‘e’ antigen. Anti-Fy5
appears to arise as a result of an interaction between Fy and Rh blood groups, and has
been reported to cause delayed haemolytic transfusion reactions in patients with
sickle cell disease, who usually develop this antibody along with other Rh group or Fy
antibodies (Chan-Shu, 1980).
Anti-Fy6 is a monoclonal mouse anti-human antibody and has been used to block
malarial invasion of erythrocytes, as well as demonstrate the presence of DARC on
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erythroid and other tissues (Nichols et al., 1987), and block chemokine binding
(Horuk et al., 1993a). Human antibodies recognising Fy6 epitope have not been
reported to date.
1.9.4.1 Clinical aspects of anti-Duffy antibodies
Duffy antibodies are not a common cause of haemolytic transfusion reactions, but
there is considerable experience in Fy(a–b–) multiply transfused patients, usually in
the setting of sickle cell disease and the presence of multiple allo-antibodies. In this
context, implicated Fy system antibodies are usually anti-Fya (Le Pennec et al., 1987)
or occasionally anti-Fy3, and particularly this latter antibody can lead to significant
difficulties in the provision of numerous units of suitable blood, given the under-
representation of donors of African origin in many Western donor populations. It has
been noted that anti-Fy3 develops after anti-Fya in persons having received multiple
red cell transfusions for sickle cell disease (Vengelen-Tyler, 1985).
HDFN can be caused by Fy antibodies. The prevalence of anti-Fya during pregnancy is
up to 5.4 percent (Goodrick et al., 1997), while Fyb antibodies are far less common
and have been found to cause only mild HDFN. A case series revealed that only 2 of
18 neonates required exchange transfusion for low haemoglobin due to anti-Fya
related HDFN, with no cases requiring intra-uterine transfusion or early delivery
(Hughes et al., 2007), although another noted that 2 intra-uterine transfusions were
required for severe anaemia out of 68 pregnancies in which anti-Fya was detected
(Goodrick et al., 1997). Hence anti-Fya can lead to severe HDFN in a small number of
cases, and correspondingly alloimmunised pregnancies should be monitored closely.
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1.9.5 The Duffy antigen, as a receptor for chemokines
The Duffy blood group antigen was recognised as a chemokine receptor during the
investigation of a promiscuous chemokine binding protein on erythrocytes (Darbonne
et al., 1991, Neote et al., 1993, Horuk et al., 1994), and this lead to its designation as
the Duffy antigen / receptor for chemokines. As already mentioned, Fy(a–b–)
individuals with the FYB(ES) genotype continue to express endothelial DARC (Peiper
et al., 1995), and this tissue localisation of DARC has been investigated further,
particularly in its role pertaining to chemokine homeostasis. DARC binds at least 20
human inflammatory chemokines of the CC and CXC families with varying affinity
(Darbonne et al., 1991, Neote et al., 1993, Horuk et al., 1994, Gardner et al., 2004,
Szabo et al., 1995) (See Table 1.2 from most recent study).
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The structure of DARC is very similar to other chemokine receptors, but in notable
contrast, DARC does not have the aspartyl-arginyl-tyrosine (DRY-) motif found in the
second intracellular loop of all other chemokine receptors which couples them to G
proteins and is required for GPCR signalling and triggering of intracellular calcium
flux (Neote et al., 1994). The extracellular N-terminal domain of DARC carrying the
blood group determinant and P. vivax binding regions forms, in combination with the
Strong binding Weak binding No binding
Chemokine Ki (nM) Chemokine Ki (nM) Chemokine Ki (μM)
CCL5 (RANTES) 5.6 CCL8 (MCP-2) 151.0 CXCL12 (SDF-1α) >1
CCL7 (MCP-3) 6.6 CXCL9 (MIG) 162.0 CCL3 (MIP-1α) >1
CXCL11 (I-TAC) 12.7 CCL18 (PARC) 206.2 CCL4 (MIP-1β) >1
CXCL8 (IL-8) 21.3 CCL16 (HCC-4) 257.7 CCL19 (ELC) >1
CXCL5 (ENA-78) 28.8 CXCL13 (BLC) 304.5 CCL20 (LARC) >1
CCL13 (MCP-4) 32.8 CCL1 (I-309) 309.3 CCL21 (SLC) >1
CCL2 (MCP-1) 34.9 CXCL10 (IP-10) 622.4 CCL22 (MDC) >1
CCL17 (TARC) 58.0 CCL23 (MPIF-1) >1
CXCL6 (GCP-2) 66.7 CCL25 (TECK) >1
CCL11 (Eotaxin) 67.3 CCL27 (CTACK) >1
CCL14 (HCC-1) 91.8 XCL1(Lymphotactin) >1
CX3CL1
(Fractalkine) >1
Table 1.2 Chemokine binding to the human Duffy antigen.
Chemokines were divided into three categories based on Ki values: those showing strong binding (Ki < 100 nM),
weak binding (Ki = 100 nM–1 μM), and no binding (Ki > 1 μM). The chemokines are named according to the
new nomenclature with the former nomenclature in parentheses. Results shown are geometric means of three
separate determinations. CXCL4 is not included, but is suggested to be a weak DARC ligand (Szabo et al., 1995).
From Gardner et al., 2004.
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fourth extracellular domain via a disulphide bond, a “pocket” with promiscuous
chemokine binding properties (Tournamille et al., 1997, Tournamille et al., 2003).
DARC cDNA has significant similarities with rabbit and human CXCL8 receptors,
which also bind inflammatory chemokines with high affinity (Chaudhuri et al., 1993).
Given the absence of any detectable cell signalling following cognate chemokine
binding to DARC in the form of measurable calcium flux (Neote et al., 1994)
alterations in GTPase activity (Horuk et al., 1993b) or gene transcription (Lee et al.,
2003b), this receptor was postulated to act as a chemokine decoy. However, in vitro
models have demonstrated that following chemokine binding, DARC is redistributed
from the basolateral membrane via an intracellular vesicular compartment onto the
apical membrane and was associated in particular with microvilli (Pruenster et al.,
2009). Only cognate chemokines are transported and minimal degradation of
chemokines occurs. Supporting these findings, it has been shown that monocyte and
neutrophil migration toward cognate chemokine was enhanced across an endothelial
monolayer expressing DARC (Lee et al., 2003b, Pruenster et al., 2009). This was
confirmed in vivo by intradermal and intraperitoneal injection of CXCL1 into
transgenic mice which over-expressed DARC on the endothelium, revealing
significantly greater neutrophil recruitment in the mice overexpressing DARC,
compared with wild-type animals (Pruenster et al., 2009). The likely biological role of
DARC appears therefore to be internalisation and transport of chemokines across
endothelial cells, and enhancement of leukocyte recruitment.
Although internalisation of chemokines by DARC does not lead to their degradation,
DARC may still remove chemokines from extracellular environments, and thus e.g.
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negatively influence angiogenesis induced by pro-inflammatory chemokines. This was
demonstrated using mice over expressing endothelial DARC which had reduced
angiogenic responses to CXCL2 (Du et al., 2002). In the context of tumour related
vascularisation, reduced angiogenesis and decreased melanoma tumour growth was
observed in mice overexpressing endothelial DARC (Horton et al., 2007), but tumours
contained greater numbers of infiltrating leukocytes in comparison to control mice,
which supports a role for endothelial DARC in promoting leukocyte migration. The
angiogenesis attenuating effect has been confirmed using implanted DARC transfected
breast cancer lines, with DARC expression also leading to reduction of tumorigenesis
and metastasis.
DARC-expressing non-small cell lung cancer tumours transplanted into SCID mice had
increased necrosis and reduced cellularity in contrast to DARC deficient control
tumours (Addison et al., 2004). DARC deficient mice used in a transgenic model of
prostate cancer developed tumours with increased vessel density, greater intratumour
angiogenic chemokine levels and augmented tumour growth (Shen et al., 2006).
CD82, a tetraspanin, was identified as a prostate cancer metastasis suppressor gene,
and in the investigation of its function, it was demonstrated that attachment by
metastatic cancer cells to the vascular endothelium occurred through direct
interaction with DARC, consequently resulting in growth arrest of cancer cells and the
induction of senescence. Furthermore, DARC KO mice were shown to have increased
prostate cancer metastasis in comparison with controls (Bandyopadhyay et al., 2006).
Clinical data also support the negative regulatory role of DARC in tumour progression.
Patients with breast cancers with high DARC expression have had better survival than
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those with DARC-negative tumours, with additional negative correlation between
DARC expression and lymph node metastasis (Wang et al., 2006). It appears therefore
that DARC has direct and indirect effects on tumour development and metastatic
spread, at least in part by removing angiogenic chemokines from the extracellular
environment.
A further functional facet of DARC activity may reflect its ability to affect the
signalling by classical chemokine receptors expressed in cis geometry with DARC.
DARC was shown to heterodimerise with CCR5 leading to reduced calcium flux and
chemotaxis in respond to the CCR5-cognate chemokines (Chakera et al., 2008).
Internalisation of CCR5 ligand binding however was unaffected by DARC.
1.9.5.1 The role of DARC in chemokine homeostasis
Erythroid DARC was originally described as a “sink” for chemokines (Darbonne et al.,
1991) and this function was further supported when DARC was shown to reduce
excessive increases in blood-borne inflammatory chemokines, dampening the
subsequent activation of leukocytes (Dawson et al., 2000). It is thought that
erythrocyte DARC may serve in the preservation of leukocyte sensitivity to ELR+
chemokines by shielding blood leukocytes from overstimulation of their receptors and
associated desensitisation. However, evidence suggests that previous exposure to
chemokines may lead to leukocyte priming for enhanced chemokine induced
migration (Brandt et al., 1998) or other effects induced by different chemokines
(Green et al., 1996, Hauser et al., 1999). These two opposing potential outcomes may
help explain conflicting observations in DARC deficient mice exposed to inflammatory
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stimuli (Dawson et al., 2000, Luo et al., 2000, Mei et al., Vielhauer et al., 2009,
Reutershan et al., 2009, Zarbock et al., 2010), which will be discussed henceforth. An
initial study (Dawson et al., 2000) administered LPS to mice, and a marked increase
in neutrophil infiltrate in the lungs and livers of DARC KO animals was described.
Contemporaneous to this, another group (Luo et al., 2000) using a similar
methodology described decreased lung and peritoneal neutrophil recruitment in
DARC KO animals. However in a subsequent retraction of this paper the authors
stated that their own re-analysis of data apparently produced findings consistent with
increases in LPS-induced neutrophil infiltrate in organs of DARC KO mice. Using
different methodology, Lee and colleagues (Lee et al., 2003a), instilled human CXCL8
into pulmonary airspace of DARC KO mice and observed significantly less leukocyte
infiltrate in the broncho-alveolar lavage. This latter group subsequently undertook
studies which more closely examined the differential roles of DARC on erythrocytes
and endothelium using bone marrow chimeric mice (Lee et al., 2006b). It was
demonstrated that following intra-tracheal LPS instillation, mice lacking erythrocyte
DARC showed significantly fewer airspace neutrophils. The lack of endothelial or lung
parenchymal DARC was associated with higher chemokine concentrations in the
airspaces compared with experiments where DARC was absent on erythrocytes. The
authors suggest that DARC in different sites alters the availability of chemokines
produced during inflammation and that the overall effect of DARC is to reduce
chemokine concentrations in the airspace, lung tissue and to increase plasma
chemokine concentrations. However, another group published conflicting findings
describing diametrically opposite outcomes. Reutershan et al., 2009, studied
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neutrophil recruitment following a higher dose LPS inhalation in a DARC KO model of
acute lung injury, and showed increased neutrophil migration into the alveolar space
in DARC KO animals, along with elevated CXCL1, 2 and 3. In chimeric animals, the
absence of haematopoietic DARC appeared to be the most significant factor in
determining leukocyte trafficking.
The likely reason for the different results may be due to the degree of injury: more
severe LPS induced injury is likely to be associated with increased microvascular
permeability and reductions in inflammatory chemokines. It is suggested that the role
for erythroid DARC as a sink becomes more significant (Reutershan et al., 2009), by
limiting excessive leukocyte infiltration into tissues and thereby opposing the
pro-inflammatory properties of endothelial DARC. Of note RBC-bound chemokine
concentrations during severe systemic inflammation amounted to 30% of plasma
chemokine concentration suggesting a limited sink effect of erythrocyte DARC during
severe inflammation (Reutershan et al., 2009). This result would need verification as
others have noted several hundred fold increases in chemokines from erythrocyte
lysates following endotoxin challenges in humans (Mayr et al., 2008).
Further investigation into the role of DARC in acute lung inflammation revealed that
DARC deficiency in mice results in down-regulation of CXCR2 on neutrophils because
of high levels of circulating chemokines during severe inflammation (Zarbock et al.).
DARC was essential for chemokine mediated leukocyte recruitment, in that DARC KO
animals were protected from acid induced lung injury and experienced preserved
oxygenation, lack of neutrophil recruitment and lower BAL fluid protein levels. This
was suggested to occur as a result of impaired leukocyte arrest on endothelial cells
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and a block on pulmonary neutrophil recruitment during severe lung injury. Using a
system of adoptive transfer of neutrophils, the latter effect was shown to be
dependent on neutrophils and independent of endothelial cells and erythrocytes,
suggesting that the role of DARC is in the maintenance of homeostasis between
receptors and cognate ligands. In addition further protection was conferred by
reduced neutrophil-platelet aggregates, which are instrumental for further neutrophil
recruitment and acute lung injury. CXCR2 blockade reversed this, and also reversed a
platelet related bleeding defect also observed in this study.
Renal models of inflammation have shown that DARC deficient mice are protected
from ischaemic and LPS induced acute renal injury. Furthermore, chemokine
presentation on renal endothelial cells was absent, and renal neutrophil recruitment
was impaired, in the context of lower inflammatory chemokine levels during systemic
inflammation (Zarbock et al., 2007). In contrast however, Vielhauer and colleagues
(Vielhauer et al., 2009) used two models of prolonged renal inflammation (tubule-
intestitial and glomerulonephritic) in DARC deficient mice, demonstrating effective
leukocyte infiltration of kidneys, which was even enhanced in the early phases.
However this accelerated recruitment of leukocytes did not result in worse or altered
renal injury at later time points. Macrophage and T lymphocytes were recruited
equally well in DARC KO and wild-type mice, suggesting that DARC does not
influence disease progression.
Both human and murine studies suggest that DARC can sustain inflammatory
chemokines levels on erythrocytes and in plasma (Jilma-Stohlawetz et al., 2001,
Fukuma et al., 2003), but the purpose of this is not clear. When investigated on DARC
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KO mice, basal plasma CCL2 (MCP-1) levels were noted to be one third lower in the
knock-out animals. When eotaxin (CCL11) or hMGSA (CXCL1) were administered
intravenously, levels of these chemokines fell more rapidly in the plasma of the DARC
KO animals (Fukuma et al., 2003). In humans, healthy volunteers phenotyped Fy(a–
b–) were noted to have significantly lower CCL2 levels than other Fy phenotypes
(Jilma-Stohlawetz et al., 2001). Using a human endotoxaemia model of inflammation,
this group (Mayr et al., 2008) subsequently administered endotoxin to Fy positive or
negative subjects, and noted higher peak levels of plasma CCL2 in Fy-positive subjects.
CCL2 and CXCL1 levels but not CXCL8 or CCL4 (MIP1-β) were higher in erythrocyte
lysates in Fy positive individuals at baseline, and CCL-2 and CXCL8 but not CCL4
increased significantly in Fy-positive subjects following endotoxin. Given that CXCL8
(Wong et al., 2008) and CCL2 (Bozza et al., 2007) levels have been shown to be
predictive of survival and correlate with sepsis severity, it might be tempting to
speculate that the loss of DARC expression may lead to loss of a buffering or sink
activity as possibly provided by DARC. However it has been recently suggested that
chemokines with different DARC binding affinities can affect the levels of other
chemokines bound either on erythrocyte DARC or present freely in the plasma,
affecting resultant leukocyte responses (Mei et al., 2010) by inducing changes in the
sensitivity of relevant receptors. These findings are also in concordance with the
conclusions by Zarbock et al., 2010. In addition heparin and activated coagulation
factors elute chemokines off erythrocyte DARC (Schnabel et al., 2010). Thus the
methods used to take blood or using serum or plasma introduce additional variables
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which further obscure our understanding of the role of erythrocyte DARC in
chemokine homeostasis.
Recently, differences in plasma and serum chemokine levels were reported in persons
with DARC variants Fya or Fyb (Schnabel et al., 2010), and although the mechanism
for this is not yet apparent, a further genome-wide study supported this finding in
Hispanic children (Voruganti et al., 2012). Further work revealed Fy(a–b+) RBCs
possess reduced surface DARC expression compared to Fy(a+b–) RBCs. It is already
known there are fewer antigenic sites on Fy(a–b+) cells; however, surface DARC
binding affinity for chemokines was not appreciably different between the two
phenotypes (Xiong et al., 2010). The impact of differential chemokine levels between
Fy serotypes on human disease therefore requires further investigation.
As discussed above, DARC, expressed on venular endothelial cells, (Peiper et al.,
1995, Chaudhuri et al., 1997, Kashiwazaki et al., 2003), functions as a transcytosis
receptor transporting chemokines from the baso-lateral to the apical side only
(Pruenster et al., 2009). Thus, DARC expression is important for chemokine-induced
leukocyte migration. DARC is expressed and upregulated in veins, and appears in
vessels usually devoid of it, in the context of inflammation, infection and transplant
rejection (Geleff et al., Bruhl et al., 2005, Gardner et al., 2006, Lee et al., 2003a, Liu
et al., 1999, Patterson et al., 2002, Segerer et al., 2000). It is not clear whether DARC
over-expression is a consequence of the development of these lesions or a pre-
requisite. A further potential function for DARC may be one of elimination of
chemokines from tissues by transcytosis across venular endothelial cells, although it is
probably more likely to occur in most tissues by chemokines diffusing between
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endothelial cells, or alternatively via lymphatics. Although lymphatic vessels do not
express DARC, a small segment, termed the podoplanin-dull precollectors, have been
shown to express DARC. This suggests that chemokine mediated cell trafficking may
occur in this section of the lymphatic vasculature (Wick et al., 2008).
1.9.6 DARC and human disease
1.9.6.1 Ethnic neutropaenia
The consequences of loss of erythrocyte DARC expression, as observed in populations
homozygous for FYB(ES), is little understood. Recently genome wide association
studies have linked benign ethnic neutropaenia to persons with this genotype. The
first report aimed to study the entire genome for a locus that would account for the
difference in white blood counts between North American populations of African and
European ancestry. Admixture mapping was used to analyse data from 6005 African
Americans and demonstrate that the only causal variant was the FYB(ES) genotype (P
= 3.8 x 10-5), termed the rs2814778 T allele. Importantly they also verified that these
results were not as a result of linkage disequilibrium by undertaking analysis of
shotgun sequencing data (Reich et al., 2009, Nalls et al., 2008). This study was
extended to include 16388 self-identified African American individuals (Reiner et al.,
2011), confirming the FYB(ES) association (P<10-236 for neutrophils), and introducing
three further lesser associations, CXCL2 gene (rs9131 T allele) and CDK6 (rs445 T
allele) and PSMD3-CSF3 (rs4065321 T allele). CDK6 or cyclin-dependent kinase 6,
and PSMD3 are cell cycle regulators expressed in HSPC (Meyerson and Harlow, 1994,
Bailly and Reed, 1999). Finally, the associations for DARC and PSMD3-CSF3 have also
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been described in another genome wide association study with 13923 individuals of
African ancestry (Crosslin et al., 2012).
Leukopaenia was been observed in persons of African ancestry for several decades,
having been first recognised in 1941 (Forbes et al., 1941) and was subsequently
confirmed by later studies (Sadowitz and Oski, 1983, Broun et al., 1966, Rippey,
1967). It is generally considered that the neutropaenia seen in certain ethnic groups
such as those of African ancestry (Rana et al., 1985), certain Middle Eastern groups
(Denic et al., 2009) including Yemeni Jews (Shoenfeld et al., 1988) is not associated
with any implications for sepsis risk (Shoenfeld et al., 1985), giving rise to the term
‘benign ethnic neutropaenia.’ It has been suggested that benign ethnic neutropaenia
should be defined as a neutrophil count of less than 1.5 x 109 / L in subjects who are
otherwise well (Hsieh et al., 2007, Haddy et al., 1999), and is found in up to 5% of
African Americans compared with 0.8% of Caucasian Americans. On average, African
American subjects have a 20% lower neutrophil count (rising to 38% lower in
individuals homozygous for FYB(ES)) (Reich et al., 2009). Researchers noted a
neutrophil count lower than 0.5 x 109 /L in two completely well Kuwaiti Arab brothers
(Denic et al., 2009), with no other explanation for the neutropaenia. In terms of
underlying mechanisms for this condition, a theory for ‘pseudoneutropaenia’
(Karayalcin et al., 1972), which suggested that neutrophils were being retained in the
marginal pool, was considered the most likely explanation for the phenomenon. Initial
studies determined no difference in the myeloid or other haematopoietic progenitor
composition of the bone marrow of neutropaenic subjects (Mintz and Sachs, 1973).
However, studies have shown a lower peak neutrophil count after infection and
91
exercise (Phillips et al., 2000, Pastorek et al., 1996) and suggested a reduced capacity
for granulopoiesis in persons with benign ethnic neutropaenia, as the peak neutrophil
count following glucocorticoid stimulation remains lower than in controls (Mason et
al., 1979, Shoenfeld et al., 1982). One proposed mechanism was a defect in release of
neutrophils from the bone marrow storage pool (Shoenfeld et al., 1982, Mintz and
Sachs, 1973). Of note, the reduced neutrophil increment on glucocorticoid
administration was seen in all members of an ethnic group, not merely those with a
lower neutrophil count (Mason et al., 1979, Shoenfeld et al., 1982). More recently it
has been shown that bone marrow colony forming units for granulocytes are reduced
in benign ethnic neutropaenia, suggesting that capacity for neutrophil production is
lower but qualitative difference could not be detected (Rezvani et al., 2001). Other
authors have described higher levels of CXCL8 and G-CSF, 50 and 70% respectively,
in volunteers of African origin as well as a reduced oxidative burst capacity in
stimulated neutrophils from volunteers of African descent (Mayr et al., 2007). In
addition to CXCL8, high levels of G-CSF have also been recently described as
predictive of survival from acute lung injury as well as a relationship with severe
sepsis (Suratt et al., 2009). The exact implications of this are not clear. Although it
has been noted for some time that persons of African origin appear to fare worse in
analyses of health outcomes compared with many other populations, it has been
ascribed to be due to a complex mix of socio-economic factors (Barnato et al., 2008).
The inference of biological factors however is intriguing. A study demonstrating
substantial anti-microbial effects by neutrophils against tuberculosis infection, also
noted that the likelihood of acquiring this disease appeared to correlate inversely with
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neutrophil counts (Martineau et al., 2007). Study subjects of African origin tended to
have lower neutrophil counts and the highest incidence of tuberculosis infection,
compared with other groups (including South Asians) in the South London cohort.
Unfortunately it is only recently that the strong link between FYB(ES) genotype and
benign ethnic neutropaenia has been uncovered, and therefore it is not possible to
classify participants in these studies in any way other than exhibiting neutropaenia
and being from a particular ethnic group. Other genetic polymorphisms may play a
role in modifying or contributing to the observations.
The interplay between the three factors of neutropaenia, loss of erythrocyte DARC
expression and malaria has not previously been studied in detail. Notably, it has been
reported that higher neutrophil counts are associated with a higher malarial parasite
load, and correlate with the severity of disease and the risk for cerebral malaria
(Ladhani et al., 2002). This latter factor was corroborated in a mouse model where
neutrophil depletion was shown to prevent cerebral malaria (Chen et al., 2000).
However this finding has yet to be confirmed in human studies. The association of
reduced malaria severity with lower neutrophil counts nevertheless represents a
possible second mechanism whereby the FYB(ES) gene protects from malaria, and
that this would not be restricted to plasmodium vivax malaria.
1.9.6.2 Malaria susceptibility
DARC may have hither-to unexplored effects on erythrocyte invasion by Plasmodium
species other than vivax. Platelet Factor 4 (CXCL4) and DARC have been described as
being required for the platelet related killing of plasmodium falciparum with CXCL4
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endocytosed by erythrocyte DARC and subsequently involved in directly killing this
plasmodium intracellularly (McMorran et al., 2012). However, this mechanism
remains contentious (Nibbs and Graham, 2013) especially the fact that CXCL4 is a
DARC ligand. The earliest study of DARC as the erythroid chemokine receptor
indicates that CXCL4 weakly binds to erythrocyte DARC but not at all to DARC
expressed on K562 cells (Chaudhuri et al., 1994). Subsequently, Szabo et al., 1995,
demonstrated in chemokine binding-competition assays that CXCL4 was able to
displace 0.5nM CCL5 at 200nM only, considered to be non-specific by the authors, but
could not displace CXCL2 (MIP-2α/Gro-β) at all. The critical role of DARC in the
process of intracellular killing P. falciparum was established by its reduction with anti-
Fy6 antibody, or within DARC-deficient erythrocytes. Although only implied but not
demonstrated directly, the most contentious mechanistic aspect of the study by
McMorran et al is that DARC on plasmodium infected cells internalises CXCL4, a
hitherto undescribed role for erythrocyte DARC. The implication of this work would
be that the loss of DARC, presumably evolutionarily selected to protect against P.
vivax, puts the individual at a disadvantage when faced with P. falciparum, a more
deadly pathogen. However other researchers could not show an association between
DARC genotype and risk for P. falciparum (King et al., 2011, Kasehagen et al., 2007,
Woldearegai et al., 2013).
1.9.6.3 Human Immunodeficiency Virus
DARC has been implicated in modifying the epidemiology and course of another
serious infectious disorder, the human immunodeficiency virus (HIV), with significant
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geographical overlap in the prevalence of both HIV and the FYB(ES) gene. Initial
reports indicated that erythrocyte DARC adsorbed HIV (Lachgar et al., 1998), and
thereafter transferred virions to CD4+ T cells (He et al., 2008) but not if incubated
with anti-Fy6 antibody. However, others have noted that HIV appears to bind to
erythrocytes independent of DARC phenotype, suggesting that DARC may not be the
only binding mechanism (Beck et al., 2009).
An association between DARC genotype and HIV susceptibility was noted, with
increased likelihood of infection, by as much as 40%, if the host was FYB(ES)
homozygous, with subsequent and paradoxical slower CD4 decline (He et al., 2008).
It was calculated that up to 11% excess HIV infections in Africans might be as a result
of this genotype. The authors suggested that the loss of erythroid DARC may reduce
the pro-inflammatory state established during primary HIV infection thereby
increasing the risk of sero-conversion by affecting circulating levels of inflammatory
chemokines, including the HIV-suppressing CCL5. Conversely, absence of erythroid
DARC would represent a loss of reservoir for HIV virions, and the continuous pro-
inflammatory state induced by ongoing HIV infection may be ameliorated owing to
loss of erythrocyte chemokine buffering activity and translating into slower disease
progression. However there is little evidence to support this model and the effects of
erythrocyte DARC on chemokine homeostasis are complex. Four other groups, (Walley
et al., 2009, Horne et al., 2009, Winkler et al., 2009, Julg et al., 2009), were not able
to reproduce the findings by He et al. The discrepancy was ascribed to the methods
used to adjust for population admixture, as 30 to 40% African Americans are
phenotypically DARC positive. Nevertheless, further work described in a large cohort
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of African American subjects an association between leukopaenia and HIV
progression: leukopaenic subjects of African ancestry homozygous for FYB(ES) had a
survival advantage compared with all non-FYB(ES) study participants. This was found
to be independent of CD4 count and viral load, which are known predictors of AIDS
development and progression (Kulkarni et al., 2009). In particular this survival benefit
was conferred to those FYB(ES) homozygotes with lower white blood counts.
Recently, a relationship between FYB(ES), leukopaenia and HIV infection was
investigated (Ramsuran et al., 2011) in 142 South African women at high risk of HIV
infection. It appears that both loss of DARC expression on erythrocytes and a
reduction in neutrophil count are risk factors for acquiring HIV. A 36% increase for
each 1 x 109/L drop in the neutrophil count was noted in the risk of acquiring HIV. In
particular those subjects typed as -46 C/C (homozygous FYB(ES)) had a three times
higher risk of contracting HIV. Taken together these findings suggest the prevalence of
homozygous FYB(ES) modifies the risk of infection by HIV in that the reduction in
neutrophil counts increases the risk of infection, but in contrast a survival advantage
is given to HIV infected subjects with low neutrophil counts, thereby lengthening the
duration of the infected state.
Following on from this work, another group examined the association of neutrophil
counts in mothers and in new-borns at risk of infant perinatal HIV infection in the
BAN cohort (Breastfeeding, Antiretrovirals, and Nutrition) study of 2369 mothers
infected with HIV and their new-borns in Malawi (Kourtis et al., 2012). Higher
neutrophil counts in both mother and neonate were associated with a lower risk of
perinatal HIV infection. The association of infant neutrophil counts with perinatal HIV
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infection persisted after adjustment for maternal CD4 counts, treatment with co-
trimoxazole during pregnancy, maternal viral load and infant’s gender and birth
weight. This further supports the notion that the neutropaenia seen in homozygous
FYB(ES) individuals renders them at higher risk for HIV infections; however a
mechanism for this association requires elucidation.
1.9.6.4 Other disease associations
There are associations of DARC genotype with other human diseases. The Fy(a–b–)
phenotype in Africans co-segregates with sickle cell disease, another disorder
associated with protection from malaria and conferring survival advantage in the
heterozygous state. However one study found no effect of DARC genotype on sickle
cell disease severity or changes in chemokines levels during vaso-occlusive crises
(Schnog et al., 2000). Similarly another group (Nebor et al., 2010) found no
correlation between Duffy serotype and end organ damage, although markers of
haemolysis were higher in Duffy positive individuals, as were CXCL8 and CCL5.
However Afenyi-Annan et al., 2008, with more subjects, indicated that renal disease
was more likely in Fy(a–b–) subjects. More recent investigators (Drasar et al., 2013)
noted markers of renal injury due to sickle cell disease to be more elevated in Duffy
positive individuals and furthermore the development of leg ulcers was more likely in
Duffy positive individuals. The number of hospital admissions and the length of
hospital stay was lower in Fy(a–b–) individuals. These studies suggest an effect of
higher leukocyte numbers, which are more activated in sickle cell disease (Lard et al.,
1999), leading to both more frequent sickling episodes, and consequently more end
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organ damage. In sickle cell patients DARC expression on the erythrocytes is
associated with the constitutive activation of leukocyte VLA-4, a counter-ligand for
VCAM-1 on endothelial cells (Durpes et al., 2011). Integrin activation is further
enhanced by the presence of CXCL8 or CCL5 (Durpes et al., 2011).
Higher CXCL8 levels were also measured in pregnant Fy(a–b–) pre-eclamptic women
(Velzing-Aarts et al., 2002a, Velzing-Aarts et al., 2002b), with an increased number of
Fy(a–b–) subjects having a history of pre-eclampsia when compared against Duffy
positives. Higher susceptibility to asthma along with higher IgE levels observed in a
group of patients of African origin were considered due, in part, to the Fy(a–b–)
phenotype (Vergara et al., 2008).
Blood transfusion is a predisposing condition for acute lung injury in the critically ill
individuals, and mortality risk increases with further transfusions (Shaz et al., 2011).
Although allogeneic leukocytes have been implicated, leukoreduction has not
alleviated these complications. Because the mortality increases with increasing age of
the transfused red cells, it was suggested that the changes undergone by red cells in
storage, the ‘storage lesion’ (Bessos and Seghatchian, 2005), may contribute to
transfusion related morbidity. In a mouse model of systemic endotoxaemia followed
by a secondary red cell transfusion challenge, (Mangalmurti et al., 2009) aged red
cells increased lung airspace chemokine concentrations and enhanced the lung
microvascular permeability. In addition in vitro work done with human erythrocytes
demonstrated reduced DARC expression and chemokine scavenging for CXCL1 and
CCL2 but not CXCL8 occurred with increasing storage (Mangalmurti et al., 2009).
This group next used chimeric mouse models to investigate the effects of transfusing
98
red cells from DARC KO mice into wild-type animals, and noted more pronounced
parameters of acute lung injury in comparison with wild type mice receiving wild type
blood. These data suggest that reduced DARC expression on stored blood erythrocytes
has decreased chemokine binding capacity, affecting local chemokine gradients and
thereby promoting the entry of neutrophils into the pulmonary airspaces. It is of note
that actual DARC expression on murine red cells was not assayed in this study owing
to a lack of reliable anti-mouse DARC antibody.
From a clinical perspective, it is already established that African Americans have
poorer survival compared to other groups treated in intensive care, due to a complex
mix of altered co-morbidity profiles compared with the general population, and other
socio-economic factors (Barnato et al., 2008, Esper et al., 2006b). Further work
examining the significance of DARC in modulating inflammatory responses during
acute lung injury compared the outcome between 127 patients studied under the
ARDS Network (Kangelaris et al., 2012), 67% of which were DARC negative. This
study reports that there is a two-fold higher risk for mortality and likelihood for
ongoing mechanical ventilation at 60 days in DARC negative patients. Taken together
with the findings of Mangalmurti et al., 2009 FYB(ES) individuals are at higher risk
for acute lung injury following an insult, possibly as a result of loss of chemokine
scavenging by DARC.
The absence of DARC on erythrocytes has demonstrable effects on chemokine levels in
human subjects, and there is a very strong association between FYB(ES) genotype and
neutropaenia. However mechanisms for this and disease associations have not been
defined and it is possible that other factors may account for some observations.
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1.10Objectives
Chemokines are directly implicated in haematopoiesis, and the release of leukocytes
from the bone marrow under homeostatic conditions and during periods of acute need
such as inflammation is under the control of two chemokine-receptor axes, CXCL12-
CXCR4 and ELR+ chemokines-CXCR2. The atypical chemokine receptor DARC
(ACKR1), which binds among its many ligands also the ELR+ chemokines, is
expressed within the bone marrow. A common human polymorphism with the
promoter region of the DARC (ACKR1) gene results in the complete abolishment of its
transcription in haematopoietic cells. This polymorphism is highly prevalent in Africa
and is hypothesised to have arisen under natural selection to protect against p. vivax
infection. It has also been strongly associated with reduced blood leukocyte counts in
individuals homozygous for this polymorphism.
The aims of this thesis are to examine the role of erythrocyte DARC in haematopoiesis
and dissect mechanisms giving rise to the neutropaenia in the absence of erythroid
DARC. Given the abundance of erythroid cells in the bone marrow, it is hypothesised
that loss of DARC expression in this compartment modulates the bone marrow micro-
environment leading to altered kinetics in neutrophil mobilisation. I sought to study
the impact of FYB(ES) on haematopoiesis, from stem cells to mature cells, and how
chemokine signals might be altered by the absence of erythroid DARC. This was done
using DARC-deficient mice as well as developing two new transgenic mouse models,
expressing either FYB(ES) or FYB human polymorphisms of DARC in a murine-DARC
KO background. Novel observations on skewed HPSC and granulocyte lineage
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development in the DARC-deficient and FYB(ES) transgenic mice were further
underlined by gene expression arrays and multiplex cytokine analysis. The impact of
the Duffy-negative phenotype on survival from acute myeloid leukaemia was
examined in a large multi-centre UK-based phase III study.
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The role of erythrocyte and endothelial DARC in
haematopoiesis in reciprocal irradiation bone marrow
chimeric mice
2.1 Materials and methods
2.1.1 Mice
All mice used were either C57Bl/6 (CD45.2) or BoyJ (CD45.1). DARC deficient mice
(DARC KO) (Dawson et al., 2000) mice were backcrossed for at least 12 generations
onto a C57Bl/6 background. Mice were kept in a specific pathogen-free facility of the
Biomedical Services Unit, University of Birmingham. All experimental procedures
were approved by the Animal Ethics Committee, University of Birmingham and the
Home Office, UK. All mice were used at 8–16 weeks of age. Within experiments, sex
and aged matched and, if possible, littermate controls were used.
2.1.2 Bone marrow preparation for FACS analysis
Bone marrow was flushed from femurs and red cells were lysed using ACK lysis buffer
where required. Cells were washed for 10 minutes (min) at 375g and were counted
using a Cellometer automatic counter or in a Neubauer chamber under microscope.
Cells were then added to either a 96 well plate or 1.5 ml tubes and blocked on ice for
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fifteen minutes with 10% foetal calf serum and anti-mouse CD16/CD32 antibody, if
appropriate.
2.1.3 Adoptive bone marrow transfers
The whole bone marrow was transplanted following lethal irradiation of murine
recipients (9 Gy) by tail vein injection of 107 cells in 200µl PBS from either C57Bl/6
(WT) or DARC KO animals, with bone marrow transfers undertaken between WT and
KO and vice versa, as well as KO to KO and WT to WT, to serve as radiation controls.
Recipients received prophylactic endofloxacin (Baytril, Bayer AG, Germany) for a
week prior to and after irradiation for all experiments.
The degree of donor chimerism, the expression of DARC on erythrocytes, was
established by anti-mouse DARC antibody, directly conjugated to AF488 (kind gift of
Prof Ulrich von Andrian, Boston USA) or anti mouse/rat DARC-APC (R&D systems,
UK). Blood was collected for analysis whilst taking blood for neutrophil counting (see
below). One million red cells were incubated with either 0.5µl of anti-mDARC-AF647
or 10µl of anti-mouse/rat DARC-APC for 30min, and then washed at 1000g for 10min.
Samples were analysed using a BD FACS Calibur.
2.1.4 Peripheral blood cell counts
The full blood count was determined using an automated ABX Pentra 60 (HORIBA
ABX S.A.S., Northampton, UK) blood counter.
Absolute and differential leukocyte counts were measured by collecting blood by tail
bleed (not more than 7.5% of blood volume per week) into 100µl PBS + 10mM
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EDTA. Fifty microlitres of the sample was transferred to a Trucount FACS tube
containing a 20 µl PBS with 1µl of anti-Ly6G-PE (BD Bioscience, UK) using a reverse
pipette technique. Subsequently the sample was incubated at room temperature for
30min and then red cells were lysed using 1x BD Pharmlyse (BD Bioscience, UK).
Alternatively, blood samples with antibodies were incubated as described in ordinary
polystyrene FACS tubes, and subsequent to lysis 20µl of CountBright (Invitrogen, UK)
counting beads were added to the sample by reverse pipetting and frequent mixing.
The samples were then analysed using a FACS Calibur, counting at least 2500 bead
events, and the number of cells calculated according to the manufacturer’s
recommendation, as per the formula:
              ℎ       .         =                                    
                                   
×                    
                                       
The value for ‘Volume of blood sampled’ was adjusted to compensate for varying
volumes of blood obtained during tail-bleeding, e.g. total volume collected in 100µl of
buffer was 150µl, therefore volume of blood sampled in the experimental tube
16.67µl.
2.1.5 Analysis of bone marrow populations
The following monoclonal antibodies were used for FACS analysis of bone marrow
stem and progenitor cells: anti-mouse lineage panel-APC (BD Biosciences) or anti-
mouse lineage panel-e450 (eBioscience), anti-c-Kit-APC-Cy7, anti-Sca-1-PE/Cy7 or
anti-Sca-1-RPE, anti-CD127-Pacific Blue, anti-CD34-FITC, anti-CD16/CD32-PE/Cy5.5,
biotinylated anti-CD135, anti-CD135-RPE, anti-CD127-e450 or APC, anti-VCAM-e450
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and anti-CD62L-APC (all eBioscience, UK). Biotinylated antibodies were visualised
with streptavidin-PE-Texas Red (BD Bioscience) or streptavidin-e450. The HSC
population was defined as c-Kit+, Sca-1+ and lineage negative (LSK population), and
at least 1x106 total bone marrow events were analysed per sample as per Ross et al.,
2008.
Antibodies used for myeloid surface antigen analysis included: anti-CD45-PerCP, anti-
Ly6G-PE-Cy7, anti-Ly6C-FITC (BD Biosciences); anti-CD115-PE, anti-CD11b-e450,
anti-CD11c-APC (eBioscience). Lymphoid populations were determined using anti-
CD45-PerCP, anti-B220-FITC, anti-CD3-PE, anti-CD19-PECy7, anti-CD4-APC and anti-
CD8-e450.
Erythroid precursors were examined using anti-CD71-PE and anti-Ter119-FITC
(eBioscience), and directly labelled anti-mDARC-647. Gating was set using a method
from Socolovsky et al., 2001. Bone marrow cell populations were quantified and
phenotyped using a CyAn ADP flow cytometer (Beckman Coulter, UK).
2.1.6 Preparation for flow cytometry
Staining was carried out in a rigid 96-well plate coated with heat-inactivated foetal
calf serum (FCS, Sigma) on ice. Phosphate buffered saline without calcium or
magnesium ions supplemented with either 1% bovine serum albumin (BSA) or 2%
FCS was used as antibody diluent and wash solution. Cells were washed with 200µl
wash solution at 375g for 4min at 4°C. Wash solution was removed by inversion of the
plate. Cells were incubated with antibodies on ice for 30min to one hour depending
on the antibody cocktail, in the dark. Following incubation, cells were washed twice
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and re-suspended in 200µl wash solution, and transferred to polypropylene tubes.
Fluorescence was then measured on an 11-parameter CyAn flow cytometer (Becton
Dickinson).
In some experiments, cells stained with isotype control antibodies were used to
determine the level of background non-specific binding. Compensation was performed
using cells stained with each fluorochrome conjugated-antibody individually. Doublets
were excluded by gating on the forward scatter versus pulse width. Debris and
platelets were excluded from analysis by gating on forward and side scatter. Dead
cells were identified by the use of either LIVE/DEAD Fixable Aqua Dead Cell Stain Kit,
for 405 nm excitation, or LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit, for 633 or
635 nm excitation (Life Technologies, UK), by first washing antibody stained cells in
200µl phosphate buffered saline (PBS) containing no proteins, twice, and then
incubating cells on ice for 30min with the 1:1000 concentration of the relevant
viability stain, after which cells were washed in PBS and re-suspended in wash buffer.
2.1.7 Statistical analysis
Statistical significance was determined for all analysis where n<20 with Mann-
Whitney test, or unpaired Student t test for larger sample sizes: * p<0.05, ** p<0.01,
*** p<0.001, **** p<0.0001. Relative or proportional data is presented as box-and-
whisker plots showing minimum and maximum values, a horizontal line indicating
the median, and the boxes represent the 25th to 75th percentiles. Absolute data values
are presented as scattered-dot plots, with median. Where more than one population of
cells is presented, bar graphs are used, with data presented as mean ± standard
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deviation (SD). For purposes of clarity, numbers of animals studied per group are
shown in some figures, or are described in the figure legend. Statistical tests were
performed using Microsoft Excel 2013 (Redmond, USA), Graphpad Prism software
version 5 (San Diego, USA) or SPSS (IBM, USA) version 21. According to
experimental design, two way ANOVA with Bonferroni multiple comparisons was used
to determine whether genotype was a significant source of variation. This statistical
methodology and figure layout was used throughout this thesis, unless otherwise
stated.
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2.2 Results
2.2.1 Peripheral blood cell counts
To study the potential effects of DARC expression on neutrophil counts, reciprocal
irradiation bone marrow chimeras were prepared as described in Material and
Methods section, creating four groups of mice (Figure 2.1).
Figure 2.1 Scheme representing bone marrow transfers following irradiation (9 Gy) and resultant DARC
phenotypes.
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Chimeric mice reflecting the human Duffy negative phenotype (‘WT-KO’) had
consistently lower neutrophil counts compared with all other DARC chimeric mice.
Neutropaenia was detectable as early as 4 weeks post bone marrow transfer, and
evident at 8 weeks post transfer, Figure 2.2. Thus neutropaenia set on already when
the percentage of recipient erythrocytes in the blood was still approximately 40-60%,
Figure 2.2 b and c.
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Figure 2.2 Enumeration of blood neutrophils in irradiation chimera. Representative gating (a) used for
determination of neutrophil count at 4 weeks (b) and 8 weeks (d) post irradiation and bone marrow transfer. (c)
& (e) DARC chimerism in peripheral blood measured as % of DARC positive erythrocytes at sampling times as in
(b) & (d) respectively. Graphs show one out of two independent experiments with five mice each in each
chimeric group. WT-WT (WT recipient, WT donor), WT-KO (WT recipient, DARC KO donor), KO-WT (DARC KO
recipient, WT donor), KO-KO (KO recipient, KO donor). n=5 per group
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In mice lacking DARC on erythrocytes the spleen weights were mostly higher, but not
significantly different, and bone marrow cellularity was reduced, Figure 2.3.
2.2.2 Myeloid analysis
Bone marrow neutrophils were elevated in chimeras lacking endothelial DARC, Figure
2.4, and although overall bone marrow and blood monocytes were not different, there
was a significant increase in the proportion of non-classical monocytes in blood of the
WT-KO chimeras. Myeloid cells as a proportion of total nucleated blood cells were
higher in KO-WT and KO-KO mice but not significantly different (data not shown).
a b
*
*
* *
Figure 2.3 Spleen weights and bone marrow cell counts. Graph showing spleen weight as a percentage of total
body weight, (a), n=5 per chimera group, except KO-KO n=3. Bone marrow total nucleated cell counts per two
femurs, (b), data from two experiments, WT-WT n=10, WT-KO n=10, KO-WT n=10, KO-KO n=8
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Figure 2.4 Analysis of myeloid cells in bone marrow and blood of chimeric mice. Representative gating (a).
Proportions of myeloid cells in chimeric bone marrow (b) – neutrophils: CD45+, CD11b+ and Ly6G+, and (c)
Monocytes: CD45+, CD11b+, Ly6G low/neg, and CD115+. Blood total monocytes (d) and monocyte subgroups (e):
non-classical monocytes: CD45+CD11b+, Ly6Glow/neg, CD115+, Ly6Clow/neg in blood. Monocyte subgroups in bone
marrow were no different across chimera phenotypes (not shown). Experiment with n=5 mice per chimera
group except KO-KO n=3
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2.2.3 Lymphoid analysis
The proportions of lymphocyte subsets were also examined in the chimeric DARC
mice, Figure 2.5. Relatively more T cells were present in the bone marrow of KO-WT
and KO-KO mice, whereas fewer blood T cells were observed in the peripheral blood
of WT-KO mice. Peripheral blood B cells were reduced in KO-WT chimeric mice.
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Figure 2.5 Analysis of lymphoid cells in bone marrow and blood of chimeric mice. Representative gating (a). Bone
marrow T cells (b) and (c) B cells, and these respective populations in peripheral blood, (d) and (e). Experiment
with n=5 mice per chimera group except KO-KO n=3.
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2.2.4 Erythroid analysis
Ter119+ cells of the erythroid lineage, were significantly reduced in the bone marrow
of WT-KO mice, Figure 2.6. KO-KO mice had fewer early erythroblasts, and KO-WT
and KO-KO animals had significantly more late erythroblasts in the bone marrow,
suggesting that more mature erythroid precursors were being retained in the bone
marrow of these mice. Pro-erythroblasts were not significantly different across the
chimeric groups (data not shown).
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Figure 2.6 Analysis of erythroid maturation in unlysed bone marrow of chimeric mice, representative gating (a).
Ter119+ cells were reduced in WT-KO in comparison to all other phenotypes, (b), n=5. Furthermore, comparison
of erythroblast subtypes (c) shows a relative decrease in earlier erythroid forms, and increase in late erythroblasts
in chimeras lacking endothelial DARC, as compared to WT-WT. Experiment with n=5 mice per chimera group
except KO-KO n=3.
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2.2.5 Stem and progenitor cell analysis
2.2.5.1 Myeloid Progenitors and LSK
In order to ascertain whether underlying HSPC alteration might be contributing to the
observed phenotype, bone marrow myeloid progenitors and LSK cells from chimeric
mice were examined, Figure 2.7. Myeloid progenitors were reduced in chimeric
phenotype lacking erythroid DARC. This was as a result of pronounced reductions in
GMP cells, Figure 2.8.
LSK populations were significantly increased in the KO-WT mice. In particular, the
KO-WT and KO-KO mice have reduced numbers of multipotent progenitors, and
correspondingly high early precursor numbers (LT- & ST- stem cells), although these
were not significantly different in the KO-KO.
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Figure 2.7 Progenitor and stem cell populations in bone marrow of chimeric mice, (a) representative gating. (b)
Myeloid progenitors (Lin- cKit+ Sca1-). (c) The stem cell enriched LSK fraction (Lin- cKit+ Sca1+). Experiment
with n=5 mice per chimera group except KO-KO n=3
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2.2.5.2 Multipotent progenitors
Multipotent progenitor populations (MPP) were analysed as per representative gating
in Figure 2.9
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Figure 2.8. Progenitor and stem cell sub-populations in bone marrow of chimeric mice. Myeloid progenitor
subtypes, GMP (Lin- cKit+ Sca1- CD34+ CD16/CD32high) (a) and CMP (Lin- cKit+ Sca1- CD34+ CD16/CD32low/neg)
(b) were examined. The LSK population (c) was examined as per gating in Figure 2.7. MPP, multipotent
progenitors (Lin- cKit+ Sca1+ Flt3high), ST-HSC (Lin- cKit+ Sca1+ Flt3low) and LT-HSC (Lin- cKit+ Sca1+ Flt3neg).
Experiment with n=5 mice per chimera group except KO-KO n=3
119
Sub-division of the MPP contained with the LSK population, Figure 2.10, shows
significant reductions in the GMP-primed progenitors in the MPP of the WT-KO mice.
Conversely the KO-WT mice had increases in both the GMP-primed and LMPP
progenitors. This was in parallel to the peripheral blood findings, where both
neutrophils and lymphoid cells were altered in these phenotypes.
Figure 2.9 Representative gating for analysis of multipotent progenitors in bone marrow of chimeric mice. GMP-
primed progenitors, Lin- cKit+ Sca1+ VCAM+ CD62L+ Flt3low/mid; LMPP Lin- cKit+ Sca1+ VCAM+ CD62L+ Flt3high,
CMP Lin- cKit+ Sca1+ VCAM+ CD62L+ Flt3neg.
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Figure 2.10 Analysis of multipotent progenitors in bone marrow of chimeric mice. The multipotent progenitors
were subdivided on the basis of their VCAM and CD62L expression into (a) GMPP (b) LMPP (c) CMP as per
gating in Figure 2.9. Experiment with n=5 mice per chimera group except KO-KO n=3
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2.3 Discussion
The results in Figure 2.3 are the first experimental demonstration of the association
between the lack of erythroid DARC expression and reduced peripheral blood
neutrophil counts (Nalls et al., 2008, Reich et al., 2009). Of note, neutropaenia
occurred early in the bone marrow grafting period. Due to radio-resistance and long
half-life of erythrocytes, erythroid engraftment leads to the complete exchange of
erythrocytes only at approximately 60 days post-transplant. Neutropaenia occurred in
WT-KO mice when half of their erythrocytes were still of recipient origin and thus still
expressed DARC. These data are suggestive of an alteration within the bone marrow
micro-environment due to early erythroid cell, and not peripheral erythrocytes, which
may account for the reduced neutrophil count in the blood of WT-KO chimeras. A
potential explanation for these findings may be that DARC on erythroid cells patterns
chemokines within the bone marrow micro-environment thus affecting myelopoiesis.
The localisation of erythroid cells in erythroblastic islands may lead to the optimum
distribution or retention of chemokines for myeloid development.
The higher peripheral neutrophil counts in the KO-WT and KO-KO suggest a role for
endothelial DARC in negatively regulating the release of cells from the bone marrow,
or alternatively, a requirement for endothelial cell DARC to optimally direct
neutrophil margination within the peripheral circulation or their homeostatic exit
from the circulation into the peripheral tissues. In the bone marrow, KO-WT and KO-
KO mice also had higher neutrophil proportions than WT-WT and WT-KO mice
(Figure 2.4a) Therefore it is not likely that endothelial DARC is a negative regulator of
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bone marrow release of neutrophils, but, on the contrary, may be required for the
optimum release of neutrophils from the bone marrow, and also their margination or
departure from the circulation into tissues.
It has been shown that in the peripheral tissues, the role of endothelial DARC is pro-
inflammatory, by promoting the transmigration of leukocytes across the endothelium,
whilst erythroid DARC is globally anti-inflammatory, by buffering chemokine levels
and reducing leukocyte receptor sensitivity. Nevertheless chemokine reservoir
function of erythrocyte DARC has also been suggested (Novitzky-Basso and Rot,
2012). It is attractive to speculate that, in line with the latter function, DARC
expressed by the erythroid cells in the bone marrow may function to retain
chemokines and pattern them whilst endothelial DARC in bone marrow vasculature
may modulate the local distribution of ELR+ chemokines optimising their availability
for homeostatic release of neutrophils into the circulation.
Other leukocyte populations such as total monocyte numbers were not altered in
blood or bone marrow, although peripheral blood non-classical monocytes were
significantly elevated in the WT-KO phenotype.
The KO-WT and KO-KO mice showed reductions in blood B cells as a proportion of all
nucleated cells, which was significant in KO-KO mice. This may be due to the larger
myeloid proportions seen in these mice, particularly since there is no significant
difference in bone marrow B cells amongst the DARC phenotypes. The biological
significance of the bone marrow T cell increase in the KO-WT and KO-KO is not clear,
particularly given the transient nature of the mature T cells in the bone marrow.
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Notably bone marrow erythroid cells were reduced in WT-KO, which may account for
the slight reduction in overall bone marrow cellularity observed in this phenotype.
Increased spleen size in mice without erythroid DARC may indicate a compensatory
mechanism. In contrast to humans, the murine spleen is a haematopoietic organ
under physiologic conditions, and these data suggests that bone marrow erythro- or
haematopoiesis may be replaced by those in the spleen.
Examination of haematopoietic precursors revealed a reduction in myeloid
progenitors in mice lacking erythrocyte DARC which was accounted for primarily by a
substantial and significant reduction in GMPs. This suggests a role for the erythroid
DARC in optimal myeloid development. This finding was further corroborated in the
LSK stem-cell enriched fraction, which harbours earlier progenitors. In this
population, GMP-primed progenitors were proportionally reduced, suggesting a
lineage effect. CMP were not different, and there was an increase in lymphoid-primed
multipotent progenitors in mice without endothelial DARC, which was significant in
the KO-WT mice. The MPP group as a whole was reduced in chimeric mice lacking
endothelial DARC. It is not known whether the absence of endothelial DARC affects
the stem cell niche micro-environment, particularly the perivascular niche. There may
be alterations in the expression of other adhesion molecules in the endothelium, or
alternatively other changes in the micro-environment may modulate signals to
transcription factors and other signalling pathways regulating cell lineage fates and
HSC turnover, potentially explaining these findings. However this has no relevance to
studies in humans as no populations are deficient in endothelial DARC.
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Despite the utility of the irradiation bone marrow chimeras in demonstrating different
roles for DARC expressed in haematopoietic and endothelial cells, there remain
substantial drawbacks in using this method. Primarily, irradiation induces significant
inflammation due to cellular damage. This may account for the increased baseline
neutrophil counts in all animals compared with non-irradiated WT mice, and the
higher counts in the KO-WT and KO-KO at 4 weeks after the graft. In addition, bone
marrow studies requiring the setting of gates on lineage negative cells are affected by
experimental variation, and the use of non-irradiated WT mice is not a suitable
substitute. Furthermore, irradiation with 9 Gy, currently the maximal dose allowed
under the Home Office guidelines, is insufficient to eradicate all the host cells,
particularly dendritic cells and T cells, which may have subtle effects on the take and
function of the bone marrow graft. Finally, irradiation causes animal suffering and a
genetically modified animal model would reduce this harm, and animal numbers
needed in the development of chimeras.
In order to study the contribution of erythrocyte DARC on haematopoiesis without the
effects of inflammatory stimuli induced by irradiation, and to follow the animal
husbandry principles of the 3Rs (replacement, reduction and refinement), we
conceived a humanised mouse model reflecting two common human DARC
polymorphisms. We set to produce transgenic mice expressing human DARC on the
vascular endothelium but not on erythrocytes, as encoded by the FYB(ES) allele, or on
both endothelium and erythrocytes, as encoded by FYB allele. We postulated that the
establishment of such models would permit clearer dissection of the role of erythoid
DARC in haematopoiesis.
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The development of FYB(ES) and FYB transgenic strains
3.1 Introduction
The FYB(ES) and FYB transgenic models were developed to study the role of erythroid
DARC in haematopoiesis and investigate the mechanisms which may underlie the
peripheral blood neutropaenia in chimeric mice lacking erythroid DARC. Furthermore
it was postulated that the development of these strains would decrease technical
experimental variations induced by irradiation as well as reduce animal use and
suffering.
126
3.2 Materials and methods
3.2.1 Molecular Biology
3.2.1.1 DNA extraction from human blood
Human blood was taken from healthy volunteers following the ethical approval by the
Ethics Committee of the School of Medical and Dental Sciences, University of
Birmingham following informed consent. DNA was extracted using the DNeasy Blood
& Tissue Kit (Qiagen). Briefly, blood samples were lysed with proteinase K, and the
lysate centrifuged in a silica-based spin column which absorbs DNA, allowing the pass
through of contaminants and enzyme inhibitors during two wash steps, after which
DNA was eluted in ddH2O.
3.2.1.2 Cloning of human DNA
Cloning was undertaken using the High Fidelity Phusion DNA polymerase (Thermo
Scientific), which generates amplified genomic DNA of interest with a very low error
rate. The following cloning primers were designed:
Forward Primer: ACA TGG TTT GAA CTG CCT TTC C
Reverse Primer: CCT CTG GGT AGA GGG TGA ATT TGC
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3.2.1.3 DNA purification
DNA was purified using Fermentas GeneJET PCR Purification Kit. Briefly, DNA
containing reaction was combined with a binding buffer (containing a chaotropic
agent to denature proteins) and was put through a spin-column with a silica-based
membrane after which an ethanol wash step removed impurities. Then DNA was
eluted with a buffer.
3.2.1.4 Ligation into plasmid vector
The CloneJET PCR Cloning Kit (Thermo Scientific, UK) was used as per the
manufacturer’s instructions. The pJET1.2/blunt cloning vector contains a lethal gene
which is disrupted by ligation of DNA insert into the cloning, permitting cells only
with recombinant plasmids to propagate. Using the blunt-end protocol, reaction
buffer, purified DNA, pJET1.2/blunt cloning vector and T4 DNA Ligase were
combined on ice, vortex mixed, and incubated at room temperature for 5min, and
then used for transformation of bacteria.
3.2.1.5 Bacterial transformation
Gold Efficiency α-Select Chemically Competent Cells (Bioline, UK) were used to
incorporate and amplify the ligated plasmid vector. Briefly, cells were thawed on wet
ice and 50µl of cell suspension was mixed with ligation mixture or control PCR
product and incubated on ice for 30min, thereafter undergoing heat shock in 42°C
water bath for 30 seconds, and then subsequently returned to ice for 2min. Then the
transformation mixture was diluted in SOC medium: 2% tryptone, 0.5% Yeast extract,
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0.4% glucose, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10 mM MgSO4, and tubes were
agitated for 60min at 37°C. SOC medium was used as it improves the transformation
efficiency.
3.2.1.6 Plasmid DNA purification for clone selection
GeneJET Plasmid Miniprep Kit (Thermo Scientific, UK) was used to purify plasmid
DNA from bacterial cultures. Briefly, cultured bacteria were pelleted and subjected to
lysis with an alkali, releasing free plasmid DNA. The lysate was neutralised and
centrifuged so that debris and precipitates were pelleted, and the supernatant
containing plasmid DNA was added to a spin column containing a silica membrane
which bound the plasmid DNA. The DNA was then washed with an ethanol containing
buffer, and was then eluted with 50µl of the supplied elution buffer.
3.2.1.7 Restriction enzyme digestion for analysis
EcoRI restriction enzyme recognises G^AATTC sites and is predicted to cut the DARC
gene sequence at position 1090 and 2996, giving 1090bp and 1906bp fragments. The
reaction was prepared by mixing ddH2O on ice, with 10x EcoRI Buffer, 1µg DNA,
EcoRI 5u, and then incubated for 1-4 hours at 37°C. There after the product was run
on 0.7% agarose electrophoretic gel for band analysis.
3.2.1.8 Restriction enzyme digestion for removal of vector
The restriction enzymes XhoI (recognises C^TCGAG), XbaI (T^CTAGA) and PvuI
(CGAT^CG) do not cut DARC gene, and were used to remove the vector from the
construct.
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3.2.1.9 DARC KO genotyping
Tissue was lysed using 75µl of lysis buffer (25mM NaOH, 0.2 mM EDTA), for 45min
at 95°C, after which 75µl of neutralisation buffer (40mM Tris-HCl, pH 5.5) was
added, and the sample vortexed for 60 seconds.
Standard PCR conditions were: 1.2µl of 10x PCR buffer, 0.2mM dNTP, 1.5mM MgCl2,
0.5µM Primer Duffy KO1, 1µM Primer Duffy KO2, 0.5µM of Primer Duffy Neo, ddH2O,
0.25 units of Taq polymerase (Biotaq, Bioline, UK), 25-300ng of template in 1-2µl, run
37 cycles of 30s, 94°C; 30s, 60°C; 30s, 72°C, final 2min 72°C.
Sequences for primers were used from Dawson et al., 2000 as below:
Duffy KO1: GCT AGA TGC CCT GAC TGT CC
Duffy KO2: CCA GTA GCC CAG GTT GCA TA
Duffy Neo: TAT GGC GCG CCA TCG ATC TC
The presence of a wild-type allele gives a 400bp product, whilst the Neo (DARC KO)
allele gives a 300bp product.
3.2.1.10 Genotyping of hDARC transgenic mice
In order to genotype animals containing human DARC gene, primers were designed
using Primer 3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi), using
entire human DARC gene sequence. Results that detected murine targets were
excluded. Potential primers were analysed using Eurofins Oligo Analysis Tool
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(http://www.operon.com/tools/oligo-analysis-tool.aspx), to analyse potential self-
and cross-primer hybridisation potential.
The following primers were selected:
Forward: TGF62 TCA GCC GCC CTT CCA CTC CA
Reverse: TGR402 TTA CCC CAC GCC CAC TGC CT
The reaction was optimised and standard PCR conditions for detection of human
DARC gene were: 1x PCR buffer, 0.2mM dNTP, 1.5mM MgCl2, 0.5µM of Primer
TGF62, 0.5µM of Primer TGR402, ddH2O, 0.25 units of Taq polymerase, 25-300ng of
template in 1-2µl, run 37 cycles of 30s, 94°C; 30s, 69°C; 30s, 72°C, final 2min 72°C.
The presence of human DARC corresponds with a product of 327bp. This primer pair
does not distinguish between FYB and FYB(ES) alleles.
3.2.1.11 Human DARC Genotyping for Polymorphic Alleles
The detection of human DARC alleles was undertaken using the method described in
Mullighan et al., 1998. DNA was extracted using the Qiagen Blood DNA extraction kit.
Four separate reactions were undertaken, containing the primers to detect FYA, FYB,
wild-type GATA sequence in the GATA erythroid promoter region of DARC, and the
FYB(ES) promoter region mutation. Human growth hormone (HGH) gene primers
were used to control that the PCR mix amplified template.
Standard PCR conditions were: 1x PCR buffer, 0.2mM dNTP, 2mM MgCl2, 0.56 µM
Primer A, 0.56 µM Primer B, 0.2 µM HGH1, 0.2 µM HGH2, ddH2O, 0.06µl of Taq
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polymerase, 10-100ng of template in 1-2µl, run 37 cycles of 30s, 94°C; 30s, 60°C; 30s,
72°C, final 2min 72°C.
Primer mixes used:
FYA expressed: FYA and Fy expressed
FYB expressed: FYB and Fy expressed
FYB(ES): FyB and Fy Null
All FY primer reactions give a 700 bp band while HGH primer reactions give a 345bp
band on electrophoretic gel.
Primer sequences:
Fy expressed: TCA TTA GTC CTT GGC TCT TAT
Fy null: TCA TTA GTC CTT GGC TCT TAC
FYA: GCT GCT TCC AGG TTG GCA C
FYB: GCT GCT TCC AGG TTG GCA T
3.2.2 Assessment of mRNA levels and DARC gene expression
3.2.2.1 Sample preparation
Animals were culled by cervical dislocation, and organs were removed and preserved
in RNAlater (Invitrogen).
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3.2.2.2 RNA extraction
RNA was extracted from 20mg tissue pieces using an RNeasy kit (Qiagen), according
to manufacturer’s instructions. Briefly, tissue was added to 600µl Buffer RLT with β-
mercaptoethanol, and homogenised using a rotor homogeniser, thereafter 350µl of
70% ethanol was added. The sample was applied to a column and centrifuged for 15s
at 13000g to bind the sample to the column. The flow-through was discarded, 700µl
of Buffer RW1 was added to the column, the sample was centrifuged for 15s at
13000g, and the flow-through discarded. Then 500µl of Buffer RPE was added to the
column and the sample was centrifuged for 15s at 13000g after which the flow-
through was discarded. A further 500µl of Buffer RPE was added and the sample was
centrifuged for 2min at 13000g. The column was transferred to a new collection tube.
Finally, 30µl RNase-free water was added to the column, and the sample was
centrifuged for 1min at 13000g to elute the RNA.
Extracted RNA underwent DNA digestion, using the Promega RQ1 RNase-Free DNase
kit as per manufacturer’s instructions. Briefly, up to 8µl of RNA, 1µl RQ1 10x reaction
buffer, 1 unit of RQ1 DNase per microgram of RNA were incubated at 37°C for 30min,
after which 1µl of RQ1 DNase Stop Solution was added, and the mixture incubated at
65°C for 10min to inactivate the DNase. The reaction was scaled up to treat all RNA.
After DNA digestion, RNA underwent column clean-up as per RNeasy kit
manufacturer’s instructions. Briefly, the sample volume was adjusted to 100µl with
RNase-free water, and 350µl of Buffer RLT and 250µl 100% ethanol were added.
Following mixing by pipetting, the sample was transferred to an RNeasy Mini spin
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column in a 2ml collection tube, and centrifuged for 15s at 8000g. The follow-through
was discarded, 500µl of Buffer RPE was added to the column and the sample was
centrifuged for 15s at 13000g after which the flow-through was discarded. A further
500µl of Buffer RPE was added and the sample was centrifuged for 2min at 13000g.
The column was transferred to a new collection tube. Finally, 30µl RNase-free water
was added to the column, and the sample was centrifuged for 1min at 13000g to elute
the RNA, to be stored at -80°C until used.
3.2.2.3 First-strand cDNA synthesis (reverse transcription, RT)
The concentration of total RNA in each sample of purified RNA was determined using
a spectrophotometer (Nanodrop 2000c, Thermo Scientific, UK) whereby the
absorbance of each sample was measured at a wavelength of 260 nm (A260). Distilled
H2O was used as a reference (0), since this was used to elute samples. RNA quality
was determined from the A260:A280, indicating the degree of protein in the sample.
Only samples giving values approximately 1.9-2.1 were used for RT.
RT was then performed using SuperScript VILO cDNA Synthesis Kit (Invitrogen Life
Technologies, UK) according to the manufacturer’s instructions. Briefly, a master mix
was prepared with the following components for each reaction: 5x Vilo Reaction Mix
4µl, 10x SuperScript Enzyme Mix 2µl, RNA 1µg and RNase-free water to make up a
reaction volume 20µl. Tube contents were mixed and incubated for 10min at 25oC,
then 42oC for 60 min, and the reaction was terminated at 85oC for 5min. cDNA was
stored at -20oC until used.
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3.2.2.4 Measurement of gene expression by Quantitative Real Time PCR
Gene expression was measured utilising Applied Biosystems Taqman Gene expression
system.
A master mix with 1x DARC Taqman Gene Expression assays with 1x Taqman
Universal PCR Master Mix (Applied Biosystems, CA, USA), was added to wells of a
384 well plate along with test cDNA. Wells contained Taqman assays specific for
human DARC and housekeeping gene GAPDH and/or HPRT according to previous
optimisation experiments. The plate was loaded into an ABI 7900HT Real-time PCR
System (Applied Biosystems) and run with the following program: 50oC for 2min,
95oC for 10min, and then 95oC for 15s, 60oC for 1min, for 40 cycles. Fluorescence
analysis was performed utilising SDS v2.4 software (Applied Biosystems). The
threshold was set manually at the logarithmic phase of the PCR reaction.
The threshold cycle (CT) value obtained was then used to calculate the fold change in
the expression of each gene relative to the housekeeping gene by using the 2  ∆∆   
method, and the relative quantification was plotted. Genes which had a CT value >40
were below the level of detection of the assay and were assigned an RQ value of zero.
For measurement of relative gene expression, the reciprocal of the difference in CT
value between the target and housekeeping gene was used (  
∆   
).
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3.2.3 Flow Cytometry
3.2.3.1 Erythrocyte flow cytometry
Fluorescent antibody staining of erythrocytes (human or mouse) was undertaken by
diluting whole blood so that 1x106 erythrocytes were present in 100µl of wash buffer.
Samples were incubated with heat inactivated FCS and purified anti-mouse or -human
CD16/CD32, centrifuged at 375g for 10min, and then incubated with appropriate
antibody mix, usually anti-murine DARC conjugated to Alex-Fluor 488 or Alexa-Fluor
647, and Ter119. Alternatively, erythrocytes were incubated with anti-Fy6 for 30min
on at 4-8oC, and then washed, after which the sample was incubated with goat anti-
mouse IgG-PE for 20min at 4-8oC. Cells were washed, re-suspended in wash buffer
and transferred to polypropylene tubes.
3.2.4 Immunofluorescence
Frozen sections were acetone fixed for 20min at 4oC after cryosectioning and were
rehydrated with PBS supplemented with 10% fetal calf serum and anti-mouse
CD16/CD32 for 10min. Sections were incubated at room temperature in PBS
supplemented with 1% bovine serum albumin for 10min, then washed for 5min in
PBS. Secondary antibodies were incubated for 30min at room temperature. Sections
were immersed in DAPI for 1min for nuclear staining, then mounted with Vectashield
(Vector Labs) and kept in the dark at 4˚C.  
Anti-Fy6 binding was detected with goat anti-mouse IgG2b Alexa Fluor 555. A Zeiss
LSM 510 Meta confocal microscope (Zeiss) was used to visualise staining on sections.
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Images were captured and processed using Zeiss LSM Image Examiner software
(Zeiss).
3.2.5 Competition binding to human DARC of chemokines and the
anti-Fy6 antibody
The method described by Tournamille et al., 1997 was used with modifications.
Briefly, blood was taken from Duffy-positive laboratory donors and 106 red cells were
incubated with increasing concentrations (10-11 – 10-7 M) of cognate (CXCL8,
mCXCL1) and non-cognate (hCCL21, mCXCL12) chemokines, in 100 µl PBS with
0.5% BSA for 1 hour at 37oC and subsequently 1µl of anti-human Fy6 (mouse IgG2b,
a kind gift from Dr M Uchikawa, Japanese Red Cross) for 30min, and finally 1µl of R-
PE goat anti-mouse antibody added (Southern Biotech, USA). Cells were washed at
1000g for 10min and analysed on a FACS Calibur flow cytometer. Mean fluorescence
index was read and IC50 calculated using GraphPad Prism software version 5.
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3.3 Development of FYB(ES)TG murine model
The development of FYB(ES)TG murine model of the Duffy-negative phenotype was
undertaken using the methods as described in Chaudhuri et al., 2004, with a key
difference that the human transgene was inserted into oocytes from DARC KO mice
instead of wild-type mice. Importantly, the entire DARC gene including all potential
regulatory regions were included, specifically incorporating 1kbp before and after the
open reading frame of the main exon.
Initial design of the construct and cloning was performed by Dr MH Ulvmar. The work
was continued as part of this thesis.
Following cloning from FYB(ES) homozygous donor and selection of suitable clones,
10ml of LB media with 100µg/ml of carbenicillin and ampicillin (CAM) in a universal
container were cultured overnight at 37°C with bacterial colonies (designated clone
7(2)), after which 10µl from these cultures were added to further LB broth with CAM
and allowed to grow over eight hours. Large scale amplification was undertaken using
500µl of bacterial culture in 500ml of LB broth with CAM. Plasmid DNA was extracted
using Qiagen Maxiprep (Maxi) kit. The final elution was undertaken into 400µl of
water. The amount of DNA in the preparation was routinely determined by measuring
OD260 on a spectrophotometer, with a concentration of 1657ng/µl giving a total of
654.5µg for this amplification step.
Restriction analysis was undertaken utilising EcoRI restriction enzyme, which
produced bands as expected, indicating the correct product had been amplified.
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In order to remove the vector backbone, 2 samples of 10µg product were incubated
with 20µl of 5x Tango buffer, Xba1 30 units (New England), Xho1 15 units (New
England) PVU1 15units (Promega) and 65µl ddH2O overnight 37°C (16 hours).
Subsequently DNA from one digest was purified using Fermentas Purification Kit, with
final total DNA 8µg.
Digested product was run on 0.7% agarose gel, and FYB(ES) DARC gene (a 3.2kbp
product) was excised (Figure 3.1 a & b), cleaned up using Fermentas Gel Purification
Kit, and analysed by EcoRI restriction enzyme digestion, giving two products (1906bp
and 1090bp) as expected, (Figure 3.1 c) total DNA 2.44µg.
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a
b
c
Figure 3.1 Representative 0.7% agarose gels following Xho1, Xba1, Pvu1 digestion of plasmid DNA (first 13
lanes) before excision of DARC gene product (a) and after (b), and restriction enzyme analysis of excised gene
product by EcoRI (c).
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The amplified gene product was fully sequenced using primers, which would cover the
whole gene sequence. Sequencing was undertaken at the University of Birmingham
School of Biosciences Sequencing Service. Sequence data were extracted using
Sequence Scanner 1.0 (Applied Biosystems), and aligned with DARC gene sequence
using NCBI BLAST (http://blast.ncbi.nlm.nih.gov/). Initial screening confirmed the
presence of T-46C GATA-1 promoter mutation, and the presence of A at position
1142, indicating the FYB(ES) DARC allele was incorporated in the clone. No
mutations leading to alterations in DARC protein sequence were detected.
Construct micro-injection into oocytes from super-ovulated DARC KO mice was
undertaken by Dr Andrea Bacon.
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3.4 Development of FYB Transgenic mouse strain
Donor blood was collected and DNA extracted by MH Ulvmar from a FYB homozygous
donor. Cloning was undertaken using the High Fidelity Phusion DNA polymerase
(Thermo Scientific) according to manufacturer’s protocol, with template 50ng DNA
per 100µl reaction.
Product was purified through Fermentas GeneJET PCR Purification Kit according to
manufacturer’s instructions, and eluted into 50µl AE Buffer, with a concentration of
21.9ng/µl as measured on Nandodrop. Gel electrophoresis on 0.7% agarose gel
Figure 3.2. Layout of pJET1.2 plasmid. Restriction enzyme digestion sites are highlighted in bold orange font,
followed by position on sequence cut.
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revealed a single 3.2kbp product, consistent with amplified DARC gene.
Fifty nanograms of purified gene product was ligated into the pJET1.2/blunt Cloning
vector (Figure 3.2). Given the 3.2 kbp size of the product, a 3:1 product-to-vector
ratio was used as per kit protocol.
Four microlitres of the ligation mixture containing cloned DARC gene and 2µl of
ligation mixture and separately control PCR product (supplied with kit) were used
directly for transformation of Alpha-Select Gold Efficiency bacteria, as per
manufacturer’s instructions.
Either 50µl or 100µl of transformation reaction was spread onto 10 LB agar plates
containing 100µg/ml of carbernicillin and ampicillin (CAM). Cultures incorporating
vector with control PCR product were run in parallel. Plates were incubated overnight
at 37°C.
Individual colonies were picked and incubated overnight in 5ml cultures of LB broth
at 37°C and agitated at 200 rpm.
Plasmid DNA was purified using the Thermo Scientific GeneJET Plasmid Miniprep Kit,
from 2ml of overnight cultures, yielding between 2.5µg and 8.8µg of plasmid DNA.
Approximately 500ng of plasmid DNA was used for restriction enzyme analysis,
undertaken utilising EcoRI restriction enzyme (Fermentas), which is predicted to cut
product at position 1090 and 2996, giving a 1906 fragment and vector backbone. Gel
electrophoresis on 0.7% agarose gel revealed the presence of predicted bands in 9 out
of ten clones.
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All clones were sequenced, and initial screening confirmed the absence of T-46C
GATA promoter mutation, and the presence of A at position 1142, indicating the FYB
DARC allele was incorporated in clones.
Clone 3 was selected, and fully sequenced. The following mutations were noted:
Position from beginning Change in sequence
627 G/C
808 T deleted
3126 G/A
2635-2638 GTGT deleted
Table 3.1 Mutations detected in FYB construct C3. All were present in non-coding and non-
regulatory regions.
As all mutations were located present outside coding and regulatory regions, it is
unlikely that these mutations are of implication in the gene product.
Gene product was amplified as detailed for the FYB(ES) construct. Restriction analysis
was undertaken utilising EcoRI restriction enzyme with 100ng of plasmid DNA, and
expected bands were visualised with gel electrophoresis on 0.7% agarose gel. Repeat
sequencing was undertaken, and no further mutations were noted in the amplified
product. Vector excision was then performed as for the FYB(ES) construct.
Gene product (1µg) was provided to Dr Andrea Bacon for micro-injection into
fertilised oocytes from DARC KO mice.
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3.5 Results
3.5.1 FYB(ES) and FYB transgenic mouse strains
3.5.1.1 FYB(ES)TG founder screening
Screening for founders was undertaken through genotyping PCR utilising F62/R402
primers recognising only human DARC gene. One positive female founder was mated
with DARC KO male and offspring were genotyped (Figure 3.3).
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Given the presence of background bands, RT-PCR based genotyping was undertaken
using Taqman gene expression assays for human DARC and murine GAPDH in a
multiplexed system Figure 3.3b. This also allowed the determination of relative gene
dosage as per Wishart et al., 2007 in offspring relative to the founder. Assuming that
the founder animal has an arbitrary gene dosage of 1, dosages of approximately 1, 0.6
a
b
Figure 3.3 Agarose Gel electrophoresis of PCR products from potential FYB(ES)TG founders (a). Lane ‘L8-7’ is
positive, other lanes exhibit background bands (see DARC KO and POS CONTROL lanes). RT-PCR of lysed tissue
using Taqman primers confirmed the genotype, revealing three possibilities for genetic transmission of transgene
(b).
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and 0.3 were detected. It is therefore likely that there are 3 insertions of FYB(ES)
DARC transgene, two of which are likely in close chromosomal proximity
(dosage=0.6) as breeding of this substrain does not lead to offspring with gene
dosage of 0.3. Offspring of animals harbouring gene dosage 0.6 or 1.0 were used in all
experiments.
3.5.1.2 Screening for FYBTG founder
Screening for founders was undertaken through the transgenic genotyping PCR using
the same F62/R402 primers recognising only human DARC gene, as used for
FYB(ES)TG. One positive male founder was mated with DARC KO female and
offspring were genotyped, Figure 3.4.
Figure 3.4 Agarose gel electrophoresis of PCR products from potential FYBTG founders. Lane ‘B1-3’ is positive,
other lanes exhibit background bands (see DARC KO and POS CONTROL lanes). FYB Human donor used as
positive control.
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3.5.1.3 DARC gene expression
To determine whether genomic transmission correlated with gene transcription, RNA
was extracted from organs and tissues of FYB(ES)TG and FYBTG mice and transcribed
into cDNA, after which relative DARC gene expression was quantified against a house
keeping gene GAPDH, Figure 3.5a. Notably DARC expression is relatively low in
FYB(ES)TG bone marrow samples rather than absent, as probably the endothelial cells
have been flushed out and account for the low level of DARC expression.
3.5.1.4 Erythrocyte DARC expression
Approximately 1 x 106 erythrocytes from DARC KO, FYB(ES)TG and appropriate
positive control erythrocytes (either human FYB or C57Bl/6 wild-type) were
incubated with anti-Fy6 (followed by anti-mouse fluorescent antibody) or directly
lablled anti-murine DARC-488 and examined by flow cytometry. Neither of these
antibodies bound to FYB(ES)TG erythrocytes (Figure 3.5c and d), indicating neither
human nor murine DARC are present in normal conformations FYB(ES)TG erythroid
cells. In contrast, anti-Fy6 incubation with FYBTG erythrocytes followed by secondary
fluorescent antibody showed binding similar to human FYB erythrocytes.
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3.5.1.5 Detection of DARC expression in tissues by immunofluorescence
Acetone fixed frozen sections of human or murine spleen were incubated with anti-
Fy6 antibody, followed by appropriate secondary antibody, which revealed positive
staining in FYBTG and FYB(ES)TG in a distribution similar to human, along venules of
red pulp and larger veins, Figure 3.6b and e, none of which was present in WT, Figure
3.6f, or DARC KO spleen (not shown).
a
b c
Figure 3.5 Relative DARC gene expression in humanised DARC FYB(ES)TG and FYBTG mice and genotype
negative control tissues (a), results from one animal examined for each strain. Erythrocyte expression of human
DARC was measured in FYB(ES)TG and FYBTG with anti-Fy6 antibody, with DARC KO and human DARC-
positive controls (b), and erythroid cell antibody staining confirmed the absence of murine DARC (c). Graphs
representative of erythroid DARC expression in at least 7 animals of respective strains
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Similarly, frozen section of human and FYB(ES)TG skin showed positive staining with
anti-Fy6 antibody which were not present in WT, Figure 3.6c and d.
a b
c d
e f
Figure 3.6 anti-Fy6 Immunofluorescent staining of (a) Human spleen 25x tile scan, (b) FYB(ES)TG spleen 40x
tile scan, (c) human skin 25x, (d) FYB(ES)TG skin 40x, (e) FYBTG spleen 10x and (f) WT spleen 10x
magnification. For this particular staining, goat anti-mouse IgG2b FAB2 Alex Fluor 555 was used, to reduce
potential background in a ‘mouse-on-mouse’ system. Human DARC staining is highlighted along venules and the
red pulp of the spleens, whereas in the skin sections it is most evident along the venous plexus and smaller
vessels.
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3.5.2 Binding of mouse chemokines to human DARC
It has been established that human chemokines bind to murine DARC (Luo et al.,
1997, Lee et al., 2003b). To explore whether human DARC is a functional receptor for
mouse chemokines we made use of the known cross-competition of chemokines and
the anti-Fy6 antibody binding to human DARC (Tournamille et al., 1997). Anti-Fy6
recognises an epitope within the chemokine binding pocket of DARC and does not
recognise DARC ligated by a chemokine. Preincubation of human erythrocytes with
increasing concentrations of murine CXCL1, a ligand for DARC, and with human
CXCL8 (a positive control), lead to decreased anti-Fy6 binding. Conversely neither
human CCL21 (not a DARC ligand, negative control), nor murine CXCL12 cross-
competed for binding of anti-Fy6 antibody, Figure 3.7.
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a
b
c
d
Figure 3.7 Chemokine-anti-Fy6 antibody binding competition assay. Human CXCL8 is a high affinity hDARC
ligand (a), whilst hCCL21 is not (c). Anti-Fy6 fluorescence on human erythrocytes is not reduced following
incubation with mCXCL12 (d) but is reduced with murine CXCL1 (b). Approximately 1x106 DARC-positive
erythrocytes in suspension with PBS + 0.5% BSA were incubated with PBS or chemokine, and then anti-Fy6
antibody (or isotype control where stated) was added, followed by secondary antibody and the samples washed.
Along each FACS plot a non-linear curve of best fit for that experiment is shown.
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3.6 Discussion
Two strains of mice were created to study the role of erythroid DARC and examine
mechanisms leading to the peripheral neutropaenia seen in chimeras lacking erythroid
DARC. The main human polymorphisms of DARC, FYB(ES) and FYB, were cloned and
gene sequences amplified after which they were injected into the fertilised oocytes of
DARC KO mice. Founders were screened and two new colonies established. DARC
expression was determined by analysis of gene expression and immunofluorescence.
These results demonstrated that transgenic expression of the human DARC alleles
FYB(ES) and FYB in a mouse host allowed for effective transcription and translation
of the human DARC following the expression pattern similar to human. Both in
homozygous human carriers of the FYB(ES) allele and mice of the FYB(ES)TG strain
there is an absence of DARC expression on erythrocytes. Conversely, expression on the
endothelium is maintained in both FYB(ES)TG and FYBTG strains as shown in spleen
sections. Thus in FYBTG human DARC is expressed both in mouse endothelium and
erythrocytes concordant with the human expression pattern in the carriers of the FYB
These models have been subsequently used for dissecting the role of DARC in specific
compartments, namely bone marrow erythroid DARC, and blood erythrocyte DARC.
Given the abundance of erythroid cells in the bone marrow expressing DARC, a
receptor for ELR+ chemokines, significant questions on the role of erythroid DARC on
HSPC and granulocyte lineage development in the DARC-deficient and FYB(ES)
transgenic mice remain. As discussed above, individuals of African ancestry have
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changes in HSPC cell cycle kinetics and mobilisation, in particular relating to effects
on HSPC gene expression and maturation, and the mechanisms for these changes are
unknown. The relationship of these alterations in HSPC with peripheral blood
leukopenia exhibited by Duffy negative humans and WT-KO chimeric mice requires
mechanistic dissection and in particular the role, if any, of homeostatic and mobilising
chemokines and cytokines within the bone marrow environment and peripheral blood.
The DARC deficient, FYB(ES)TG and FYBTG mouse strains have been utilised in order
to investigate these and related questions, as shown in Chapter 4.
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Haematopoietic phenotypes of DARC KO, FYB(ES)-
transgenic and FYB-transgenic mice
4.1 Introduction
In order to ascertain the contribution of DARC on erythroid cells to the bone marrow
homeostasis, the fundamental parameters of haematopoiesis were compared in WT,
DARC KO, FYB(ES)TG and FYBTG mice. Owing to time limitations imposed by the
development of the FYBTG mice, only a limited number of observations and not all
parameters are available for this strain.
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4.2 Materials and methods
The development of mouse strains used and the preparation of bone marrow for FACS
analysis are detailed in Chapter 2.
4.2.1 Adoptive bone marrow transfers in irradiated hosts:
competitive mixed chimerism
The whole bone marrow was transplanted following lethal irradiation (9 Gy) of BoyJ
murine recipients expressing CD45.1 by tail vein injection of 107 cells in 200µl PBS.
The experiment was setup such that competitor bone marrow cells, from either
CD45.2 DARC KO or wild-type mice, were mixed with CD45.1xCD45.2 competitor
cells. The injected cells were analysed to confirm correct mixing before injection.
The analysis of the degree of donor chimerism, and the expression of DARC on
erythrocytes was undertaken as detailed in Chapter 2.
Peripheral blood cell counts were assayed at 6, 9 and 12 weeks post transfer by
collecting blood by tail bleed in 100µl PBS + 10mM EDTA, and the proportions of
competitor cells determined. Fifty microlitres of the sample was incubated using
antibodies against Gr-1 (FITC), CD43 (PE), CD45.1 (PE-Cy5), CD11b (PE-Cy7), B220
(Pacific Blue), CD4 and CD8 (both on APC), and CD45.2 (APC-Cy7), all from
eBioscience, UK. The samples were then analysed using a CyAn ADP flow cytometer
(Dako, Ely, UK).
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The LSK selected chimera experiment was conducted identically, except that bone
marrow cells from either CD45.2 DARC KO or wild-type mice were FACS sorted (see
section “4.2.3 FACS sorting”) for LSK cells, and 500 cells from either CD45.2 DARC
KO or wild-type were mixed with 106 CD45.1xCD45.2 competitor cells prior to
injection into each irradiated host mouse. In this experiment, peripheral blood cell
counts were assayed at 4, 8 and 16 weeks post transfer.
4.2.2 Peripheral blood cell counts
Absolute and differential leukocyte counts were determined as detailed in Chapter 2,
but the following antibodies were used: 1µl of anti-Ly6G-PE, 1µl of CD11b-FITC, 1µl
of CD3-APC antibodies (eBioscience, UK) and 1µl of anti-B220-PerCP (BD Bioscience,
UK)
The total blood leukocyte count was calculated as the sum of the counts of CD11b+,
CD3+ and B220+ cells. This was correlated with the total white cell count obtained by
the automated ABX Pentra 60 (Figure 4.1).
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4.2.3 FACS sorting for HSPC
Bone marrow of wild-type or DARC KO mice was flushed as described, and cells
stained with lineage-APC (BD), CD34-FITC, CD16/CD32-Biotin, cKit-PE, Sca1-PECy7
(eBioscience) in 500µl buffer, for one hour on ice. Cells were washed twice and then
incubated with streptavidin PE-Cy5.5 (Invitrogen) in 500µl buffer for 20 minutes on
ice. The cells were sorted on a Mo-flow MultiLaser flow cytometer (Beckman Coulter)
operated by Mr Roger Bird, an experienced technician. First, an enrichment step was
undertaken, with gates set based on forward and side scatter characteristics for
lineage negative and either GMP cells (lineage-negative, ckit-positive, Sca1-negative,
CD34-positive, CD16/CD32 positive) or LSK cells (lineage-negative, ckit-positive,
Sca1-positive). Then, the enriched populations then underwent a second ‘purity’
sorting step on the same gating profiles. Cells were collected in Eppendorf tubes and
kept on ice. The final GMP and LSK populations were determined to be more than
0.9612
0.9238
Figure 4.1 Correlation between total leukocyte counts obtained by FACS-based method using counting beads (y-
axis) and Pentra automated cell analyser (x-axis), p<0.0001
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94% pure. After sorting, Eppendorf tubes containing sorted cells were centrifuged at
5000g for 5min and the supernatant was carefully removed by pipette, after which the
tubes were immediately placed on dry ice for storage at -80oC until used.
4.2.4 mRNA Microarray
RNA was extracted from FACS sorted GMP and LSK populations by Mr Stephen
Kissane using Trizol (Life Technologies) as per manufacturer’s directions. 25ng of
each source sample RNA was labelled with Cy3 dye as per the protocol detailed in the
Low Input Quick Amp Labelling Kit (Agilent Technologies). A specific activity of
greater than 6.0 was confirmed by measurement of 260nm and 550nmwavelengths
with a NanoDrop ND-1000 Spectrophotometer. 600ng of labelled RNA was hybridised
for 16 hours to Agilent SurePrint G3 Human 8x60K microarray slides. After
hybridisation slides were washed as per protocol, and scanned with a High Resolution
C Scanner (Agilent Technologies), using a scan resolution of 3µm. Feature extraction
was performed using Agilent Feature Extraction Software, with no background
subtraction.
Scanned microarray images were analysed using Agilent’s Feature Extraction software
by Dr Wen Bin Li. Feature intensities were background-subtracted according to the
normal-exponential convolution model (Silver et al., 2009) and normalised using
quantile normalisation (Bolstad et al., 2003). Microarray annotation (GPL13497) was
downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/). Differentially expressed
genes were identified using limma (Smyth, 2004) with fold change >1.5 and p<0.01.
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4.2.5 Low density gene array
Low density gene array cards (LDA), also known as microfluidic cards, were custom
ordered from Applied Biosystems. Each assay contained gene-specific primers, probes
and a reaction buffer for reverse transcription and real-time PCR. Gene expression of
FACS sorted LSK and GMP cells from WT, DARC KO and FYB(ES)TG mice were
analysed using a LDA containing 32 real-time PCR assays per sample (listed in
Appendix 7.4 and 7.5,). Genes were selected from micro-array results based on their
differential expression or importance in regulating HSPC development. In total, 29
genes were selected, and up to four samples per genotype were analysed in triplicate.
Each card was designed such that a WT, DARC KO and FYB(ES)TG sample were
analysed simultaneously. For some genes, real-time PCR assays contained primers
designed within a single exon and would detect genomic DNA. Therefore RNA was
treated with DNase to remove contaminating genomic DNA. Gene 18S was selected as
a positive control, and GAPDH and HPRT were used as housekeeping genes.
4.2.5.1 Bone marrow cell preparation and FACS sorting
Bone marrow cells from WT, DARC KO and FYB(ES)TG mice were prepared and FACS
sorted as detailed in section 4.2.3, and at least 6000 LSK or GMP cells were collected
per genotype.
4.2.5.2 RNA extraction from FACS sorted cells
RNA was extracted using the Qiagen RNeasy Micro Kit as per the manufacturer’s
instructions. Briefly, cell pellets were thawed at room temperature and loosened by
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flicking, then disrupted by adding 75µl RLT buffer, and were homogenised by
vortexing for 1min. 75µl 70% ethanol was added and mixed thoroughly by pipetting.
The sample was transferred to an RNeasy MinElute spin column placed in a 2ml
collection tube and centrifuged for 15s at 8000g, and the flow-through discarded.
700µl buffer RW1 was added to the spin column and centrifuged for 15s at 8000g,
and the flow-through discarded. The spin column was placed in a new 2ml collection
tube and 500µl buffer RPE was added, after which the column was centrifuged for 15s
at 8000g, and the flow-through discarded. 500µl 80% ethanol was then added to the
spin column. The spin column was placed in a new 2ml collection tube and
centrifuged at full speed (16,000g) with the lid open, after which flow-through and
collection tube were discarded. The spin column was placed in a new 1.5ml collection
tube and 14µl RNase-free water was added to the spin column membrane. The lid was
closed and the tube was centrifuged at full speed resulting in 12µl eluate containing
RNA.
4.2.5.3 Digestion of contaminating genomic DNA
RNA was treated with DNase to remove contaminating genomic DNA. Briefly, the
RNA eluate was mixed with 10µl buffer RDD and 2.5µl DNase I and made up to a
total volume of 100µl. The mixture was incubated at room temperature for 10min.
350µl of buffer RLT was added and mixed, after which 250µl 100% ethanol was
added and mixed by pipetting. The sample was transferred to an RNeasy MinElute
spin column placed in a 2ml collection tube and centrifuged for 15s at 8000g and the
flow-through discarded. The sample was then treated as detailed earlier (using buffer
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RW1, 80% ethanol and RPE buffer) and a 12µl eluate containing RNA with genomic
DNA removed was obtained.
4.2.5.4 First-strand cDNA synthesis (RT)
The concentration of total RNA was determined as detailed above and RT performed
using SuperScript VILO cDNA Synthesis Kit (section 3.2.2.3).
4.2.5.5 Quantitative real-time PCR
Quantitative real-time PCR was performed as per the manufacturer’s instructions.
Briefly, 50µl of sample cDNA and 50µl of TaqMan Gene Expression Master Mix
(Applied Biosystems) were thoroughly mixed and loaded into each port of the
microfluidic card. The microfluidic card was centrifuged twice at 300g for 1min in a
vertical Heraeus centrifuge fitted with the Heraeus custom buckets and card holders.
The plate was sealed using a TaqMan Array Micro Fluidic Card Sealer (Applied
Biosystems) and the filling strips were cut off. The card was then placed in an Applied
Biosystems 7900HT Fast Real-Time PCR cycler. The cycling program was provided by
the manufacturer by means of a configuration file; the conditions for real-time PCR
were 50˚C for 2min, 95˚C for 10min then 40 cycles of 95˚C for 15s and 60˚C for 
1min.
Fluorescence analysis was performed utilising SDS v2.4 software with a threshold set
manually during the logarithmic phase of the PCR. The threshold cycle (CT) value was
then used to calculate the change in expression of each gene relative to the geometric
mean of the housekeeping genes GAPDH and HPRT for WT samples (∆C  ), resulting in a
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∆∆C  value for DARC KO and FYB(ES)TG samples. The fold change of each gene relative
to the housekeeping genes was obtained by the 2  ∆∆    method, and the relative
quantification was plotted. Genes which had a CT value >40 were below assay detection
level and were assigned an RQ value of zero. Statistical significance was calculated using
the ∆∆C  values and the unpaired Student t test.
4.2.6 Multiplex cytokine array and chemokine ELISA
For protein array measurement using Luminex-based platform (Luminex, USA), bone
marrow supernatant was obtained from tibias and femurs of wild-type, DARC KO and
FYB(ES)TG mice by centrifuging each bone with epiphysis cut-off in a 200µl pipette
tip at 500g for 8 minutes, a method from Ergen et al., 2012. The supernatant was
pooled and protein contents quantified. Alternatively, for chemokine ELISA, both
femurs were flushed in 1ml of PBS containing EDTA 2mM, and the supernatant
removed by pipette after centrifugation at 3000g for 10 minutes. Afterwards, samples
were stored at -80°C until assayed. Serum was obtained by allowing blood to clot for 2
hours following cardiac puncture of anaesthetised mice, and thereafter centrifuged at
10,000g for 10 minutes. Samples were stored at -80°C until assayed. Multiplex
cytokine array assay was undertaken using Millipore mouse 32plex plates, as per the
manufacturer’s recommendations, washed with a magnetic plate washer, and
analysed using a Biorad Bioplex 200 using the manufacturer’s software. Analytes
included G-CSF, CCL11 (eotaxin), GM-CSF, interferon gamma, IL-1A, IL-1B, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12P40, IL12P70, LIF, IL-13, CXCL5 (LIX), IL-5, IL-
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17, CXCL10 (IP-10), CXCL1 (KC), CCL2 (MCP-1), CCL3 (MIP-1A), CCL4 (MIP-1B),
CXCL9 (MIG), CXCL2 (MIP-2), CCL5 (RANTES), VEGF, TNF-Alpha.
CXCL12 ELISA was carried out using Mouse CXCL12 DuoSet according to the
manufacturer’s instructions (R&D Systems).
4.2.7 Bone marrow cell cultures
Methylcellulose supplemented with cytokines and growth factors as detailed below
(M3434, Stem Cell, France) and penicillin 100iu/ml and streptomycin 100iu/ml was
used for bone marrow colony assay. This medium was selected as it is formulated to
support optimal growth of erythroid, granulocyte-macrophage and multi-potential
murine myeloid progenitors. The methylcellulose in Iscove’s medium contained fetal
bovine serum and bovine albumin, recombinant human (rh) insulin, iron-saturated
human transferrin, 2-mercaptoethanol, recombinant murine (rm) stem cell factor,
rmIL-3, rmIL-6, rh-erythropoietin and other supplements not revealed by the supplier.
Cells were grown in 35mm plates (Stem Cell, France) in triplicate in a humidified
atmosphere with 5% CO2. Cells were harvested from mouse bone marrow, red cell
lysed and resuspended at a concentration of 2x105/ml in buffer. Four hundred
microlitres of this solution were added to 4ml of M3434 media using a 2ml syringe
and blunt end needles (Stem Cell, France). The mixture was well mixed and bubbles
allowed to disperse, whereupon 1.1ml of media was added to plates and evenly
dispersed. Cells were grown for 7 days and then colonies were scored. Occasionally,
colonies would be selected, mixed into 100µl of phosphate buffered saline, and
cytospun for confirmation of colony type. Colonies were washed off with PBS, and
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washed twice in 50ml conical tubes. The total number of cells present was counted
with a disposable haemocytometer. In some experiments, the cells were incubated
with fluorescent antibodies as previously described, and analysed by flow cytometry.
In some experiments, 200,000 cells were also selected for re-culture, and were
prepared as above. Two sequential re-platings were performed.
In addition, LSK cells were FACS-sorted as described previously, and suspended in
400µl. This mixture was added to 4ml of M3434 media and processed as described
above.
4.2.8 Measurement of bone marrow cell proliferation by the BrdU
incorporation assay
In order to assay cell proliferation of the bone marrow cell populations, the BD
Bioscience APC BRDU flow kit (BD Bioscience, UK) was used as per the
manufacturer’s instructions. 5-bromo-2’-deoxyuridine (BrdU) is a thymidine analogue
which is incorporated into DNA during cell cycle. Briefly, 1mg of BRDU as supplied in
the kit was injected intra-peritoneally into wild-type, DARC KO or FYB(ES)TG mice
and the animals were culled after 2 hours. Femurs were cleaned and flushed with PBS
+ 2% BSA + 2mM EDTA, and bone marrow was lineage depleted using the mouse
lineage depletion kit from Miltenyi Biotec (Surrey, UK) as per the manufacturer’s
instructions. Bone marrow cells were incubated with biotinylated lineage antibodies,
washed and incubated with magnetic beads linked to streptavidin, permitting removal
of lineage positive cells after passage through a magnetic column. Subsequently
lineage negative cells were washed and incubated with streptavidin e450, anti-c-Kit-
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APC-Cy7, anti-Sca-1-PE/Cy7, anti-CD127-e450, anti-CD34-FITC, anti-CD16/CD32-
PE/Cy5.5, anti-CD135-RPE (all eBioscience, UK), for one hour on ice. Cells were then
washed, fixed and permeabilised, and then stained with anti-BRDU-APC before
analysis by flow cytometry.
4.2.9 Measurement of bone marrow cell apoptosis by Annexin V
staining
Rates of apoptosis were analysed in WT, DARC KO and FYB(ES)TG bone marrow cells
by staining for Annexin V expression using the Annexin V-FITC Apoptosis Detection
Kit I (BD Biosciences, UK) and 10X Annexin V Binding Buffer (BD Bisociences, UK)
containing 0.1 M Hepes/NaOH (pH 7.4), 1.4M NaCl, 25mM CaCl2 according to the
manufacturer’s protocol with modifications. Dead cells were detected using Sytox Blue
(Life Technologies, UK), a nucleic acid stain which penetrates cells with damaged
membranes but does not cross intact cell membranes.
Femurs were cleaned and flushed with PBS + 2% BSA + 2mM EDTA, red cells lysed
and bone marrow cells were blocked with blocking buffer containing 10% FCS and
anti-CD16/CD32 antibody on ice for 10min. Cells were then centrifuged at 300g for
10min twice and stained with anti-mouse lineage panel-e450, anti-cKit-PE and anti-
Sca1-PE-Cy7 antibody cocktail in rigid 96 well plates for 45min on ice. Cells were then
centrifuged at 300g for 10min and washed twice with ice-cold PBS, and 106 cells from
each sample were resuspended in polypropylene tubes with 500µl 1x binding buffer
(1 part 10x binding buffer diluted with 9 parts distilled water) and 2.5μl of Annexin
V-FITC, and incubated in the dark on ice for 30min. Then 500µl binding buffer was
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added and cells were kept on ice until analysed. Immediately prior to analysis, Sytox
Blue was added at a final concentration of 1:50,000 to each tube, and samples were
analysed by flow cytometry using a CyAn ADP flow cytometer within an hour of
Annexin V staining. Unstained cells were used as negative controls, and positive
controls were prepared by incubating 106 whole bone marrow cells in 500μl staining
buffer at 60oC for one hour, which were then stained for Annexin V expression or
Sytox Blue as detailed above.
4.2.10 Preparation of frozen bone marrow sections and
immunofluorescence
Femora from wild-type, DARC KO or FYB(ES)TG mice were taken, cleaned and placed
in 4% paraformaldehyde for 7 hours at 4oC following which they were rehydrated
with 15% sucrose solution for 4 hours and subsequently 30% sucrose solution.
Femora were sent by courier to the laboratory of Cesar Nombiela Arrieta (Boston,
USA) where they were frozen and stored at -80C. Frozen tissues were sectioned using
a CryoJane Tape-Transfer System (Leica Biosystems), transferred onto slides and
stored at -80C. These were returned to Birmingham, UK for immunofluorescent
staining.
Frozen sections were firstly rehydrated with PBS supplemented with 10% fetal calf
serum for 10 min. Subsequently 100µl of purified mouse anti-rat CD31 antibody
(eBioscience) at 1:50 concentration was incubated at room temperature with PBS
supplemented with 1% bovine serum albumin for 30 minutes, then washed for 5 min
in PBS. The sections were then incubated with donkey anti-rat Alex Fluor 647 (Life
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Technologies) at 1:100 concentration for 30 minutes, and then were washed. CD11b
and Gr-1 antibodies (eBioscience) both biotin conjugated (1:100) were incubated for
30 minutes, and the slides then washed. Finally streptavidin-555 (1:200, Life
Technologies) and Ter119-FITC (1:100, eBioscience) were incubated for 30 minutes,
after which the sections were washed and mounted in ProLong Gold Antifade Reagent
with DAPI (Life Technologies).
A Zeiss LSM 510 Meta confocal microscope (Zeiss) was used to visualise staining of
sections. Images were captured and processed using Zeiss LSM Image Examiner
software (Zeiss).
4.2.11 Analysis and quantification of immunostained bone marrow
sections
Bone marrow sections were captured at 25x and 40x magnifications. Images were
analysed using ImageJ (http://rsb.info.nih.gov/ij/) software, which has the facility for
automation of several procedural steps by the use of macros. This was undertaken as
per Inman et al., 2005. Briefly, the thresholds previously determined from a negative
control slide were applied. This procedure converted the image from multiple 8-bit
channels, each of which contains intensity data from 0 to 255 for a specific
fluorophore, to multiple 1-bit channels containing only positive or negative values (0
or 1) for each fluorophore. The number of pixels of each colour was then
automatically counted and presented as a proportion of the total number of pixels in
the area under analysis. The percentage area of each colour in the area of interest was
then calculated for each image.
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Myeloid cell clustering was determined by standardising the image brightness such
that all cells were visible in their entirety. The images were then thresholded and
converted to binary images. Circles were drawn manually around individual or
clustered myeloid cells, and the number of cells in each cluster noted. The mean
number of myeloid cells per cluster was then determined.
4.2.12 Binding of radiolabelled CCL5 to erythroid cells
Five µCi of radioiodinated CCL5 was purchased from PerkinElmer, UK or Hartmann
Analytic, Germany, depending on availability, and re-constituted in 200µl of PBS with
0.5% BSA. Unlysed bone marrow from WT or DARC KO mice was prepared as
described above, and incubated with a cocktail of fluorescently labelled antibodies
comprising anti-Ter119, CD71, CD11b and B220 (eBioscience). FACS sorting for
erythroblasts was undertaken by gating on larger cells (higher FS), and a negative
dump gate for CD11b+ and B220+ cells was used to minimise leukocyte
contamination. Erythroblasts were selected as Ter119+ and CD71+ cells, and were
collected into RPMI and transferred into 1.5ml Eppendorf tubes. Then 200nM
125I-CCL5 was incubated with each sample in duplicate or triplicate (106 cells)
depending on cell sorting yield. MDCK cells expressing D6 were used as control for
binding and degradation of chemokines. A ‘No Cells’ tube was used as a negative
control. After 3 or 18 hours of incubation at 37ºC with agitation in 200µl of RPMI, the
samples were centrifuged at 300g for 5 min. The supernatant was removed, the pellet
resuspended in RPMI, centrifuged again (supernatant added to Sample S) and then
200µl 10x PBS or 100iu/ml of heparin in 200µl of RPMI were added to the cell pellet
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which was resuspended and incubated for either 3 minutes in PBS or for 10 minutes
in heparin. After incubation, the sample was centrifuged, the supernatant removed
(Sample W), the pellet resuspended in RPMI, centrifuged again (supernatant added to
Sample W) and then the pellet was incubated with 200µl Triton-X 0.5% for 10min
under agitation. After incubation, the sample was centrifuged, the supernatant
removed (Sample C), the pellet resuspended in RPMI, centrifuged again (supernatant
added to Sample C). Then 400µl of 20% TCA was added to all the supernatant tubes,
and the samples incubated on ice for one hour. The tubes were then centrifuged at
16000g for 10min, and the supernatant placed into lidded tubes. The remaining
pellets were resolved in 800µl NaOH 2N and 0.05% SDS before being transferred into
lidded FACS tubes. A calibrated Packard Cobra gamma counter (PekinElmer, USA)
was used to assay the samples. Background was subtracted from the resultant counts.
To control for specific labelling of chemokine the 125I-CCL5 starting material was
assayed by TCA precipitation (Figure 4.2).
Figure 4.2 125I-CCL5 analysis of specificity for labelling.
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4.3 Results
4.3.1 Fundamental parameters and peripheral blood counts
Principally DARC KO and FYB(ES)TG mice have larger spleens as a proportion of
animal weight, Figure 4.3a, and FYBTG have spleen weights similar to WT mice.
Coulter-counter-type analysis showed unchanged haemoglobin and platelets (in WT,
DARC KO and FYB(ES)TG mice) but counts of leukocyte subsets were significantly
reduced in the FYB(ES)TG, Figure 4.4c-e.
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Leukocyte differential count was determined by FACS using counting beads (Figure
4.4). The absolute neutrophil, B220+ and CD3+ lymphocyte counts were significantly
reduced in FYB(ES)TG mice (Figure 4.4b). These measured parameters in FYBTG are
similar to WT mice, suggesting that the absence of haematopoietic DARC is the
principle effector of the changes observed in FYB(ES)TG. The reason for the lower
haemoglobin in FYBTG is unclear; examining the peripheral blood parameters of more
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Figure 4.3 (a) relative spleen weights in wild-type, DARC KO, FYB(ES)TG and FYBTG. Readout from full blood
count: (b) haemoglobin, (c) platelet count and d) white cell count.
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animals may clarify this. It is of note that data comparing the peripheral blood counts
between human Caucasian and African-ancestry groups showed similar a peripheral
blood profile i.e. lower total WBC and lower neutrophils counts in individuals of
African-ancestry (Bain, 1996).
a
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b
Figure 4.4 Differential blood leukocyte counts in WT, DARC KO, FYB(ES)TG and FYBTG mice. (a) Peripheral
blood neutrophils by bead counting and (b) absolute counts of peripheral blood leukocytes divided into main cell
types, WT n=12, DARC KO n=10, FYB(ES)TG n=10, FYBTG n=5.
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4.3.1.1 The bone marrow myeloid cells
In order to further define the haematopoietic profile of the FYB(ES)TG and FYBTG
phenotypes, bone marrow was examined by flow cytometry (Figure 4.5). Bone
marrow cellularity was similar in FYBTG, FYB(ES)TG and WT mice, and slightly
reduced in DARC KO (Figure 4.5a). Of note, bone marrow neutrophil (CD45+ CD11b+
Ly6Ghi) proportions were increased in DARC KO, and more so in FYB(ES)TG, but
unchanged in FYBTG, compared to WT mice (Figure 4.5b). The proportion of bone
marrow monocytes (CD45+ CD11b+ Ly6Gneg CD115+) were lower in FYB(ES)TG as
compared to DARC KO mice, possibly as a result of their higher neutrophil proportions
(Figure 4.5c). There was no difference in blood monocyte numbers (Figure 4.5d),
however the subset of Ly6Clow monocytes was notably increased in DARC KO and
FYB(ES)TG mice (Figure 4.5e).
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Figure 4.5 Bone marrow cellularity and myeloid cell composition. Bone marrow cellularity (a), relative
proportions of bone marrow neutrophils (b), and monocytes (c). Examination of blood revealed no difference in
monocyte numbers (d). There is an increase in Ly6Clow monocytes in DARC KO and FYB(ES)TG (e). Absolute bone
marrow neutrophil numbers (f) suggests no difference between WT, DARC KO and FYBTG mice, although in
FYB(ES)TG neutrophils are significantly elevated.
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Absolute neutrophil numbers are substantially increased in the bone marrow of the
FYB(ES)TG as compared to WT, DARC KO and FYBTG mice (Figure 4.5f).
Neutrophils in the bone marrow of DARC KO, FYB(ES)TG and FYBTG have lower
CD11b expression (Figure 4.6a), whilst blood CD11b expression is unchanged in
DARC KO compared to WT or FYBTG mice and is increased in FYB(ES)TG
a b
*** ***
24 22 27
*
24 21 28
c
*** **
11 13 10
Figure 4.6 Expression of surface molecules on bone marrow and blood neutrophils. Absolute CD11b expression in
bone marrow neutrophils (FSMed-Hi SSCHi CD45+ CD11b+ Ly6GHi) (a). (b) Blood neutrophils CD11b expression
relative to WT: four experiments were combined, and expressed as percentage of WT for each experiment. (c)
CD16/CD32 expression of bone marrow neutrophils (Live, FSmed-Hi, SSCHi).
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(Figure 4.6b). The reasons for these contrasting phenotypes (bone marrow vs. blood)
are not clear. However, increased systemic G-CSF as measured in DARC KO and
FYB(ES)TG mice, may lead to upregulation of neutrophil adhesion molecules in the
peripheral circulation (see section 4.4 Discussion).
Furthermore, the expression of CD16/CD32, the FcγRIII and FcγRIIa, is higher on the
neutrophils of the DARC KO, FYB(ES)TG and FYBTG bone marrow (Figure 4.6c).
4.3.1.2 Spleen myeloid cells
Examination of the spleen myeloid cells (Figure 4.7) revealed no significant change in
neutrophils in FYB(ES)TG, but their absolute numbers were increased due to the
increase in spleen size.
a b
*
Figure 4.7 Spleen myeloid cell analysis. (a) Neutrophils and monocytes as a proportion of CD45+ cells in the
spleen; WT n=6, DARC KO n=5, FYB(ES)TG n=5. (b) Absolute neutrophil numbers in the spleen.
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4.3.1.3 Lymphoid cells in bone marrow and spleen
B lymphocytes comprise approximately one-third of the murine bone marrow
(Dogusan et al., 2004); however in the DARC KO these proportions are reduced,
probably given the expanded myeloid series (Figure 4.8). T Lymphocytes are also
slightly reduced, possibly on the same basis. The FYB(ES)TG spleen harbours more B
lymphocytes, proportionally, but fewer T lymphocytes. Given the substantial splenic
enlargement in the FYB(ES)TG it is unlikely that this represents any actual reduction
in lymphocyte numbers.
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FYBTG bone marrow analysis of total lymphoid cells (both B and T lymphocytes)
show that lymphocytes are increased compared to FYB(ES)TG (Figure 4.9), with
results for FYBTG similar to WT mice (data not shown).
a
****
**
**
b
*
**
Figure 4.8 B and T Lymphocytes as a proportion of CD45+ cells in the bone marrow (a), and the spleen (b). WT,
n=12, DARC KO, n=12, FYB(ES)TG, n=6, in bone marrow, WT, n=11, DARC KO, n=11, FYB(ES)TG, n=6 in
spleen.
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4.3.1.4 Bone marrow and splenic erythropoiesis
In order to account for the larger spleen seen in DARC KO and FYB(ES)TG mice
compared to WT mice, erythroid proportions were examined in both bone marrow
and spleen of these mice, with preliminary results for FYBTG shown (Figure 4.10).
There was a significantly reduced erythropoietic component in both DARC KO and
FYB(ES)TG bone marrow. Spleens of FYBTG mice in contrast show erythroid
proportions comparable to WT mice. In FYB(ES)TG mice there was a significantly
altered erythroblast maturation profile, with reduced early erythroblasts and more
late erythroblasts. Within the spleen, erythropoiesis comprised a significantly large
proportion of all cells in the FYB(ES)TG, although there was no difference in DARC
KO compared to WT mice.
**
Figure 4.9 B and T Lymphocytes as a proportion of CD45+ events in the bone marrow (CD3+ and B220+), results
of preliminary experiment comparing FYB(ES)TG and FYBTG mice, n=5. Mean lymphoid proportions in FYBTG
are similar to WT (data not shown, see Figure 4.8 for WT)
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The maturation profile in the spleen was opposite to bone marrow with significantly
more mid erythroblasts in the DARC KO and FYB(ES)TG mice spleens but only DARC
KO showed significant difference in late erythroblasts, reduced in turn, suggesting
that the spleen has fewer mature erythroblasts in DARC KO. This may be due to
erythrocytes leaving the spleen into the blood sooner upon maturation.
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Figure 4.10 (a) Erythroid cells, as a proportion of all cells in unlysed bone marrow, (b) proportions of erythroid
progenitors, as a proportion of all Ter119+ cells, WT n=6, DARC KO n=6, FYB(ES)TG n=11, FYBTG n=5. (c)
Splenic erythroid cells as a proportion of all unlysed cells, n=6 per genotype, and (d) proportions of splenic
erythroid progenitors, as a proportion of all Ter119+ cells, n=6 per genotype.
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Since the spleen is a haematopoietic organ in mice, and given the differences in these
profiles, the data could be interpreted as suggesting that the more prominent myeloid
mass in the bone marrow directs a ‘compensatory’ erythropoiesis in the spleen of
FYB(ES)TG mice. Alternatively the chemo- or cytokine profile may be less favourable
towards bone marrow haematopoiesis. It is well known from human pathology that
ineffective haematopoiesis or erythropoiesis gives rise to extramedullary
haematopoiesis (Greer and Wintrobe, 2004), and splenomegaly is a feature of these
conditions. Potentially a pro-granulocyte haematopoietic environment may lead to a
translocation of erythropoiesis to the spleen in the maintenance of normal
haemoglobin levels.
4.3.1.5 Bone marrow stem and progenitor cell profiles
Myeloid and lymphoid progenitors
FYB(ES)TG mice, and to a lesser extent DARC KO, have increased myeloid cells in the
bone marrow but reduced lymphoid and erythroid cells, yet in the peripheral blood
there is a relative neutropaenia in FYB(ES)TG compared to WT mice. However it is
not clear whether this represents over-production of myeloid cells or a failure to
release these cells under homeostatic conditions.
Examination of the HSPC populations revealed that myeloid progenitors are reduced
in FYB(ES)TG and DARC KO mice, in particular due to reduction in GMP (Figure
4.11), which are reduced by approximately a third in both absolute and relative
terms. MEP were also reduced implying altered maturation in the myeloid lineage.
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a b
d
Figure 4.11 Analysis of myeloid progenitor cells. (a) Representative gating of lineage negative cells and myeloid
progenitors in WT, DARC KO and FYB(ES)TG mice. (b) Myeloid progenitors in WT (n=6), DARC KO (n=5),
FYB(ES)TG (n=5), (c) GMPs as a proportion of all cells in WT (n=6), DARC KO (n=5), FYB(ES)TG (n=5). (d)
Other myeloid progenitor populations. Data from one experiment, representative of 4 independent experiments.
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As a proportion of all cells, CLP (Lin– cKit+ Sca1+ IL7RA+ Flt3Hi) were reduced in both
DARC KO and FYB(ES)TG (Figure 4.12). In a preliminary experiment, (Figure 4.13),
FYBTG had a GMP profile similar to WT mice, although myeloid progenitors were not
different, and CMP were reduced in comparison to FYB(ES)TG. These results will
require validation, but it is notable that the GMP difference between transgenic mice
with and without erythroid DARC, show the same pattern as in chimeras, and WT and
FYB(ES)TG respectively.
a
Figure 4.12 Analysis of lymphoid progenitor cells. (a) Representative gating of lineage negative cells and common
lymphoid progenitor (CLP) region in WT, DARC KO and FYB(ES)TG mice. (b) CLP cells as a proportion of all cells.
Data from one experiment (n=6 per genotype), representative of 3 independent experiments.
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LSK cells
DARC KO and FYB(ES)TG mice had reduced granulocyte progenitors and lymphoid
progenitors, whereas preliminary analysis of FYBTG mice bone marrow appeared
similar to WT mice. In order to determine where the reduced GMP and CLP might be
due to alterations in MPP maturation, the LSK cells were examined. LSK cells were
reduced in DARC KO and FYB(ES)TG, mainly due to a reduction in MPP cells, by
approximately a third to a half in some cases. LT- & ST-HSC were not altered as a
proportion of all cells (Figure 4.14).
a b
*
c d
*
Figure 4.13 Preliminary analysis of sub-populations of myeloid progenitor cells as a proportion of all cells in
FYB(ES)TG and FYBTG, n=5 per genotype. (a) Myeloid progenitors, (b) GMPs, (c) MEPs and CMPs, and (d) CLP.
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Preliminary examination of LSK cells in the FYBTG bone marrow (Figure 4.15) reveals
that LSK cells are no different in proportions of total bone marrow compared to
FYB(ES)TG mice. As a proportion of all cells, ST-HSC and LT-HSC were reduced and
a
c d
Figure 4.14 Analysis of LSK cells. (a) Representative gating of lineage negative cells and LSK region in WT, DARC
KO and FYB(ES)TG mice. (b) LSK cells as a proportion of all cells. LSK populations as a proportion of (c) all cells;
and (d) as a proportion of parent population. Data from one experiment (n=6 per genotype), representative of 4
independent experiments.
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MPP cells were not different in FYBTG mice. However as a proportion of LSK sub-
groups, MPP cells in FYBTG mice are increased relative to FYB(ES)TG, and ST-HSC
are reduced, and these findings are similar to those observed in WT mice. Verification
of this finding and analysis of LSK sub-populations of FYBTG mice is required.
It is unclear as to the reasons why LSK cell proportions are not different in FYBTG
mice comparison to those of FYB(ES)TG mice, given the prominent phenotypic
similarity of FYBTG to WT mice.
a
b c
Figure 4.15 (a) LSK were unchanged between FYB(ES)TG and FYBTG mice, and (b) MPP were unchanged as a
proportion of all cells, they were increased in FYBTG (c), similar to WT mice. Data from one experiment (n=5
per genotype), a preliminary experiment comparing FYB(ES)TG and FYBTG mice.
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Multi-potent progenitors
As described earlier, MPP can be divided into three populations depending on VCAM-
1, CD62L, and expression of FLT3, with a population with mainly GM potential, GMPP
(VCAM-1+, CD62L+, Flt3lo), a population with mainly lymphoid potential, termed
LMPP (VCAM-1-, CD62L+, Flt3Hi), and a CMP population with retained
megakaryocytic-erythroid potential (VCAM-1+, CD62L-, Flt3neg). DARC KO and
FYB(ES)TG mice had a significant reduction in GMPP of approximately 50% whereas
FYB(ES)TG also exhibited a reduction in CMP. This in concordance with both the
reduced GMP and overall reduction in myeloid progenitors (Figure 4.16).
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a
b
Figure 4.16 Analysis of multi-potent progenitor subtypes. (a) Representative gating of lineage negative cells and
LSK region in WT, DARC KO and FYB(ES)TG mice. (b) Multipotent progenitors as a proportion of LSK cells. Data
from one experiment (n=6 per genotype), representative of 3 independent experiments. CMP, common myeloid
progenitors; GMPP, Granulocyte macrophage primed progenitors; LMPP, lymphoid multipotent progenitors.
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A hitherto unexplained aspect of DARC expression is whether any stem or progenitor
cells normally express this atypical chemokine receptor, at any stage of maturation.
Conceivably, the altered myelopoiesis present in DARC KO and FYB(ES)TG may be
due to DARC expression on HSPC playing a role in immobilising or internalising
chemokines for normal development. Previous studies confirmed the absence of DARC
expression on peripheral blood leukocytes (Dunstan, 1986). However, expression in
HSPC has not previously been examined. Firstly, DARC expression was examined in
developing erythroid cells in WT mice. From the pro-erythroblast stage, DARC
expression could be detected (Figure 4.17), and was highest at earlier stages of
maturation, thereafter declining slightly.
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The lineage negative fraction was subsequently examined, including LSK and myeloid
progenitors. Neither LSK nor MEP, CMP or GMP expressed DARC (Figure 4.18). Other
cell types, such as megakaryocytes and platelets, lymphoid and myeloid cells also did
not express DARC protein (data not shown).
Figure 4.17 Analysis of DARC expression in developing erythroid cells of WT mice. DARC is expressed from the
pro-erythroblast stage. Data representative of two independent experiments
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Figure 4.18 Examination of DARC expression in lineage negative cells of WT and DARC KO mice by flow
cytometry. Data representative of two independent experiments
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4.3.2 Bone marrow cultures
The in vitro short term haematopoietic cell culture system permits identification and
determination of HSPC (Nishijima et al., 1997), through the use of colony formation
assays (Ito et al., 2003). Cells are grown in methyl cellulose or other viscous medium,
which reduces cell movement and permits individual proliferating cells to develop into
colonies. The colonies containing differentiated cells, termed Colony Forming Units
(CFU), are derived from single progenitor or stem cells. The CFU can be further
classified according to the main differentiated cell type observed: CFU-GEMM are
multi-lineage colonies containing granulocyte, erythrocyte, megakaryocyte and
monocyte precursors, CFU-GM contain mainly granulocyte and monocyte precursors,
and CFU-G or CFU-M, granulocyte and monocyte precursors only, respectively.
The proliferation potential of unfractionated DARC KO bone marrow cells was
investigated utilising methyl cellulose cultures and compared to that of WT bone
marrow cells. Owing to limitations of time and resources, DARC KO bone marrow
cells were selected for investigation since these exhibited a similar phenotypic profile
to FYB(ES)TG. Cultures were initially prepared with 20,000 nucleated bone marrow
cells from WT and DARC KO mice following erythrocyte lysis (see representative
images of colonies and constituent cells, Figure 4.19). Seven-day culture
demonstrated that significantly fewer colonies, which were also less cellular, were
present in cultures from DARC KO mice, (Figure 4.20a, b). Representative colonies
were picked, cell suspensions cytospinned and analysed under the microscope to
confirm identity (Figure 4.20c).
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A potential alternative explanation for the reduction in colony numbers could be that
relatively fewer LSK cells are present in the bone marrow of DARC KO mice,
potentially leading to reduced numbers of CFU and cells (Figure 4.20a). Therefore
subsequent cultures were undertaken starting from 500 FACS sorted LSK cells
revealing an identical pattern, with DARC KO cultures producing significantly fewer
colonies than their WT counterparts (Figure 4.20b). Colony scoring revealed a relative
paucity of CFU-GM colonies, and which account for most of the deficit in total colony
number grown from DARC KO LSK as compared to WT LSK (Figure 4.20c). Cell
counts were also significantly reduced, indicating that the proliferative rate of the
cells culture from DARC KO LSK was reduced (Figure 4.20d). Following the first 7
days of culture, colonies were washed off plates, cells resuspended and 20,000 cells
were replated in triplicate. DARC KO cells demonstrated a significant increase in the
number of resultant colonies and cell numbers (Figure 4.20e), compared to WT cells.
Subsequent replating revealed no significant difference between WT and DARC KO
colony numbers (data not shown).
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a Wild-type colonies b DARC KO colonies
c
CFU-GM CFU-M CFU-G BFU-E
Figure 4.19 Images of colony appearances following 7 day culture of FACS sorted 500 LSK cells plated in semi-
solid methycellulose medium (Methocult M3434), Wild-type (a), and DARC KO (b) at 10x magnification.
Representative CFU-GM shown. (c) Representative colonies for CFU-GM, CFU-M and BFU-E, above, and
corresponding images cytospin, below, of same colonies selected for further examination.
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a b
Figure 4.20 (a) Total number of CFU present after 7 days of culture of 20,000 bone marrow nucleated cells. Data
presented as means and SD of 3 experiments, with triplicate cultures per genotype. Two-way ANOVA df(1,12) p=0.01
(b) Total number of CFU present after 7 days of culture of FACS sorted 500 LSK cells per plate, data presented as
means and SD of 4 experiments with triplicate cultures per genotype. Two-way ANOVA df(1, 15) p=0.006
c d
Figure 4.20(c) Distribution of colony types in cultures of 500 FACS sorted LSK per genotype. Data shown are results
from one representative experiment, of 4 experiments, with triplicate cultures per genotype. Two-way ANOVA df(1, 15)
p=0.0003, (d) Total cell count following 7 days cultures of 500 FACS sorted LSK per genotype. Data presented as
means and SD of 3 experiments, with triplicate cultures per genotype. Two-way ANOVA df(1, 12) p=0.047.
e f
**
Figure 4.20 (e) Total number of CFU present after 7 days of culture of 20,000 replated cells from colonies arising
during the culture of LSK cells. Data presented as means and SD of 3 experiments, with triplicate cultures per genotype.
Two-way ANOVA df(1, 15) p=0.003. (f) Distribution of colony types after 7 days following replating of 20,000
cultured cells, no significant differences were observed in colony distributions by two-way ANOVA. Data shown are
results from one representative experiment, of 3 experiments. Shown on all graphs is the statistical significance of
genotype as an independent factor in ANOVA calculation.
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Flow cytometric analysis of culture cells revealed no significant difference in
proportions of myeloid population (CD11b-positive, Ly6G-positive) between WT and
DARC KO (Figure 4.21).
a
b
c
Figure 4.21 Representative myeloid profiles of cells from cultures of 500 FACS sorted LSK cells cultured for 7
days (a, b: wild-type, DARC KO, respectively). Proportions of myeloid cells from WT and DARC KO cultures, (c).
Analysis of 4 cultures per genotype.
CD11b+
86.2%
CD115+
9.37%
Gr-1+
28.7%
10
0
10
1
10
2
10
3
10
4
CD115
10
0
10
1
10
2
10
3
10
4
G
r-1
0
20K
40K
60K
Si
de
sc
at
te
r
0 10
1
10
2
10
3
CD11b
CD11b+
79.0%
0 10
1
10
2
10
3
CD11b
0
20K
40K
60K
Si
de
sc
at
te
r
CD115+
14.2%
Gr-1+
14.6%
10
0
10
1
10
2
10
3
10
4
CD115
10
0
10
1
10
2
10
3
10
4
G
r1
197
4.3.3 BrdU proliferation assay
In order to determine whether altered cell-cycle kinetics may be responsible for the
reduced numbers of LSK cells in DARC KO and FYB(ES)TG mice, the BrdU uptake
assay was undertaken as described in Methods. Briefly, BrdU, an analogue of the
nucleotide thymidine was allowed to incorporate into DNA. Only cells entering and
progressing through the S phase of the cell cycle incorporate BrdU into their newly
synthesised DNA (Kobayashi et al., 1998). The incorporated BrdU was detected with
specific anti-BrdU fluorescent antibodies; the levels of cell-associated BrdU are then
measured by flow cytometry permitting the determination of cells that are actively
synthesizing DNA (Lacombe et al., 1988, Dean et al., 1984).
Experiments showed a significantly reduced BrdU uptake in the LSK cells and myeloid
progenitor compartments of FYB(ES)TG mice (Figure 4.22). Apart from MEP, all
myeloid progenitor subsets and LSK cells show reduced BrdU uptake suggesting
reduced proliferation under homeostatic conditions.
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Figure 4.22 BrdU incorporation in myeloid progenitors and LSK cells of WT, DARC KO and FYB(ES)TG mice,
representative gating (a). BrdU incorporation in (b) myeloid progenitors, divided by progenitor sub-type (myeloid
progenitor two-way ANOVA df(2, 11) p=0.001), and (c) in LSK cells and subpopulations (LSK two-way ANOVA
df(2, 11) p=0.001). Data presented as means and SD, n=5-7 per group. Shown on graphs is the statistical
significance of genotype as an independent factor in ANOVA calculation.
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4.3.4 Apoptosis
To investigate further potential mechanisms leading to reduced LSK and progenitor
populations in the DARC KO and FYB(ES)TG mice, levels of apoptosis were examined
in these cells by Annexin V staining as detailed in Methods. Apoptosis is a normal
physiological process, which occurs in the maintenance of normal tissue growth and
development, as well as in embryonic development (Horvitz, 1999). The underlying
mechanisms of apoptosis involve an energy-dependent sequence of molecular events,
which can be intrinsic (mitochondrial) or extrinsic, responding to receptor stimulation
(Igney and Krammer, 2002). These converge on a final pathway, characterised by
morphological features, such as the loss of plasma membrane integrity and
condensation of the nucleus and cytoplasm (Hacker, 2000). Apoptotic cells show
biochemical alterations such as DNA degradation, protein cross-linking and cleavage,
and membrane changes that lead to their recognition by phagocytes (Hengartner,
2000). One of the earliest features of apoptosis is the translocation of the membrane
phospholipid phosphatidylserine from the inner to the outer aspect of the cellular
plasma membrane (Bratton et al., 1997). These changes can be detected by Annexin
V, which is a Ca2+ dependent phospholipid-binding protein with a high affinity for
phosphatidylserine (Koopman et al., 1994). Fluorochrome conjugated Annexin V
staining occurs prior to the loss of membrane integrity, which takes place only at the
later stages of cell death. Therefore cell viability dyes, such as Sytox Blue are used in
conjunction, as viable cells with intact membrane exclude Sytox Blue, while the
membranes of dead cells are permeable to Sytox Blue. Cells that are Annexin V-
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positive and Sytox Blue positive are considered dead, whereas cells that are Annexin
V-positive and Sytox Blue negative are deemed as entering apoptosis.
Experimental results reveal that myeloid progenitors and LSK cells from FYB(ES)TG
and LSK cells from DARC KO mice are relatively resistant to apoptosis and necrosis
(Figure 4.23).
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Figure 4.23 Apoptosis analysis of stem and progenitor cells in normal bone marrow from WT, DARC KO and
FYB(ES)TG mice, (a) representative gating. The myeloid progenitor and LSK compartments were examined for
rates of apoptosis (Annexin+ Sytox Blue–) and cell death (Annexin+ Sytox Blue+). (b) Graph showing
proportions of apoptotic myeloid progenitors and LSK cells. (c) Graph showing proportions of dead cells in
myeloid progenitors and LSK cells. n=9-11 per group.
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4.3.5 Multiplex cytokine array analysis
FYB(ES)TG and DARC KO mice have reduced levels of both proliferation and
apoptosis within the myeloid progenitors and LSK cells resulting in sum in reduced
MPP and reduced GMP numbers. I hypothesised that changes in signalling molecules
such as ELR+ chemokines in the bone marrow of DARC KO or FYB(ES)TG mice may
lead to the bone marrow maturation profiles seen in these mice.
A function of DARC on erythrocytes is that of a chemokine sink or a reservoir, helping
to potentially maintain chemokine gradients, and possibly also leukocyte sensitivity to
them (Mei et al., 2010). Since the large erythroid mass within the bone marrow
expresses DARC, we aimed to determine the effect of differential erythroid DARC
expression on chemokines and cytokines levels in the bone marrow supernatant of
these mice. A 32-plex cytokine array panel of inflammatory chemokines and cytokines
was used to investigate this question (Figure 4.24). In addition serum was chosen for
similar analysis as it was desirable to determine the whole blood chemokine fraction.
Within the bone marrow supernatant, prepared as described in Methods, CCL11 was
more clearly elevated, in both DARC KO and FYB(ES)TG, as was MIG (CXCL9).
CXCL1 was reduced in DARC KO but not FYB(ES)TG. In the serum, the most
significant result was the increase of G-CSF in both DARC KO and FYB(ES)TG.
Furthermore CCL11 was elevated in the serum of FYB(ES)TG. There were no apparent
differences in levels of CCL2, CCL5, CXCL1, CXCL5, CXCL9 and CXCL10.
The full panel of results is contained in Appendix 7.6 and 7.7
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Figure 4.24 (a) Serum cyto- and chemokine analysis by multiplex cytokine array assay, in WT (n=6), DARC KO
(n=6) and FYB(ES)TG (n=6) mice. (b) Bone marrow supernatant analysis by multiplex cytokine assay. WT
(n=19), DARC KO (n=16) and FYB(ES)TG (n=16). Only DARC ligands or results with significant differences are
shown. Mann-Whitney test used to calculate significance. See appendix for full panel of results.
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4.3.6 Bone marrow competitive chimeras
Bone marrow competitive chimeras are tools utilised to measure, amongst others,
differences in cellular proliferation and efficiency of engraftment. In addition, it was
hypothesised that in a DARC replete environment, the engraftment of DARC positive
cells may modify chemokine availability within the bone marrow and lead to a
normalisation of the DARC KO and FYB(ES)TG myeloid maturation profiles. Typically
cells can be introduced in a 50:50 or other ratio to determine proliferation potential
and engraftment kinetics in-vivo. The DARC KO model was developed on a C57Bl/6
background with CD45.2 antigen expressed on leukocytes. Animal welfare
considerations at the University of Birmingham Biomedical Services Unit limit the
doses of gamma irradiation which can be used for myeloablation to a total of 9 Gy. In
addition, while haematopoietic stem cells engraft and begin to differentiate towards
mature cells, mature progenitors are required to maintain mature haematopoietic cell
production temporarily, ensuring animal survival. For these reasons, a
CD45.1xCD45.2 competitor within a CD45.1 host was used, such that residual host,
competitor and donor proportions can be precisely determined. Figure 4.25a details
general experimental procedure: CD45.1 BoyJ irradiated (2 x 4.5 Gy) hosts were
injected with 106 bone marrow cells, which were 50% CD45.1xCD45.2 and either
CD45.2 WT (designated WT-WT) or CD45.2KO (designated WT-KO), n=5 per group.
Examining peripheral blood proportions by tail bleed revealed CD45.2 DARC KO had
half the engraftment efficiency of CD45.2 WT. In addition Figure 4.25b demonstrates
significantly increased spleen size in animals in the CD45.2 DARC KO group, and bone
marrow cell counts were not different Figure 4.25c.
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Figure 4.25 Fundamental parameters of mixed bone marrow competitive chimeras. (a) Scheme summarising the
experimental procedure as described in Methods. Relative proportions are calculated compared to the
CD45.1xCD45.2. (b) Spleen size classified by CD45.2 competitor, and (c), cell counts in bone marrow femurs.
n=5 per group
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There was no preferential relocation of erythropoiesis to the spleen (Figure 4.26),
with no significant differences between the groups.
Total peripheral blood leukocyte, neutrophil and platelet counts and haemoglobin
were not significantly different between the two groups (Figure 4.27).
a b
c
Figure 4.26 Erythroid cells as a proportion of all bone marrow and spleen cells in mixed bone marrow competitive
chimeras, (a) bone marrow, and (b) spleen. Proportion of DARC-positive erythropoiesis in bone marrow and
spleen, c). n=5 per group
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As represented in Figure 4.28, relative to CD45.1xCD45.2, CD45.2 WT exceeded
CD45.2KO at a ratio of 1.5-2:1, confirming that DARC KO cells have reduced
proliferation compared to WT. There were no differences in peripheral blood cells
populations between the two groups.
a
b c
WT
-W
T
WT
-K
O
400
500
600
700
800
CD45.2 Phenotype
Figure 4.27 Complete blood count of mixed bone marrow competitive chimeras. Total leukocyte count (a),
haemoglobin (c) and platelet count (d) from automated analyser. Neutrophil count by FACS-based bead counting
method (b). n=5 per group.
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Figure 4.28 Analysis of blood leukocyte populations examined in mixed bone marrow competitive chimeras.
Representative gating, (a). Live cells were gated for CD11b, Gr-1, B220, CD4/CD8 and then subgated for CD45.1
and CD45.2 expression. (b) CD45.1xCD45.2+ cells were assigned a ratio of 1 (i.e. 100%) within each mouse, and
the proportion of CD45.2 cells (WT or KO) were computed. Shown are the relative contributions of CD45.2 WT or
KO to CD45.1xCD45.2 competitors for each of the main blood leukocyte populations. (c) Competitor proportions
(CD45.2 WT or KO) relative to CD45.1xCD45.2, averaged over 5 WT or 4KO samples.
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Figure 4.29 shows the results from the bone marrow analysis, which largely mirror
those of the blood. Figure 4.29c shows that myeloid and neutrophil proportions of all
cells in the CD45.2 DARC KO group (including CD45.1xCD45.2 as well as CD45.2
DARC KO) were relatively reduced, with a compensatory increase in B220+ cells, a
finding different to that seen in DARC KO or FYB(ES)TG,
a b
** ** ** ** **
**
**
**
c
*
* **
Figure 4.29 Analysis of bone marrow leukocyte populations examined in mixed bone marrow competitive
chimeras. (a) Relative contributions of CD45.2 leukocyte populations compared to CD45.1xCD45.2 population in
the bone marrow. (b) Overall CD45.2 contributions within the bone marrow relative to CD45.1xCD45.2. c)
Proportions of principle bone marrow populations. n=5 per group
210
Within the spleen (Figure 4.30) results were similar to those of the bone marrow,
although the differences between CD45.2 WT and CD45.2 DARC KO were less
pronounced. There was no significant difference in overall cellular proportions
between the groups.
a b
** ** ** **
**
**
**
**
c
**
Figure 4.30 Analysis of spleen leukocyte populations examined in mixed bone marrow competitive chimeras. a)
Relative contributions of CD45.2 compared to CD45.1xCD45.2 in the spleen. b) Overall CD45.2 contributions
within the spleen relative to CD45.1xCD45.2. c) Proportions of principle spleen populations. n=5 per group.
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Of interest, in-vivo introduction of the DARC KO haematopoietic stem cells and
progenitors in a DARC replete system did not lead to normalisation of the myeloid
progenitor profile, with a relative reduction in GMP cells in the DARC KO CD45.2
(Figure 4.31) and increase in CMP cells.
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No statistically significant difference was noted in the ratio between CD45.2 WT and
CD45.2 KO LSK cells. However, within this population, the CD45.2 DARC KO retained
the original phenotype, demonstrating a reduction in MPP cells in absolute terms,
a
b
** **
Figure 4.31 Bone marrow lineage-negative populations examined in mixed bone marrow competitive chimeras,
representative gating (a). Live cells were gated for CD45 expression, and then haematopoietic lineage-negativity.
There after subgates examining myeloid progenitors and their sub-populations (GMP: CD34+, CD16/CD32+, CMP
CD34+, CD16/CD32 low, MEP CD34- CD16/CD32-). b) CD45.1xCD45.2+ cells were assigned a ratio of 1 (i.e. 100%)
within each mouse, and the proportion of CD45.2 cells (WT or KO) were computed. Shown are the relative
contributions of CD45.2 WT or KO to CD45.1xCD45.2 competitors for each of the main progenitor populations,
(b). n=5 per group.
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with a corresponding increase in LT + ST HSC in both absolute and relative terms
(Figure 4.32b). The MPP population was similarly reduced due to the reduction in
GMPP and increase in LMPP and CMP-progenitors (Figure 4.32c).
a
b c
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Figure 4.32 Bone marrow LSK sub-populations examined in mixed bone marrow competitive chimeras,
representative gating (a). Live cells were gated for CD45 expression, and then haematopoietic lineage-negativity.
There after subgates examining LSK compartment (cKit+, Sca1+) and the sub-populations (MPP: cKit+ FLT3Hi, LT
& ST HSC, cKit+ FLT3-/low, GMPP VCAM+ CD62L+, LMPP VCAM- CD62L+, CMP VCAM+ CD62L-). (b)
CD45.1xCD45.2+ cells were assigned a ratio of 1 within each mouse, and the proportion of CD45.2 cells (WT or
KO) were computed. Shown are the relative contributions of CD45.2 WT or KO to CD45.1xCD45.2 competitors for
each of the main HSPC populations. (c) Ratios of the MPP subpopulations. n=5 per group.
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4.3.7 LSK-selected mixed competitive chimeras
Mixed chimera experiments confirmed that DARC KO bone marrow is less
proliferative than wild-type bone marrow from the same murine strain. In addition, in
vivo incubation of transferred bone marrow failed to normalise the reduced GMP and
MPP profile in the CD45.2 DARC KO fraction. This may have been as a result of the
reduced numbers of LSK cells and presence of relatively more mature progenitors, and
insufficient time permitted for full engraftment of transplanted bone marrow.
Therefore it was conceived that FACS sorted LSK cells, either CD45.2 WT or CD45.2
DARC KO would be injected into irradiated hosts with competitor cells so as to
examine whether equal number of LSK cells injected and longer periods of maturation
of LSK cells (LT-HSC, ST-HSC and MPP) in a DARC replete bone marrow environment
would alter the maturation profile of the DARC KO bone marrow.
Figure 4.33a details general experimental procedure: CD45.1 BoyJ irradiated (2 x 4.5
Gy) hosts were injected with 500 FACS sorted LSK cells, either CD45.2 WT (animals
designated WT-WT) or CD45.2KO (designated WT-KO), n=5 per group, with 106
competitor CD45.1xCD45.2 cells. Examining peripheral blood proportions by tail
bleed revealed CD45.2 DARC KO had a higher proliferative rate compared to CD45.2
WT, on average. Blood was sampled by tail bleed at 28 and 56 days, and the animals
were culled at 16 weeks post transfer.
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The fundamental parameters of the chimeric mice were examined, and the blood
leukocyte, bone marrow leukocyte and bone marrow HSPC populations were
analysed. However substantial variation in WT and DARC KO CD45.2 population
chimerism was noted (between <5 and 30%), for reasons that are not clear but may
represent uneven mixing pre-injection, or clumping of LSK cells. The results of these
analyses are contained in Chapter 6 Appendix, the reader is referred to Appendix
section “7.8 LSK-selected mixed competitive chimeras”.
a
b
Figure 4.33. Scheme summarising the experimental procedure as described in Methods, (a). Relative proportions
of CD45.2 leukocyte blood chimerism, (b), calculated relative to the CD45.1xCD45.2, n=5 per group.
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Blood leukocyte proportions between CD45.2 WT and CD45.2 KO relative to
CD45.1xCD45.2 competitor were not significantly different (Figure 4.34a) but in bone
marrow there was an increased proportion of CD45.2 KO leukocytes. This would
suggest that in the presence of a wholly DARC replete bone marrow environment,
DARC KO LSK cells may receive sufficient cytokine signals to undergo increased
proliferation. More likely however, similar to the in vitro colony assays, there may be
more immature cells (LT-HSC and ST-HSC) contained in the DARC KO LSK
population and these cells may subsequently lead to a greater output of mature cells.
To clarify this further, future experiments could be undertaken using FACS sorted LT-
HSC from WT and DARC KO, so that differences in LSK sub-populations between
these mouse strains may be controlled for. In addition, FACS sorted MPP cells could
be used instead of LSK to examine the progenitors produced by these cells and
determine the exact contributions to mature bone marrow cell population by equal
numbers of WT or DARC KO MPP cells.
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4.3.8 Comparison of the morphological appearance of
cryosectioned bone marrow in WT, DARC KO and FYB(ES)TG
mice
In DARC KO and FYB(ES)TG mice, the relative proportions of bone marrow subsets
are skewed towards myeloid differentiation. This may be reflected, in part, in changes
in the localisation of developing myeloid cells, with reference to other cells and other
myeloid cells. Therefore the distribution of maturing erythroid and myeloid cells
might be altered in DARC KO and/or FYB(ES)TG mice in comparison to WT mice.
Cryosections of paraformaldehyde fixed WT, DARC KO and FYB(ES)TG femora were
used to examine the distribution of erythroid and myeloid cells in the bone marrow of
these mice.
a b
**
**
**
** *
Figure 4.34 Analysis of blood and bone marrow leukocyte populations of mixed LSK-selected competitive
chimeras. a) Blood leukocyte competitor proportions (CD45.2 WT or KO) relative to CD45.1xCD45.2, averaged
over 5 CD45.2 WT or 4 CD45.2 KO samples. b) Bone marrow competitor proportions (CD45.2 WT or KO) relative
to CD45.1xCD45.2, averaged over 5 CD45.2 WT or 4 CD45.2 KO samples.
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As can be seen in Figure 4.35, in sections from DARC KO and FYB(ES)TG bone
marrows, there was an increase in the area of CD11b-positive immunofluorescence,
with myeloid cells forming larger aggregates whereas erythroid cells were not
significantly altered in comparison to their WT counterparts (Figure 4.36). In WT
bone marrow, myeloid clusters contained a mean of 3.01 myeloid cells (2.38-3.66) in
contrast to DARC KO bone marrow 6.38 (5-9.169) cells and FYB(ES)TG bone marrow
9.61 (5.89-12.74) cells. Thus it is possible that the absence of erythroid DARC affects
the re-distribution of maturing myeloid cells, and may lead to their accumulation by
altering the threshold for neutrophil release.
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Figure 4.35 Representative immunofluorescent images of femur sections, highlighting Ter119, CD11b and CD31
positive cells, from wild-type and FYB(ES)TG mice, (a). The absolute area of positive staining for myeloid (b) and
erythroid (c) cells was calculated from four representative areas of the femur sections. Images captured at 25x
magnification.
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4.3.9 Chemokine binding by DARC expressed on bone marrow
erythroblasts
Whilst the role of DARC on the mature erythrocyte in the peripheral circulation has
been suggested to be a chemokine sink, helping to buffer chemokine levels and
potentially maintain cognate receptor sensitivity, the role if any of erythroid DARC in
the bone marrow has remained completely obscure. 125I-CCL5 was used to examine
the chemokine binding of DARC on erythroblasts, and the contribution of DARC to
chemokine levels in the bone marrow supernatants. A MDCK cell line expressing the
atypical chemokine receptor D6 (ACKR2) which internalises chemokines and degrades
them was used as a control.
Figure 4.37 and Figure 4.38 show that DARC maintains higher levels of 125I-CCL5 on
erythroblast cell surface as well as in bone marrow supernatants, when DARC is
present. There was no difference in the non-precipitable (degraded) chemokine
* *
Figure 4.36 Analysis of myeloid cell clustering. Myeloid clustering was analysed by designating cell groupings as a
myeloid cluster where cells were considered to be in a cluster if they were within a cell-width (ca. 10µm) of each
other, and at least half of the nucleus was surrounded by red-stained (CD11b+) cytoplasm.
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between the WT and DARC KO samples, across all three compartments studied (data
not shown).
a b
c d
e f
Figure 4.37 Representative graphs of 125I-CCL5 binding assays. Following 3 hours of incubation there was no
significant difference between WT and DARC KO erythroblast in the counts per minute (CPM) obtained in the
supernatant (a) p= 0.98 (c), and intracellularly (e). Following 18 hours incubation, there was significantly more
radiolabelled chemokine detectable in the wild-type supernatant (b) and cell surface (d), with no significant
difference in the intracellular compartment (f). Analysis undertaken by combining 5 independent experiments,
and calculating counts of KO relative to WT mean (WT=100%). Mann-Whitney test used to determine whether
means significantly different. In some experiments WT and DARC KO whole bone marrow was studied in parallel,
with similar results obtained to the erythroblast samples at 18 hour incubation; however the results were not
significantly different.
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Figure 4.38 Combined mean CPM values for fractions assayed (supernatant, cell surface, intracellular) at the 18
hour time point from 5 independent experiments.
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4.3.10 Microarray
Alterations in the maturation profile of HSC and progenitor cells as seen in the
absence of erythroid DARC may occur in response to variations in the bone marrow
micro-environment as a result of signalling pathway changes, potentially mediated by
gene expression. An efficient method to screen for possibly hundreds of affected genes
is the use of microarray technology, where differences in expression across thousands
of genes can be determined.
GMP or LSK were FACS sorted (representative gating Figure 4.39) from either DARC
KO or WT mice, and after RNA extraction gene expression changes were examined on
an Agilent 8 spot chip. The on-line resource Immgen (http://www.immgen.org) was
utilised to confirm normal gene expression patterns. The full list of results is presented
in Appendix 7.2 (for LSK cells) and 7.3 (for GMP cells).
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Figure 4.39 (a) Representative gating for FACS sorting strategy used for microarray experiment. Approximate
purity, 94% (b).
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4.3.10.1 LSK
Upregulated Genes
The most upregulated genes (Table 4.1) in the LSK cells of DARC KO mice were
mainly genes expressed in maturing neutrophils and monocytes (NGP, LTF, CAMP,
S100A8, MMP8, CHI3L3, S100A9, IFITM6), with minor expression of some genes
typically found in erythroid precursors. ALAS2 is an important gene in erythroid
aminolevulinic acid synthesis, and RETNLG is highly expressed in maturing and
mature granulocytes, as well as in adipose tissue.
In summary, genes typically expressed in maturing granulocytic populations were
significantly upregulated in LSK cells of DARC KO mice.
Name Symbol Fold-change
neutrophilic granule protein NGP 656.09
resistin like gamma RETNLG 509.74
Lactotransferrin LTF 418.15
cathelicidin antimicrobial peptide CAMP 462.38
S100 calcium binding protein A8 (calgranulin A) S100A8 351.33
matrix metallopeptidase 8 MMP8 210.62
chitinase 3-like 3 CHI3L3 176.46
aminolevulinic acid synthase 2, erythroid ALAS2 182.53
S100 calcium binding protein A9 (calgranulin B) S100A9 200.48
interferon induced transmembrane protein 6 IFITM6 131.22
Table 4.1 Ten most upregulated significant genes from microarray study for sorted LSK
cells. Genes that were significantly more than 3-fold up or down regulated were selected for
analysis (See appendix for full list of genes), p<0.01.
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Down-regulated genes
Table 4.2 shows the ten most down regulated genes.
Name Symbol Fold-change
RNA component of mitochondrial RNAase P RMRP -11.7603
glutaredoxin 2 (thioltransferase) GLRX2 -8.66415
histone cluster 1, H4d HIST1H4D -6.72826
histone cluster 1, H2ak HIST1H2AK -6.60662
ATP synthase F0 subunit 6 ATP6 -6.24427
histone cluster 1, H4c HIST1H4C -6.20175
histone cluster 1, H4j HIST1H4J -6.01895
histone cluster 1, H4k HIST1H4K -5.7852
phosphohistidine phosphatase 1 PHPT1 -4.50187
forkhead box D4 FOXD4 -3.72675
Table 4.2 Ten most downregulated significant genes from microarray study for sorted LSK
cells. Genes that were significantly more than 3-fold up or down regulated were selected for
analysis (See appendix for full list of genes), p<0.01.
Candidate transcription factors in LSK cells
Candidate transcription factors which might be involved in regulation of significant
genes were determined utilising the on-line DiRE: Identification of Distant Regulatory.
Elements of gene expression resource (http://dire.dcode.org) from (Gotea and
Ovcharenko, 2008). C/EBPβ scores highest in importance in this analysis, highlighting
the pro-granulocytic gene expression profile in DARC KO LSK cells as suggested by the
most highly expressed genes from the microarray study.
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4.3.10.2 GMP
Upregulated Genes
The most upregulated genes in the GMP cells of DARC KO as compared to their WT
counterparts were those normally expressed in lineage committed maturing erythroid
progenitors and granulocytic precursors, in Table 4.3.
Of note, increased expression of one of these genes, IFI202, in HSC was shown to
reduce the proliferation of myeloid cells and reduce the ability of constitutively IFI202
expressing HSC to reconstitute irradiated mice (Ludlow et al., 2008).
a
b
Figure 4.40 Candidate transcription factors regulating differential gene expression in DARC KO LSK cells from
microarray, analysed by DiRE. a) Genes upregulated more than 3 fold, b) Genes downregulated more than 3 fold.
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Name Symbol Fold-change
cathelicidin antimicrobial peptide CAMP 1299.918
hemoglobin, beta adult major chain HBB-B1 457.9743
S100 calcium binding protein A9 (calgranulin B) S100A9 413.8867
resistin like gamma RETNLG 285.2716
lactotransferrin LTF 152.3321
neutrophilic granule protein NGP 170.9426
hemoglobin alpha, adult chain 2 HBA-A2 181.9238
hemoglobin alpha, adult chain 1 HBA-A1 147.5344
hemoglobin, beta adult minor chain HBB-B2 145.3437
interferon activated gene 202B IFI202B 131.2353
Table 4.3 Ten most upregulated significant genes from microarray study for sorted GMP
cells. Genes that were significantly more than 3-fold up or down regulated were selected for
analysis (See appendix for full list of genes), p<0.01.
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Down-regulated genes
Table 4.4 shows the ten most down regulated genes in GMP cells of DARC KO mice as
compared to their WT counterparts.
Name Symbol Fold-change
IQ motif and Sec7 domain 3 IQSEC3 0.037595
dual specificity phosphatase 23 DUSP23 0.167913
keratin associated protein 5-4 KRTAP5-4 0.179302
apolipoprotein A-II APOA2 0.220669
TOX high mobility group box family member 4 TOX4 0.251398
phosphoinositide-3-kinase interacting protein 1 PIK3IP1 0.2718
pleckstrin homology domain containing, family J
member 1 PLEKHJ1 0.282339
integrin alpha 5 (fibronectin receptor alpha) ITGA5 0.291348
tensin 4 TNS4 0.297402
v-maf musculoaponeurotic fibrosarcoma
oncogene family, protein F (avian) MAFF 0.299066
Table 4.4 Ten most downregulated significant genes from microarray study for sorted GMP
cells. Genes that were significantly more than 3-fold up or down regulated were selected for
analysis (See appendix for full list of genes), p<0.01.
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Candidate transcription factors in GMP cells
Likely transcription factors were determined using DiRE, and results were as per
Figure 4.41. Notably the C/EBP family of transcription factors is the most likely
candidate for the up-regulation of genes in GMP of DARC KO mice, in similarity to
LSK cells.
a
b
Figure 4.41 a) Candidate transcription factors regulating differential gene expression in DARC KO GMP cells from
microarray, analysed by DiRE. a) Genes upregulated more than 3 fold, b) Genes downregulated more than 3 fold.
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4.3.11 Low density gene array
A microfluidic card was designed to analyse expression of a panel of genes which
included several significant genes from the microarray experiment and housekeeping
genes. In addition, genes which have critical roles in granulocyte lineage
differentiation from the pre-GMP stage to the GMP stage were included, as were those
whose transcribed proteins (e.g. VCAM-1) were noted to be altered in surface
expression in flow cytometry experiments of LSK and sub-populations. mRNA
expression was determined by real-time PCR, and the expression of each gene was
calculated relative to the levels of GAPDH. Of the three housekeeping genes included
(GAPDH, HPRT and 18S), GAPDH and HPRT were both selected (geometric means of
their expression computed) for analysis as these showed little variation in expression
between samples. RNA was detectable for all genes, and gene expression was assessed
using RNA which was treated with DNase.
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Figure 4.42 Heatmap of relative gene expression in LSK and GMP from DARC KO and FYB(ES)TG calculated from
LDA results. Blue indicates reduced expression relative to WT, and red increased expression. The depth of colour
correlates which intensity of gene expression change from WT mean (e.g. dark blue = strongly downregulated).
Represented is the mean fold change relative to WT. LSK: WT n=5, DARC KO n=4 and FYB(ES)TG n=4; GMP:
WT n=5, DARC KO n=4 and FYB(ES)TG n=3
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a
b
Figure 4.43 Differential expression of selected genes in LSK and GMP cells from WT, DARC KO and FYB(ES)TG
mice, results from LDA: (a) selected genes from LSK analysis. WT n=5, DARC KO n=4 and FYB(ES)TG n=4 (b)
selected genes from GMP analysis. Represented is the mean fold change relative to WT. WT n=5, DARC KO n=4
and FYB(ES)TG n=3. Statistical significance was calculated using Mann Whitney test, on ΔCT values. Error bars
represent the SD of ΔCT values.
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In LSK populations, CXCR4 was significantly up-regulated in FYB(ES)TG, and VCAM-1
down-regulated in FYB(ES)TG mice. Of note, flow cytometric analysis showed a
reduction in VCAM-1+ GMPP cell numbers in FYB(ES)TG mice. In addition, CEBPD
was significantly down-regulated in FYB(ES)TG LSK. In contrast to the micro-array
results, LTF, MMP8, NGP and S100A9 did not differ from WT in expression.
GMP results indicated a number of differences compared to WT. Lymphoid genes
appeared increased in expression by several fold in DARC KO and FYB(ES)TG GMP
(CD2, CD19), and erythroid genes (HBB, GATA1) were also upregulated. Genes
characteristic of maturing granulocytic precursors were upregulated (LTF, MMP8,
NGP and S100A9) in GMP from both DARC KO and FYB(ES)TG mice. However genes
in the C/EBP group were not differentially expressed. Interpretation of these data
would suggest that the GMP have a more immature CMP-like gene expression profile,
in combination with a more mature pro-granulocytic gene expression pattern. GATA1
and GATA2 were more expressed in FYB(ES)TG GMP cells, and the implication is
unclear. Overexpression of GATA-2 leads to enforced cellular quiescence in HSC and
progenitor cells with no change in apoptosis rates (Tipping et al., 2009).
4.3.12 CXCR4-CXCL12 axis
Given the importance of the CXCR4-CXCL12 axis in modulating cellular released from
the bone marrow, CXCL12 levels in bone marrow supernatants were examined by
ELISA. These were similar between WT, DARC KO and FYB(ES)TG mice (Figure
4.44). In addition CXCR4 expression on mature neutrophils was not different across
the three mouse strains. Therefore, the CXCR4-CXCL12 axis does not appear to play a
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direct role in the increased neutrophil proportions presented in DARC KO and
FYB(ES)TG mice.
a
b
Figure 4.44. CXCR4-CXCL12 axis analysis in bone marrow from WT, DARC KO and FYB(ES)TG mice. Absolute
CXCL12 levels in bone marrow supernatant per mg of protein (a). WT n=16, DARC KO n=20, FYB(ES)TG n=5.
(b) CXCR4 relative expression in neutrophils (FSCMed-Hi, SSCHi, CD45+, CD11b+, Ly6GHi). WT n=13, DARC KO
n=12, FYB(ES)TG n=5
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4.4 Discussion
The primary aim of this work was to develop an animal model to represent the
neutropaenia present in FYB(ES) homozygous Duffy-negative humans, and to use this
model in the study of the mechanisms underpinning the neutropaenia. The
FYB(ES)TG model is a humanised transgenic mouse expressing human DARC on the
vascular endothelium and other locations but not erythrocytes similar to the human
Duffy-negative phenotype, and exhibiting a 30-40% reduction in neutrophil counts
compared to WT mice. As a control, the FYBTG mouse model was developed to
establish whether the presence of erythroid human DARC in addition to endothelial
human DARC would correct these changes. Accordingly, preliminary results from
FYBTG mice demonstrate bone marrow and peripheral blood cell proportions and
absolute counts similar to those in WT mice.
In DARC KO and FYB(ES)TG mice, increased proportions of neutrophils were found in
the bone marrow, and in FYB(ES)TG was this was associated with reduced neutrophil
count in the peripheral blood. The actual mechanism of the neutropaenia however is
unclear. DARC KO animals have normal neutrophil counts as shown in this work and
by others (Zarbock et al., 2010). Preliminary results from FYBTG revealed a
phenotype similar to WT mice, with normalisation of these parameters. In addition to
differences in neutrophil numbers and distribution in blood and bone marrow of
DARC KO and FYB(ES)TG mice, there may be changes in the nature of the neutrophils
from these mice, particularly relating to levels of neutrophil activation. Blood
neutrophil CD11b expression is increased in FYB(ES)TG and unchanged in DARC KO
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as compared to WT mice. Increased CD11b expression and avidity for endothelial Ig
receptors ICAM-1 and ICAM-2 plays a crucial role in immobilising neutrophils rolling
along the vascular endothelium and promoting transmigration, as well as other
important roles in chemotaxis and phagocytosis (Arnaout, 1990, Schymeinsky et al.,
2007). CD11b levels are increased by activation, being induced by complement C5a,
chemokines, TNF and fMLP (Mazzone and Ricevuti, 1995). It is suggested that
neutropaenia seen in clinical states such as systemic lupus erythematosus, diabetes
mellitus and haemodialysis may reflect the observed increased CD11b expression in
the neutrophils of these patients. This may imply that neutrophils from FYB(ES)TG
may circulate in a more activated state and lead to the increased CD11b expression
which may contribute to the neutropaenia seen in the FYB(ES)TG.
In addition, CD16/CD32 expression is increased in bone marrow neutrophils of both
DARC KO and FYB(ES)TG mice. Work done in the murine myeloid cell line LGM-1
reveals increased G-CSF receptor signalling is associated with increased CD11b and
FcγII (CD32) and FcγIII (CD16) receptor expression (Koay and Sartorelli, 1999).
These Fcγ receptors are ligands for IgG, and mice express FcγII-B on neutrophils
which leads to inhibitory signalling, whereas the FcγIII receptor is activating and leads
to effects on phagocytosis and the secretion of chemoattractants (Nimmerjahn and
Ravetch, 2008). Activation of FcγII receptor augments neutrophil adhesion through
CD11b (Kusunoki et al., 1994, Kocher et al., 1997), suggesting a further pathway by
which neutrophil proximity or margination to vascular endothelium is enhanced.
Taken together this supports the notion that neutrophils from DARC KO and
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FYB(ES)TG mice are more activated. Further functional experiments are required to
determine the impact of this in responses to infectious stimuli.
One of the primary hypotheses of this work was that in the absence of erythroid
DARC, an altered pattern of chemokines and cytokines necessary for optimal
haematopoiesis develops. In vitro colony assays were done to test whether
‘normalisation’ of the growth environment of DARC KO bone marrow with ideal
amounts of growth stimulants in culture could lead to normal CFU formation. The
initial colony scoring results revealed a reduction in CFU numbers and cell counts,
corresponding with a reduced homeostatic proliferation present in the bone marrow
of DARC KO mice. In particular, the CFU-GM colony type was particularly reduced in
numbers, reflecting a similar reduction in GMPs demonstrated in bone marrow FACS.
Similar colony formation rates were obtained using unfractionated bone marrow cells,
and FACS-sorted LSK cells. This suggests that the reduced colony output is not only as
a result of fewer LSK cells present in DARC KO mice but due to a reduced cellular
proliferation rate. Since cells from DARC KO may divide at a slower rate it is possible
that cells differentiate more slowly in DARC KO, compared to WT, and hence more
immature cells remain and are able to form more numerous colonies in subsequent
replated DARC KO cultures. Alternatively, subsequent increases in cell counts and
colony numbers on replating of DARC KO cultures compared to WT cultures may also
suggest that proliferation rates may be responding to the optimal growth environment
in the culture medium. Potential epigenetic changes present in the DARC KO LSK may
be removed during the 7 days of incubation, leading to subsequent maximal growth
rates. Further experiments to delineate potential mechanisms for these findings could
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include culture of stem cells FACS sorted using the SLAM code (CD150, CD48), and
single cell cultures, as well as examination for differences in receptor and gene
expression between replatings. Of note, similar reductions in HSPC and myeloid
progenitors from African American bone marrow harvests (Hsieh et al., 2010) and
reductions in CFU-GM colonies in in vitro assays from the bone marrow of individuals
of African ancestry (Rezvani et al., 2001) have been reported.
Reduced proliferation rates in DARC-negative haematopoiesis are further reflected in
the BrdU uptake studies, which reveal a significant difference in BrdU incorporation
and hence imply reduced proliferation in mice lacking erythroid DARC. This
phenomenon is present in all HSPC compartments and therefore proliferation in itself
does not account for the FYB(ES)TG mouse bone marrow phenotype. Population
based cardiovascular studies have shown that participants of African ancestry have
significantly longer telomeres in peripheral blood leukocytes (Hunt et al., 2008),
suggesting reduced cell divisions and reduced myeloid proliferation. This finding
suggests that the absence of erythroid DARC reduces cellular proliferation rates in
humans of African ancestry, most of whom are homozygous for FYB(ES).
Rates of Annexin V binding were reduced in DARC KO and FYB(ES)TG, implying that
lineage-negative cells from these genotypes are protected from apoptosis and cell
death. Typically, cell populations exhibiting high proliferation would reflect lower
rates of apoptosis. Inhibitors of apoptosis operate through several pathways, such NF-
kB and RAS. In addition survival factors such as growth factors and cytokines, activate
the JAK/Stat pathways and subsequently activate BCL-2. The bone marrow micro-
environment in DARC KO and FYB(ES)TG models may possibly contribute to this
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leading to aberrant cytokine signalling and activation of these pathways, thereby
conveying protection from apoptosis. For example, fewer haematopoietic stem cells
from mice overexpressing BCL-2 were in cell cycle and have lower apoptotic rates
(Domen et al., 2000). G-CSF ligation to the G-CSF receptor stimulates numerous
signal transduction pathways, including STAT3, the Ras/Mek/Erk1/2 pathway(Tian et
al., 1994, de Koning et al., 1998), leads to reduced apoptosis in neutrophils (Simon,
2001) and mobilised peripheral blood CD34+ cells (Philpott et al., 1997).
Furthermore, G-CSF has recently been the subject of increased attention as a result of
protective qualities it confers to injured organs expressing the G-CSF-R, such cardiac
(Ma et al., 2012), renal (Nogueira et al., 2012) and neural (Doycheva et al., 2013)
tissues. These are not necessarily based on the recruitment of bone marrow derived
progenitors to sites of injury. Recent work has shown that treatment with G-CSF
induces expansion and increased quiescence of phenotypic HSCs, but leads to a HSC
repopulating defect associated with induction of TLR expression and signalling
(Schuettpelz et al., 2014). The cited HSC repopulating defect induced by higher
circulating systemic levels of G-CSF in DARC KO mice would also support the findings
in the competitive chimera experiments, where rates of proliferation were reduced in
CD45.2 DARC KO despite the introduction of DARC+ erythropoiesis. Taken together,
this implies that reduced proliferation and apoptosis in lineage negative DARC KO and
FYB(ES)TG cells are an induced effect possibly due to the chronically increased G-CSF
levels detected in these genotypes using the multiplex cytokine array.
Whilst DARC binds to a number of inflammatory chemokines, none of these ligands is
crucial for neutrophilic development: instead these are involved in the mobilisation
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and recruitment of neutrophils from the bone marrow to site of inflammation.
Conversely several cytokines are essential for neutrophil development including G-
CSF, GM-CSF, M-CSF and IL3 (Liu et al., 1996, Ward et al., 2000). DARC KO and
FYB(ES)TG mice have reduced serum CXCL1 and the binding studies using iodinated-
CCL5 showed reduced binding to the DARC-negative erythroblast surface but also
lower chemokine levels in the supernatants.
Suboptimal retention of mobilising chemokines (e.g. CXCL1, CXCL2, CXCL5) within
the haematopoietic micro-environment due to loss of erythroid DARC may contribute
to the increased neutrophil proportions found in the DARC KO and FYB(ES)TG bone
marrow. It has been described that whilst total tissue chemokine levels may be
normal, it is their availability in specific microenvironments and ability to form
gradients which are necessary for the correct localisation of cells (Ulvmar et al.,
2014). This may explain why total chemokine levels were not dramatically altered in
the bone marrow supernatant of DARC KO and FYB(ES)TG mice. Erythropoietic DARC
may therefore be required for the optimal establishment of chemokine patterns which
would direct developing and mature granulocytes towards the perivascular areas for
release in to the circulation. A possible explanation for the neutropaenia of
FYB(ES)TG may lie with distribution of presented chemokines on the bone marrow
vascular endothelial cells, and reducing the release of cells into the blood. In addition,
immunofluorescent imaging of bone marrow sections reveals an increased clustering
of myeloid cells in DARC KO and FYB(ES)TG mice as compared to WT counterparts,
suggesting an abnormal distribution of myeloid cells throughout the bone marrow.
This effect may be extended to the circulation, where ELR+ chemokines may be
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drawn to and presented primarily along the luminal surface of DARC expressing
endothelial cells without erythroid DARC to provide a balanced distribution of these
chemokines. In addition, effects on neutrophil CXCR2 by the abnormal distribution of
cognate chemokines may be enhanced if the neutrophils have an activated phenotype.
It has been shown that G-CSF increases responsiveness of neutrophils to CXCL2
binding to CXCR2, and induces the expression of CXCR2 (Nguyen-Jackson et al.,
2010). This may further contribute to neutrophil activation, and direction of
neutrophils towards endothelial presented chemokines. The CXCR4 antagonist
AMD3100 (Plerixafor) would be useful to examine this further, since it has been
shown that the neutrophilia following the administration of this agent is due in
significant part to demargination of leukocytes (Devi et al., 2013). These findings do
not fully explain the increased G-CSF levels seen in FYB(ES)TG, unless neutrophils
remained in a state of sustained margination at steady-state, rather than entering the
tissues to be taken up by macrophages and downregulate the IL-23-IL-17 axis.
Furthermore, IL-17 was not detectable in multiplex cytokine array of serum from WT,
DARC KO and FYB(ES)TG mice. This may be for technical reasons; however,
detectably raised IL-17 levels in DARC KO or FYB(ES)TG serum would support
hypothetical activation of IL-23-IL-17 axis as being important in explaining at least in
part the observed increased G-CSF levels detected in these mice. Raised G-CSF levels
have been reported in healthy volunteers of African descent (Mayr et al., 2007),
which supports the raised G-CSF as a secondary effect in the context of the
neutropaenia seen in the FYB(ES)TG mice.
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Raised levels of CCL11 were present in the bone marrow supernatant of DARC KO and
FYB(ES)TG mice, and the serum of FYB(ES)TG mice. CCR3, the main receptor for
CCL11, is reported to be expressed on bone marrow progenitors and increased CCL11
in vivo leads to increased number of bone marrow myeloid progenitors, directing
haematopoiesis in a pro-myeloid direction (Peled et al., 1998). CCL11 is chemotactic
primarily for eosinophils which express CCR3, and has a central role in allergic
responses, airway inflammation and human diseases such as asthma (Fulkerson et al.,
2006). Further important disease associations for CCL11 have been shown in CNS
ageing (Villeda et al., 2011) and inflammation, and inflammatory bowel disease
(Rehman et al., 2013). This chemokine has gained new prominence in studies of
atherosclerosis (Emanuele et al., 2006). Whilst CCR3, the main receptor for CCL11, is
not present on monocytes, effects on monocytes are possibly mediated by
antagonising the binding of cognate chemokines on CCR2 and CCR5 expressed by
monocytes (Wang et al., 2013). Increased levels of CCL11 may explain the increased
non-classical (Ly6Clow) monocyte proportions seen in the blood of DARC KO and
FYB(ES)TG (see Figure 4.5e). Ly6Clow monocytes have important functions in
‘patrolling’ the vascular endothelium (Auffray et al., 2009), and exhibit long-range
crawling on the vascular endothelium, particularly in mesenteric and dermal
vasculature with a postulated function of surveying and scavenging pathogens, lipids
and dead cells. This monocyte subgroup has been shown to extravasate and be
important during the early inflammatory response to Listeria, and differentiate into
activated macrophages, with further roles in healing of damaged myocardium.
Increases in vascular endothelium patrolling Ly6Clow monocytes in DARC-negative
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haematopoiesis may coincide with hypothesised increased FYB(ES)TG neutrophil
margination. Further mechanistic work is required to determine the cause of the
increased CCL11, and the possible link between this phenomenon and the noted
increase in Ly6Clow monocytes, particularly since monocytes do not express CCR3.
Given the known effects of CCL11 in directing haematopoiesis toward myeloid
differentiation and proliferative effects on neutrophils, this chemokine may be
contributing to the myeloid hyperplasia seen in FYB(ES)TG.
Changes in the bone marrow environment in the absence of erythropoietic DARC
leading to differences in cellular proportions, distribution and turnover were
hypothesised to induce alterations in gene expression within the HSPC compartment.
The micro-array results of GMP cells suggested that the cells collected from DARC KO
and FYB(ES)TG had increased expression of markers normally low in these
granulocyte-macrophage precursors. Several erythroid and lymphoid genes showed
increased expression, implying that the gene expression profile was more CMP-like,
and more immature. LSK cells however had increased expression of several markers
usually found in mature neutrophils, which could suggest a scenario of enhanced pro-
neutrophilic differentiation, in response to external factors, but in the context of
reduced cell divisions which could lead to ongoing immature gene expression profiles.
This may also explain the relative reduction in GMP, as these may begin to express
more mature myeloid markers (e.g. CD11b) and hence slip into the lineage gating. In
other words, the GMP of DARC KO and FYB(ES)TG are likely CMP-type cells with
early high CD16/CD32 expression, and possibly interplay of CCL11 and G-CSF is
accelerating myeloid-neutrophilic maturation. MPP cells directed towards GMP
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development (GMPP) were similarly reduced which may be due to similar
mechanism. It remains unclear whether the GMPP are truly reduced, or appear so due
to premature altered surface marker expression changes and hence do not appear as
the expected immunophenotype of GMPP. Given the robust myeloid output within the
bone marrow of DARC KO and FYB(ES)TG, the latter may be the likely explanation. A
further alternative explanation, which is supported by some of the LDA results (high
expression of lymphoid genes) is that GMPP are truly reduced, and the deficiency is
compensated by some LMPP being directed toward GMP differentiation, which is a
known ability of this cell group, as described earlier.
Whereas CXCR4 gene expression was significantly increased in the LSK of DARC KO
and FYB(ES)TG compared to WT as shown in the LDA results, this was not present in
GMP of the same mice. This would suggest that LSK cells are more likely to be
retained in the bone marrow, although this retention signal is decreasing at the GMP
stage. CXCR4 is required for the quiescence of HSC (Nie et al., 2008), and it is
conceivable that increased expression may be associated with augmented CXCR4
signalling leading to increased HSC quiescence and correlate with the reduced BrdU
uptake seen in LSK of DARC KO and FYB(ES)TG. In contrast, as stated above, G-CSF
stimulation leads to a transient upregulation of CXCR4 followed by reduction in
CXCR4 surface expression on HSPC. DARC KO and FYB(ES)TG mice demonstrate
elevated G-CSF levels and the effects of chronic G-CSF exposure on HSPC CXCR4
expression are not known. It is possible that the raised CXCR4 expression in LSK cells
acts to counter-balance the elevated G-CSF levels in these mice.
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In contrast, VCAM-1 expression was significantly decreased in the LSK of DARC KO
and FYB(ES)TG. Mice lacking VCAM-1 show increased numbers of circulating HSPC
(Ulyanova et al., 2005). It has been described that VCAM-1 expression is reduced by
the accumulation of neutrophils in the bone marrow, whose proteases (neutrophil
elastase and cathepsin G) directly cleave VCAM-1 (Levesque et al., 2001), although
some controversy exists as to whether proteases are essential for HSPC mobilisation,
as described above. Nevertheless, G-CSF treatment has been shown to be associated
with reduction in VCAM-1 expression in wild-type mice (Levesque et al., 2004).
Whether the raised G-CSF levels or increased bone marrow neutrophil number present
in DARC KO and FYB(ES)TG are the cause of the reduced VCAM-1 levels will require
further study.
As described above, surface CXCR4 expression on mature bone marrow neutrophils is
low compared to intracellular levels, and aged neutrophils have increased CXCR4
expression which contributes to their homing to the bone marrow for clearance
(Martin et al., 2003). Neutrophil surface CXCR4 expression was the same in WT,
DARC KO and FYB(ES)TG mice. This would suggest than there is no preferential
homing for aged neutrophils in the bone marrow of DARC KO and FYB(ES)TG,
implying that is not the cause of increased bone marrow neutrophils in these mice. In
contrast to the known association with bone marrow neutrophil accumulation and G-
CSF induced reductions in CXCL12 during mobilisation, DARC KO and FYB(ES)TG
mice had similar CXCL12 levels in the bone marrow supernatant to WT mice. The
effects of chronic G-CSF stimulation on bone marrow CXCL12 levels are not known,
and it is possible that eventually a compensatory increase in CXCL12 develops. From a
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technical perspective ELISA of whole bone marrow supernatant may not detect
differential localisation of CXCL12.
Given the altered bone marrow environment in DARC KO and FYB(ES)TG mice as
shown by the changes in various cytokine and chemokine levels, it is possible that
these lead to epigenetic modifications, with implications for gene expression in
daughter HSPC. For example, chronic G-CSF stimulation is associated with persistent
HSC re-population defects (Schuettpelz et al., 2014). Some results from the mixed
chimera experiments, such as persistence of reduced GMP profile may be due to
epigenetic changes within DARC KO stem cells persisting despite localisation within
DARC replete bone marrow. This assumption is supported by the in vitro colony
assays showing reduced proliferation of DARC deficient bone marrow or LSK cells in
an optimal growth environment. It is possible that this contributes to the persistent
DARC KO phenotype of the CD45.2 DARC KO within the mixed chimera.
The loss of CXCR2 expression in mice leads to a phenotype characterised by increased
bone marrow neutrophils, reduction in erythroid cells and neutrophilia. However
mixed chimeric mice with both WT and CXCR2 KO bone marrow show increased
CXCR2 deficient neutrophils in the bone marrow and a reduction of these neutrophils
in the blood. This is explained by the presence of WT neutrophils normalising the
peripheral IL23-IL17 ‘sensor’ of neutrophil deficiency and reducing the production of
cytokines (such as G-CSF) which would increase their mobilisation as seen in CXCR2
KO mice (Eash et al., 2010). This would suggest that CXCR2 deficient neutrophils
under normal conditions have a mobilisation defect. This phenotype shows some
similarities to the FYB(ES)TG phenotype, and the mixed bone marrow chimera
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experiment was also associated with a reduction in the proportion of DARC KO
neutrophils; however this affected all peripheral blood cells including lymphocytes to
a similar degree. This further reinforces the notion that loss of haematopoietic DARC
leads not only, if at all, to a neutrophil mobilisation defect but leads also to significant
changes in gene expression in HSPC and mature cells, and that restoration of cytokine
and chemokine profiles to wild-type levels is not sufficient to return the phenotype to
normal.
Whilst this work has focused primarily on the role of the FYB(ES) polymorphism in
causing a peripheral blood neutropaenia, a potential limitation of using a murine
model to study this effect applies. Primarily, the major component of the murine
blood is lymphocytes, whereas in human neutrophils comprise more than 50% of
blood leukocytes. The reduction in blood B lymphocytes in the FYB(ES)TG mouse may
represent a G-CSF effect, since increased G-CSF levels have a suppressive effect on B-
lymphopoiesis (Winkler et al., 2013), or be representative of the reduced proliferation
in the steady state in FYB(ES)TG mice. The latter possibility is less likely, considering
that DARC KO mice have no such reduction in blood lymphocytes. A similar reduction
is noted for blood T lymphocytes in FYB(ES)TG mice. It may be possible that
lymphocytes in FYB(ES)TG may be preferentially re-locating to other sites, such as the
spleen.
Further work would be required to determine whether the differences in progenitor
receptor expression, development and cell turnover rates seen in FYB(ES)TG mice
translate to alterations in neutrophil function, chemokine receptor sensitivity and
protection from apoptosis. In addition functional work examining neutrophil
249
mobilisation and response of the FYB(ES)TG (and FYBTG) murine model to infection
and inflammation may give further insight into the role of DARC modulating cellular
mobilisation from the bone marrow and directing responding cells to inflamed tissues.
Finally the FYBTG mouse will require full characterisation to confirm the preliminary
findings and determine cell proliferation and gene expression changes.
Therefore, in summary, the FYB(ES)TG mouse model recapitulates the human Duffy-
negative phenotype, by showing that the loss of erythroid DARC directly leads to
peripheral blood neutropaenia, and is supported by irradiation chimera experiments
with the same effect. The reduced neutrophil count seen in FYB(ES)TG mice and, by
extension, in humans with ethnic neutropaenia, may be due to increased margination
as originally theorised due to abnormal neutrophil localisation within the bone
marrow and blood. Feedback to the bone marrow by way of G-CSF signalling may
lead to increased pro-myeloid haematopoietic maturation, and accumulating
aggregations of myeloid cells therein due to suboptimal patterning of chemokines.
The increased levels of G-CSF would also increase HSPC quiescence, yet contribute to
anti-apoptotic signalling, leading to fewer cell divisions and in humans potentially
protect from the development of acute myeloid leukaemia (see Chapter 5).
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The Role of DARC in Cancer Survival
5.1 Introduction
The potential importance of ethnicity in the outcome of cancer therapy is receiving
increasing attention (Bhatia, 2011, Artinyan et al., 2010). Persons of African ancestry
fare worse in analyses of health outcomes compared with many other populations,
with recent data from the United States indicating higher overall cancer death rates
for African Americans (SEER Program database, 2012). Poor cancer survival in ethnic
minority groups has been ascribed to be due to a complex mix of biological and socio-
economic factors, such as access to health-care, cancer surveillance, educational
opportunity and cultural factors (Bach et al., 2002). The inference of biological factors
however is intriguing. These include differences in disease biology, such as a higher
incidence of poor risk disease (Kadan-Lottick et al., 2003, Woodward et al., 2006),
different metabolism of drugs due to genetic polymorphisms (McLeod et al., 1994), or
susceptibility to side effects (Hasan et al., 2004) in some ethnic minority groups.
There has been recent interest in a potential role for DARC on cancer development
and outcome of cancer therapy. African American men have higher incidence of
prostate cancer (Hsing and Devesa, 2001, DeSantis et al., 2013), and increased
likelihood of more aggressive disease as well as higher death rates, compared to
Caucasian Americans.
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Studies have examined potential associations between DARC phenotype or ethnic
neutropaenia and cancer survival. An initial clinical study failed to demonstrate an
association between Duffy phenotype within a Jamaican population, and prostate
cancer risk, although the authors identified a number of confounding risk factors
(Elson et al., 2011). A further study investigated a possible association between
neutrophil count and prostate cancer risk and severity (Sadeghi et al., 2012) in
African American men. An association was noted between blood absolute neutrophil
count <1.5x106/ml and Gleason score, an indicator of prostate cancer prognosis
based on histological degree of tissue abnormality, at prostatectomy. Although only 18
individuals (5%) of 336 African American men in this study demonstrated a
neutrophil count <1.5x106/ml, the result is of interest, as it suggests a potential
functional effect of Duffy negative phenotype by way of bone marrow myeloid cell
effects, instead of direct blood chemokine effects. This may represent a complex
interaction, as neutrophils are known to have anti-tumour potential through
cytotoxicity against tumour cells, and cause damage to vascular endothelium through
oxidants and proteolytic enzymes (Di Carlo et al., 2001). In contrast substantial
evidence now shows significant pro-tumour actions of neutrophils, including
promoting tumour angiogenesis (Tazzyman et al., 2009). It remains unclear what
causes the conversion of neutrophil function from tumour suppressive to tumour
promoting, although G-CSF and IL-6, which could be produced by tumour cells
and/or stromal cells in malignant tumours (Shojaei et al., 2007), are potential
candidates for modulating neutrophils to induce their tumour-promoting function
(Yan et al., 2013). It has been previously described that G-CSF levels are elevated in
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Duffy negative individuals (Mayr et al., 2007), although no link between systemic and
intra-tumour GCSF levels and neutrophil-tumour effects have been demonstrated. In
contradiction to findings demonstrating a link between prostate cancer severity and
neutropaenia, in gastric (Jin et al., 2013) and colon cancer (Michael et al., 2006),
melanoma (Schmidt et al., 2007), nasopharyngeal carcinoma (He et al., 2012),
mesothelioma (Kao et al., 2010) and advanced non-small cell lung cancer (Teramukai
et al., 2009), higher neutrophil levels and/or higher neutrophil-to-lymphocyte ratios
are associated with poorer survival.
Treatment of leukaemia (myeloid or lymphoid) with combination chemotherapeutic
agents induces periods of profound immunosuppression, in conjunction with the
immunosuppressive effects of the underlying malignant disorder. A major cause for
presentation in these disorders and treatment related mortality remains infection,
particularly therapy-associated bacterial neutropaenic sepsis (Creutzig et al., 2004).
Susceptibility to infection in individuals of African ancestry has been a contentious
issue. A study demonstrating substantial anti-microbial effects by neutrophils against
tuberculosis infection, also noted that the likelihood of acquiring this disease appeared
to correlate inversely with neutrophil counts (Martineau et al., 2007). Study subjects
of African origin tended to have lower neutrophil counts and the highest incidence of
tuberculosis infection, compared with other groups (including South Asians) in the
South London cohort. Furthermore, US registry data revealed an increased incidence
of severe sepsis and consequent organ dysfunction in individuals of African ancestry
(Mayr et al., 2010). However this analysis of registry data is affected by potential
confounders which include socio-economic factors and access to healthcare,
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particularly in a health-care system with a substantial private-care component
(Robbins et al., 2009). In a more controlled analysis Duffy-negative African Americans
admitted to intensive care units for treatment of acute lung injury have twice the
mortality of Duffy-positive subjects of the same ethnicity (Kangelaris et al., 2012).
This finding would support an underlying biological effect of the Duffy negative
phenotype on response to severe infection/inflammation, relating to the loss of
erythrocyte function as a sink or reservoir of inflammatory chemokines rather than
neutropaenia. In addition chronic co-morbidities such as diabetes and hypertension
which are more common (Harris, 1990, Lloyd-Jones et al., 2009) in African Americans
and require high-quality medical management (affected by access to healthcare), as
well as disparities in disease prevention may contribute to the increased rates of sepsis
(Esper et al., 2006a, Dombrovskiy et al., 2007). It is not possible however to isolate
the individual components leading to the observed effect.
Regarding outcome following treatment for malignancy, a significant reduction in
survival in children of African American background has been reported following
treatment for acute myeloid leukaemia, due primarily to an increased mortality from
infectious complications (Aplenc et al., 2006). In addition an inferior outcome for
women of African ancestry has been reported following treatment for breast cancer
and this may have been due to treatment delay secondary to neutropaenia (Smith et
al., 2005, Hershman et al., 2003). It is clear that the identification of the relative roles
of genetic or environmental factors in determining the basis of any association
between ethnicity and cancer outcome therefore remains challenging.
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The role of ethnicity and DARC genotype on the outcome of acute myeloid leukaemia
in patients entered into UK clinical trials for acute myeloid leukaemia was
investigated. The UK National Health Service is an open access health care system and
therefore limits potential environmental confounding factors.
Collaboration was established with Prof AK Burnett, head of the MRC AML trials
group, who kindly agreed to provide extracted DNA from stored bone marrow aspirate
samples of patients with acute myeloid leukaemia treated as per trial protocol.
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5.2 Materials and methods
DNA was extracted by Dr Amanda Gilkes (Cardiff, UK) with the Qiagen Blood DNA
extraction kit. Extracted DNA was diluted to a concentration of 25ng/µl and stored at
-80oC until used. Human DARC allele genotyping was done by method in section
1.1.12 (‘Human DARC Genotyping for Polymorphic Alleles’) using allele-specific
primers (Mullighan et al., 1998). DNA was available from 54 patients whose ethnic
origin was described as Black or Asian. Twenty-eight subjects of self-described Asian
ancestry were genotyped for the presence of FYB(ES), along with 25 subjects of self-
described African origin.
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5.3 Results
Five year outcome data were available for 2967 patients entered into the UK MRC
AML15 trial (designed for patients under the age of 60) between May 2002 and
January 2009 and 1811 patients in the NCRI AML16 trial (designed for patients over
the age of 60) between August 2006 and May 2012. Only patients treated with
intensive chemotherapy are included in this comparison. Follow-up is complete for
AML15 to 1st January 2012, and for AML16 to 1st January 2013. Ethnic origin was
self-described by the patient at the time of trial entry. The results of the genotyping
are given in Table 5.1. The homozygous prevalence of FYB(ES) within Caucasian
subjects is 0.07-0.1% (Reich et al., 2009, Reid and Lomas-Francis, 2004) and this
group was not genotyped but assumed to carry FYA or FYB alleles.
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Approximately 61% percent of patients self-described as of African ancestry were
homozygous for the point mutation terminating transcription of DARC protein in
erythroid cells. None of the Asian patients harboured this polymorphism, and 64%
were homozygous for FYA, the allele more commonly found across Asian populations.
Genotype African ancestry Asian
FyA*FyA 0 18
FyA*FyB 2 5
FyB*FyB 1 3
FyBES*FyBES 15 0
FyBES*FyA 2 0
FyBES*FyB 3 0
N/A 2 2
TOTAL 25 28
Table 5.1 Genotyping results of non-Caucasian subjects from MRC AML15 trial for the three principal DARC
alleles.
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a)
b)
Figure 5.1 Overall 5 year survival in AML15 and AML16 studies. (a) 5 year survival from trial entry divided by
ethnicity for AML15. 2814 white patients had 1628 events, 114 Asian patients had 59 events and 52 black
patients had 27 events. Overall survival for black patients was not different compared to white patients, p=0.3
(b) 5 year survival from trial entry divided by ethnicity for AML16. 1763 white patients had 1298 events, 30
Asian patients had 22 events and 18 black patients had 8 events. Overall survival for black patients was superior
compared to white patients, p=0.02
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No differences in risk of early death or 5-year survival were observed between the
three ethnic groups, Asian, Black and White in AML15 (p=0.3) (Figure 5.1a); in the
AML16 trial for older patients, those in the Black ethnic group had better outcomes
(p=0.02) (Figure 5.1b). The outcome for ‘Duffy negative’ and ‘Duffy positive’
individuals within the Black ethnic group in AML15 was not significantly different
(HR 1.30, 95% CI (0.39-4.40), p=0.7) although numbers are too small to draw any
definitive conclusion (Figure 5.2).
Figure 5.2 5 year survival from trial entry divided by DARC genotype in Black patients for AML15. Twelve
patients homozygous for FYB(ES) experienced 6 events, whereas 8 Duffy positive individuals had 8 events.
Overall survival was not different between the genotypes, p=0.7
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5.4 Discussion
Ethnic minority origin did not adversely influence clinical outcome in this large
national study of AML treatment. A similar observation has been found in a paediatric
AML cohort when healthcare access is equalised (Pui et al., 2012). This is of particular
interest as the intensive chemotherapy regimens used during AML treatment are
associated with frequent and prolonged episodes of neutropaenia. The failure to
observe any influence of Duffy negative phenotype on clinical outcome suggests that
the moderately reduced neutrophil counts seen in ethnic neutropaenia may be
sufficient to protect patients on peripheral blood recovery following myeloablative
chemotherapy. Other factors such as the duration of severe neutropaenia, and the
biological characteristics of the malignancy may play a more important role in AML
survival.
Data from the SEER program database also indicate a lower incidence of acute
myeloid leukaemia in African Americans compared to Caucasians across the same age
group stratifications (2012). Whilst this needs to be shown in a prospective study, data
from a cardiovascular study (Hunt et al., 2008) found longer telomeres in individuals
of the African American group, as discussed above. This suggests that myeloid cells in
these individuals may have undergone fewer cell divisions and are ‘younger’. AML is
an illness affecting older individuals (Cartwright and Staines, 1992), and the
probability of accumulating genetic damage increases with cell divisions. Telomeres
help to reduce the genomic instability which leads to cancer development and shorten
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with successive cell divisions (O'Sullivan and Karlseder, 2010). It is possible that this
mechanism may contribute to the lower incidence of AML in this population group,
although other gene polymorphism may play a role.
Limitations of the present study include small numbers of individuals which are of the
ethnic minority type, restricting statistical power to large differences in outcome. In
addition, patients of the ethnic minority cohort tended to be of younger age, which in
itself confers superior survival, as biologic factors such as lower likelihood of resistant
disease and better tolerability of intensive chemotherapeutic regimes are more
relevant.
Better powered studies are likely to provide clearer results. Most clinical trials
involving acute myeloid leukaemia treatment are small, incorporating a few centres.
In addition, countries with substantial African ancestry populations and the resources
to undertake studies with the collection of high quality data are limited to the United
States. A future study to examine the role of DARC, ethnic neutropaenia and survival
from acute myeloid leukaemia might correct for socio-economic confounding factors
by including individuals only of African ancestry. In the USA, approximately 20% of
these individuals are not homozygous for the ‘Duffy negative’ promoter mutation
(Reich et al., 2009), and would therefore be a more suitable control group.
Furthermore this would control for other confounders such as those which might
potentially have been introduced in this study by immigration, for example, where
better outcome in first generation immigrants has been reported (Siemerink et al.,
2011, Keegan et al., 2010).
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Conclusion
The existence of DARC as a blood group antigen has been established for over half a
century, and subsequently its indispensable role for vivax malaria infection became
apparent. Over the last twenty years, functional aspects of the role of DARC in
inflammation and infection have been gradually dissected, with more recent findings
suggesting it may function to regulate peripheral blood neutrophil counts.
Both haematopoiesis and the release of leukocytes from the bone marrow are under
the control of two chemokine-receptor axes, involving CXCR4 and CXCR2. The ligands
of CXCR2 bind to DARC, and in this work, I have shown that loss of haematopoietic
DARC has implications for haematopoiesis in homeostasis.
The study of peripheral blood reconstitution in irradiation chimeras showed that the
introduction of DARC-deficient haematopoiesis in wildtype hosts lead to peripheral
blood neutropenia. This inspired the development of two mouse models, FYB(ES)TG
and FYBTG, that express two polymorphic variants of the human DARC gene, and
which allowed the analysis of haematopoiesis in these models and in DARC deficient
mice. Only FYB(ES)TG mice, which harbour a polymorphism of DARC where
transcription is abolished in the erythroid cells, display blood neutropenia, similar to
both humans homozygous for this polymorphism, and the irradiation chimeric mice
with DARC-deficient bone marrow. Preliminary results from FYBTG mice, where
human DARC is expressed both on erythroid and endothelial cells, show that DARC
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expression on erythroid cells leads to peripheral neutrophil counts similar to WT mice.
DARC expressed by cells of the erythroblast lineage may have a role in modulating
neutrophil release from the bone marrow, and in promoting optimal and orderly
granulopoiesis. This is substantiated by the larger numbers of neutrophils in the bone
marrow of FYB(ES)TG mice, and their development in larger aggregates. HSPC and
granulocytic lineage development were skewed in these mice as determined from
gene expression studies of these cells and enumeration of their progenitors, showing
that a pro-granulocytic gene expression profile was associated with reduced numbers
of precursors, possibly due to accelerated differentiation and the bypassing of
developmental stages.
The loss of erythroid DARC may alter the availability and distribution of ELR+ and
other chemokines within the bone marrow microenvironment. Work in this thesis
shows that erythrocyte DARC increased the concentration of cognate chemokine in the
supernatant and on the cell surface of erythroblasts. This supports the hypothesis that
DARC serves to maintain the availability of chemokines in the bone marrow. Analysis
of the bone marrow supernatant and peripheral blood of FYB(ES)TG mice showed
increased concentration of G-CSF, possibly as a response to the blood neutropenia and
contributing to the increased granulopoiesis observed in the bone marrow.
Unexpectedly CCL11, a chemokine traditionally associated with allergic responses,
was found to be highly expressed in the bone marrow and blood of FYB(ES)TG mice.
Further work is required to determine whether this is due to a loss of erythroid DARC
receptor buffering, or is a secondary response to the neutropenia. For example, mass
spectrometry analysis may determine whether this is the intact molecule, or a digested
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form detected by the assay. Erythrocyte DARC may serve to protect CCL11 from
degradation and in the absence of DARC it may digested by proteinases.
Changes in neutrophil surface molecule expression suggest a more activated
neutrophil phenotype in FYB(ES)TG mice, and there may also be implications for
CXCR2 receptor responsiveness. Reductions in availability of ELR+ chemokines due to
their altered bone marrow distribution in the absence of DARC may affect CXCR2
responsiveness and may contribute to the accumulation of neutrophils in the bone
marrow of these mice, and impair their release. Labelled neutrophil transfer
experiments could help determine whether this is the case or whether more mature
neutrophils have returned and accumulated in the bone marrow following their
release into the circulation. In addition administration of CXCR4 antagonists, G-CSF
and sympathomimetics to FYB(ES)TG mice could help to establish the release kinetics
of neutrophils from the bone marrow and their distribution in the marginated pool.
The gene expression signature of precursor LSK and myeloid progenitor bone marrow
cells from FYB(ES)TG is not only pro-granulocytic, but also with signs of errant
differentiation, with high expression of genes typically associated with other lineages.
This is associated with reduced proliferation and protection from apoptosis seen in
LSK and myeloid progenitors in FYB(ES)TG mice, and further work is required to
determine whether the restoration of erythroid DARC expression would revert these
to wildtype levels. Genetic manipulation using viral vectors to induce DARC
expression in erythroblasts of FYB(ES)TG mice may provide significant further
information in this regard. Furthermore, irradiation mixed chimeric mice harbouring
both DARC-replete and DARC-deficient haematopoiesis in a WT host did not lead to a
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normalisation of DARC KO proliferation kinetics and progenitor maturation profiles,
underscoring possible epigenetic changes on haematopoietic stem cells developing in
a DARC deficient bone marrow. Serial transplantation experiments of the LT-HSC may
confirm this hypothesis, and studies of DNA methylation and microRNA would
provide further valuable information to determine the role of epigenetic phenomena
regulating gene expression in the HSPC of FYB(ES)TG mice.
Circulating lower number but more activated neutrophils in FYB(ES)TG mice may
alter immune responses to infection and inflammation, and the investigation of the
outcomes of FYB(ES)TG mice in models of infection may give further indication as to
whether the FYBES polymorphism has implications for the study of clinical infections
in Africans.
Treatment of acute myeloid leukaemia is associated with prolonged periods of
neutropenia. Examination of the results of leukaemia survival within large UK trials
determined that FYB(ES) homozygous individuals did not experience inferior
outcomes. In particular, black individuals of all DARC genotypes in one study (which
enrolled patients over 60 years of age) had better survival 5 years post leukaemia
diagnosis. The reasons for this are unclear, but the main conclusion to be drawn is
that the reduced neutrophil counts present in FYB(ES) homozygous individuals are
not detrimental and are sufficiently protective during the recovery following
myeloablative chemotherapy.
In summary, this work has shown a new role for haematopoietic DARC, which
supports the availability of cognate chemokines in the bone marrow environment, and
266
may serve to promote the availability of chemokines for optimal haematopoiesis and
neutrophil release from the bone marrow, possibly by modulating the ELR+
chemokine-CXCR2 axis. Both erythroblast and endothelial DARC may function in
concert to promote orderly neutrophil development and release into the circulation.
Finally, this is the first functional demonstration that the loss of haematopoietic DARC
leads to the neutropenia seen in FYB(ES) homozygous humans.
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Appendix
7.1 Annotated DARC gene sequence
The human DARC gene sequence is presented below with annotations. The translated
amino acid sequence is present in capitals immediately below respective codons. The
500bp upstream and 1kbp downstream of the sequence included in FYB(ES) and FYB
transgene constructs is not shown.
7.1.1 Key
Colour highlighting code: Military green=plasmid DNA (excised); yellow=regulatory
elements, red=mutation, exons=blue, grey= terminal nucleotides, pink=restriction
enzyme analysis sites.
7.1.1.1 Polymorphic mutations
The main polymorphic mutations are presented below for illustrative purposes.
Fy(a+b-): Gly (GGT) Fy(a-b+): Asp(GAT)
GATA motif: TTA TCT mutation TTA CCT
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7.1.2 DARC sequence
-512 ctcgagtttttcagcaagatacatggcttttgaactgcctttccttggatc
-481 cagttcaaggggatggaggagcagtgagagtcagccgcccttccactccaatttcccagc
-421 acctcccttatctctgcctcacaagtcacccagcccccctctcttccttccttgtgcttg
-381 aagaatctctccttgctggaaagccccctgttttctcaatctccctttccacttcggtaa
-321 aatctctacttgctggaaagccccctgttttctcaatctccctttccacttcggtaaaat
-261 gcccactttctggtccccacctttttcctgagtgtagtcccaaccagccaaatccaacct
-201 caaaacaggaagacccaaggccagtgacccccataggcctgaggcttgtgcaggcagtgg
-141 gcgtggggtaaggcttcctgatgccccctgtccctgcccagaacctgatggccctcatta
-81 gtccttggctcttaccttggaagcacaggcgctgacagccgtcccagcccttctgtctgc
-21 gggcctgaaccaaacggtgccatggggaactgtctgcacagggtgagtatggggccaggc
M G N C L H R
40 cccagagtcccttatccctatgcccctcatttcccgtgctgtttgcccctcagtctttat
100 atctcttccttttcctcctcatcttttctcccttcctgcttttttcctcttccttcaaag
160 tctttttccttctctccttcctatgctagcctcctagctccctcttgtgtccctcccttt
220 gcctttgagtcagttccatcctggtctcttggtgccttttccttctgaccttgcactgct
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280 cctccagccccagctgccctggcttccccaggactgttcctgctccggctcttcaggctc
340 cctgctttgtccttttccactgtccgcactgcatctgactcctgcagagaccttgttctc
400 ccacccgaccttcctctctgtcctcccctcccacctgcccctcaattcccaggagactct
460 tccggtgtaactctgatggcctcctctgggtatgtcctccaggcggagctctccccctca
A E L S P S
520 actgagaactcaagtcagctggacttcgaagatgtatggaattcttcctatggtgtgaat
T E N S S Q L D F E D V W N S S Y G V N
580 gattccttcccagatggagactatgatgccaacctggaagcagctgccccctgccactcc
D S F P D G D Y D A N L E A A A P C H S
620 tgtaacctgctggatgactctgcactgcccttcttcatcctcaccagtgtcctgggtatc
C N L L D D S A L P F F I L T S V L G I
680 ctagctagcagcactgtcctcttcatgcttttcagacctctcttccgctggcagctctgc
L A S S T V L F M L F R P L F R W Q L C
740 cctggctggcctgtcctggcacagctggctgtgggcagtgccctcttcagcattgtggtg
P G W P V L A Q L A V G S A L F S I V V
800 cccgtcttggccccagggctaggtagcactcgcagctctgccctgtgtagcctgggctac
P V L A P G L G S T R S S A L C S L G Y
860 tgtgtctggtatggctcagcctttgcccaggctttgctgctagggtgccatgcctccctg
C V W Y G S A F A Q A L L L G C H A S L
920 ggccacagactgggtgcaggccaggtcccaggcctcaccctggggctcactgtgggaatt
G H R L G A G Q V P G L T L G L T V G I
980 tggggagtggctgccctactgacactgcctgtcaccctggccagtggtgcttctggtgga
W G V A A L L T L P V T L A S G A S G G
1040 ctctgcaccctgatatacagcacggagctgaaggctttgcaggccacacacactgtagcc
L C T L I Y S T E L K A L Q A T H T V A
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1100 tgtcttgccatctttgtcttgttgccattgggtttgtttggagccaaggggctgaagaag
C L A I F V L L P L G L F G A K G L K K
1160 gcattgggtatggggccaggcccctggatgaatatcctgtgggcctggtttattttctgg
A L G M G P G P W M N I L W A W F I F W
1220 tggcctcatggggtggttctaggactggatttcctggtgaggtccaagctgttgctgttg
W P H G V V L G L D F L V R S K L L L L
1280 tcaacatgtctggcccagcaggctctggacctgctgctgaacctggcagaagccctggca
S T C L A Q Q A L D L L L N L A E A L A
1340 attttgcactgtgtggctacgcccctgctcctcgccctattctgccaccaggccacccgc
I L H C V A T P L L L A L F C H Q A T R
1400 accctcttgccctctctgcccctccctgaaggatggtcttctcatctggacacccttgga
T L L P S L P L P E G W S S H L D T L G
1460 agcaaatcctagttctcttcccacctgtcaacctgaattaaagtctacactgcctttgtg
S K S
1520 aagcgggtggtttcttattttgtctggggagaagaaggagaatggagagagagacatttt
1680 tatgtcagactttcttgccagtgtctgcttctatagctggcttgggaagaaggtgaatga
1740 tgaataaataccctcagggtacacagatgttctcttgaggtgtggggtcacggccatctc
1800 aagggagaagagaagaggaaccagagcatgaggggagtcattaaaccaaaaaaaacagaa
1860 gggatggcttagctggaaaaaaagctgttctgggaagcaaatggaataggaactcaaact
1920 gagagataaacagtgaagagtgatgacaaagcccagagcaataccacctccccctgtcca
1980 acctgcccagcctctgtcttctgtctcctctctggctttgtttagtgattaggacagtgg
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2040 tggggaaggtgaaagaagcatcccaggggatgttactcagttcagggaacatatcaaggt
2100 aatttaaaaagccacttcctgggagtcatctctcccaggttcctcagcatgacctgaatg
2160 tgcgtgcgtgtgtgtgtgtgtgtgtgtgtacacatctgtttctcgatctgttagaatcta
2220 cctttatgttagatgtatgcatgtaaaaacatatgtccacccatgagcttgcatctctgt
2280 cagcacctgaactgcgcacacctgtgcgtgtgcactgacttttctcaggacccaaacccc
2340 cactcaattctgcactcatccctgttcacaggatatagaatcgggatttatgactcactc
2400 cttacccaaatgagttttctttaccctggtttttaagcctagtcttttctgtgtaggatg
2460 tgtggagggaagaaaagatcaagaagttgtgaagggtggagaaacttgaagggggaggcc
2520 ctgatttgattcatcttctgcttggaattccccgaatttccctttcagaatctcagcttt
2580 tgaaataaacctttatttcccacatacatctttccttccaccttccacacaataccccaa
2640 tcccctgggcacctttttcccaacccctgattctctggctgcttaatcatgacctttgag
2700 atttttctcagtctctacctacccaagtttagatggctggaaggacagaaacccctcctc
2760 atcaggggcacagcttttaccaccaagagcaaattcaccctctacccaagaggatctttctaga
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7.2 Microarray data: LSK
Table 7.1 Significant (p<0.01) differentially up- and down-regulated genes in DARC
KO LSK cells from microarray study.
Fold-
change Symbol Name
Parametric p-
value t-value
656.09 NGP neutrophilic granule protein 0.00053 9.773863
509.74 RETNLG resistin like gamma 1.19E-05 24.91421
462.38 CAMP cathelicidin antimicrobial peptide 0.000169 12.99951
418.15 LTF lactotransferrin 0.000193 12.58048
351.33 S100A8 S100 calcium binding protein A8 (calgranulin A) 0.000645 9.304109
290.63 CAMP cathelicidin antimicrobial peptide 2.68E-05 20.44101
210.62 MMP8 matrix metallopeptidase 8 2.03E-05 21.87719
200.48 S100A9 S100 calcium binding protein A9 (calgranulin B) 0.00085 8.676108
182.53 ALAS2 aminolevulinic acid synthase 2, erythroid 0.000154 13.29547
176.46 CHI3L3 chitinase 3-like 3 0.000285 11.42115
131.22 IFITM6 interferon induced transmembrane protein 6 0.000614 9.421482
102.05 AHSP alpha hemoglobin stabilizing protein 0.000974 8.381289
96.26 HP haptoglobin 0.00074 8.986058
92.35 HBB-B2 hemoglobin, beta adult minor chain 0.002499 6.572798
91.57 SLC4A1 solute carrier family 4 (anion exchanger), member 1 4.09E-05 18.43689
86.88 ITGB2L integrin beta 2-like 0.003455 6.034561
84.14 RHD Rh blood group, D antigen 9.97E-05 14.81026
83.34 CD300LF CD300 antigen like family member F 8.97E-05 15.20151
64.79 C3 complement component 3 0.000223 12.13369
55.94 FN1 fibronectin 1 0.00197 6.993227
48.57 SLC38A5 solute carrier family 38, member 5 0.000684 9.167096
46.30 CD300LF CD300 antigen like family member F 0.000263 11.64906
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41.27 CEBPE CCAAT/enhancer binding protein (C/EBP), epsilon 0.000206 12.38332
40.34 HBB-B1 hemoglobin, beta adult major chain 0.000189 12.64351
39.69 FAM46C family with sequence similarity 46, member C 0.000296 11.31384
37.30 LCN2 lipocalin 2 0.000861 8.64718
33.21 ERMAP erythroblast membrane-associated protein 0.000269 11.57775
30.61 PILRA paired immunoglobin-like type 2 receptor alpha 0.000711 9.076722
30.17 ITLN1 intelectin 1 (galactofuranose binding) 0.000426 10.32706
26.76 GDA guanine deaminase 0.000239 11.92209
26.47 AQP1 aquaporin 1 0.000658 9.257144
25.67 PI16 peptidase inhibitor 16 0.006276 5.138434
25.43 IFI202B interferon activated gene 202B 0.001034 8.255027
23.33 RHOU ras homolog gene family, member U 0.000237 11.94988
21.97 LGALS3 lectin, galactose binding, soluble 3 0.002935 6.300563
20.63 HDC histidine decarboxylase 0.006479 5.093721
20.32 MRGPRA2A MAS-related GPR, member A2A 0.000668 9.222977
19.58 SPNA1 spectrin alpha 1 0.000225 12.11429
19.40 PLBD1 phospholipase B domain containing 1 0.008732 4.689462
17.93 MMRN1 multimerin 1 0.005711 5.272437
17.71 CCL6 chemokine (C-C motif) ligand 6 0.000563 9.629102
15.89 C3 complement component 3 0.002858 6.345243
15.67 VPREB3 pre-B lymphocyte gene 3 0.000311 11.17124
14.66 CXCR2 chemokine (C-X-C motif) receptor 2 0.001126 8.077367
14.55 MRGPRA2B MAS-related GPR, member A2B 0.001429 7.598519
14.13 ZDHHC22 zinc finger, DHHC-type containing 22 0.002787 6.38746
14.07 PROK2 prokineticin 2 0.004893 5.49812
14.02 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 0.000484 9.998391
13.95 LILRA6
leukocyte immunoglobulin-like receptor, subfamily A
(with TM domain), member 6 0.000403 10.46906
13.72 FPR1 formyl peptide receptor 1 0.000362 10.75792
274
Fold-
change Symbol Name
Parametric p-
value t-value
13.60 GPR77 G protein-coupled receptor 77 0.002215 6.783315
13.21 PRAM1 PML-RAR alpha-regulated adaptor molecule 1 0.009999 4.514087
13.12 GDA guanine deaminase 0.000985 8.357811
12.70 GPR77 G protein-coupled receptor 77 0.001586 7.397091
12.67 PROM1 prominin 1 0.000868 8.629861
12.53 LILRA6
leukocyte immunoglobulin-like receptor, subfamily A
(with TM domain), member 6 0.000658 9.258265
11.83 MEFV Mediterranean fever 0.006395 5.112074
11.73 PILRA paired immunoglobin-like type 2 receptor alpha 0.002195 6.79945
11.64 GYPA glycophorin A 0.000601 9.470268
11.29 FECH ferrochelatase 0.000673 9.203285
11.19 MKRN1 makorin, ring finger protein, 1 0.00495 5.481013
11.08 ADD2 adducin 2 (beta) 0.002198 6.796708
10.98 NHSL2 NHS-like 2 0.000766 8.908844
10.69 MOGAT2 monoacylglycerol O-acyltransferase 2 0.003763 5.899321
10.62 PIRA7 paired-Ig-like receptor A7 0.000635 9.34147
10.51 FCGR4 Fc receptor, IgG, low affinity IV 0.006676 5.052028
10.15 ALDH3B1 aldehyde dehydrogenase 3 family, member B1 0.003212 6.15272
9.94 BC100530 cDNA sequence BC100530 0.000799 8.814366
9.70 OLFR71 olfactory receptor 71 0.001139 8.052764
9.58 CD177 CD177 antigen 0.001275 7.824199
9.56 ANKRD22 ankyrin repeat domain 22 0.001705 7.260434
9.04 CYP4F18 cytochrome P450, family 4, subfamily f, polypeptide 18 0.00518 5.41417
9.02 CD300LD CD300 molecule-like family member d 0.00183 7.128654
8.90 CDR2 cerebellar degeneration-related 2 0.004731 5.548193
8.86 S100A6 S100 calcium binding protein A6 (calcyclin) 0.00318 6.169041
8.79 MGLL monoglyceride lipase 0.009592 4.567357
8.14 IRG1 immunoresponsive gene 1 0.004082 5.772525
8.11 MGLL monoglyceride lipase 0.009761 4.544912
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7.99 STFA2 stefin A2 0.004083 5.771989
7.64 TSPAN33 tetraspanin 33 0.00233 6.693964
7.52 CRISPLD2
cysteine-rich secretory protein LCCL domain containing
2 0.002803 6.377471
7.51 BUTR1 butyrophilin related 1 0.002471 6.592366
7.49 SEMA4A
sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4A 0.006486 5.092214
7.44 IL5 interleukin 5 0.003143 6.187864
7.30 SLC2A4
solute carrier family 2 (facilitated glucose transporter),
member 4 0.001741 7.220597
7.22 SLC6A9
solute carrier family 6 (neurotransmitter transporter,
glycine), member 9 0.003596 5.970779
6.97 AMICA1 adhesion molecule, interacts with CXADR antigen 1 0.006076 5.184082
6.82 STFA2L1 stefin A2 like 1 0.004413 5.653066
6.67 APOL11B apolipoprotein L 11b 0.003045 6.239866
6.58 CEACAM2
carcinoembryonic antigen-related cell adhesion
molecule 2 0.003437 6.04305
6.52 PIRA11 paired-Ig-like receptor A11 0.001563 7.425016
6.43 CES2G carboxylesterase 2G 0.004788 5.530295
6.35 C5AR1 complement component 5a receptor 1 0.001505 7.496983
6.14 CCR2 chemokine (C-C motif) receptor 2 0.006387 5.113681
6.00 SLPI secretory leukocyte peptidase inhibitor 0.003315 6.101331
5.96
LOC100042
072 y-linked testis-specific protein 1-like 0.001764 7.196521
5.87 GATA1 GATA binding protein 1 0.007391 4.912188
5.73 NCAM1 neural cell adhesion molecule 1 0.001757 7.203295
5.59 PRKCB protein kinase C, beta 0.008444 4.733778
5.59 KLRA22 killer cell lectin-like receptor subfamily A, member 22 0.004061 5.780442
5.55 BMX BMX non-receptor tyrosine kinase 0.002982 6.274377
5.38 STFA1 stefin A1 0.002172 6.817774
5.37 E2F2 E2F transcription factor 2 0.005701 5.27512
5.31 ARID3A AT rich interactive domain 3A (BRIGHT-like) 0.008777 4.682838
5.28 SIGLECH sialic acid binding Ig-like lectin H 0.005164 5.418602
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5.20 GSN gelsolin 0.006702 5.046551
5.20 GSN gelsolin 0.005622 5.295092
4.98 GRHL2 grainyhead-like 2 (Drosophila) 0.004273 5.702184
4.86 ERMAP erythroblast membrane-associated protein 0.005854 5.237082
4.66 SLC25A37 solute carrier family 25, member 37 0.007211 4.94583
4.64 RAB44 RAB44, member RAS oncogene family 0.007148 4.95783
4.53 ADAM19
a disintegrin and metallopeptidase domain 19 (meltrin
beta) 0.00494 5.484002
4.41 CRISPLD2
cysteine-rich secretory protein LCCL domain containing
2 0.003676 5.936147
4.32 FCNB ficolin B 0.003419 6.051379
4.30 IL28RA interleukin 28 receptor alpha 0.007671 4.861939
4.29 INPP5J inositol polyphosphate 5-phosphatase J 0.005039 5.454589
4.26 SEPX1 selenoprotein X 1 0.004484 5.628984
4.16 ABCB10
ATP-binding cassette, sub-family B (MDR/TAP),
member 10 0.008563 4.715185
4.13 UBE2O ubiquitin-conjugating enzyme E2O 0.00742 4.906859
3.92 SPHK1 sphingosine kinase 1 0.004673 5.566827
3.90 NUDT4
nudix (nucleoside diphosphate linked moiety X)-type
motif 4 0.005419 5.348224
3.87 FDFT1 farnesyl diphosphate farnesyl transferase 1 0.008921 4.66149
3.65 MMP25 matrix metallopeptidase 25 0.00815 4.780797
3.64 LTB4R1 leukotriene B4 receptor 1 0.0065 5.089202
3.60 PYGL liver glycogen phosphorylase 0.00958 4.569028
3.59 OLFR1441 olfactory receptor 1441 0.008834 4.674291
3.42 ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 0.008607 4.708414
3.31 CLDN15 claudin 15 0.008081 4.792024
3.24 MFHAS1 malignant fibrous histiocytoma amplified sequence 1 0.009891 4.52793
-3.36 WFDC2 WAP four-disulfide core domain 2 0.007201 -4.94784
-3.73 FOXD4 forkhead box D4 0.008692 -4.69562
-3.73 GRCC10 gene rich cluster, C10 gene 0.008033 -4.80003
-4.50 PHPT1 phosphohistidine phosphatase 1 0.006165 -5.16354
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-5.78 HIST1H4K histone cluster 1, H4k 0.007418 -4.90731
-6.02 HIST1H4J histone cluster 1, H4j 0.006094 -5.17991
-6.20 HIST1H4C histone cluster 1, H4c 0.003784 -5.89037
-6.24 ATP6 ATP synthase F0 subunit 6 0.008363 -4.74638
-6.61 HIST1H2AK histone cluster 1, H2ak 0.007039 -4.979
-6.73 HIST1H4D histone cluster 1, H4d 0.007439 -4.90354
-8.67 GLRX2 glutaredoxin 2 (thioltransferase) 0.002577 -6.52025
-11.76 RMRP RNA component of mitochondrial RNAase P 0.008392 -4.74194
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7.3 Microarray data: GMP
Table 7.2 Significant (p<0.01) differentially up- and down-regulated genes in DARC
KO GMP cells from microarray study.
Fold-
change Symbol Name
Para-metric
p-value t-value
1299.918 CAMP cathelicidin antimicrobial peptide 0.000267 12.03715
357.0088 CAMP cathelicidin antimicrobial peptide 0.000781 9.139834
457.9743 HBB-B1 hemoglobin, beta adult major chain 9.68E-05 15.57128
413.8867 S100A9 S100 calcium binding protein A9 (calgranulin B) 0.000393 10.9049
285.2716 RETNLG resistin like gamma 9.56E-06 27.84513
152.3321 LTF lactotransferrin 0.000973 8.63404
170.9426 NGP neutrophilic granule protein 7.27E-05 16.73881
181.9238 HBA-A2 hemoglobin alpha, adult chain 2 0.000138 14.22782
147.5344 HBA-A1 hemoglobin alpha, adult chain 1 0.000379 11.01015
145.3437 HBB-B2 hemoglobin, beta adult minor chain 0.001385 7.87226
131.2353 IFI202B interferon activated gene 202B 3.89E-05 19.58281
106.59 IFI202B interferon activated gene 202B 0.000969 8.641521
86.83853 ALAS2 aminolevulinic acid synthase 2, erythroid 4.13E-05 19.29982
75.28579 RHD Rh blood group, D antigen 0.000637 9.634034
59.75624 CHI3L3 chitinase 3-like 3 0.001134 8.296324
47.22655 BETA-S hemoglobin subunit beta-1-like 0.009394 4.675196
73.45551 AHSP alpha hemoglobin stabilizing protein 0.000875 8.87404
43.09595 ITGB2L integrin beta 2-like 0.001164 8.239638
55.74978 S100A8 S100 calcium binding protein A8 (calgranulin A) 0.000536 10.07249
34.11875 SIRPB1B signal-regulatory protein beta 1B 0.004677 5.683285
44.93004 AQP1 aquaporin 1 0.000136 14.27863
45.46432 SNCA synuclein, alpha 1.29E-05 25.81321
35.87348 PLBD1 phospholipase B domain containing 1 0.001791 7.356988
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29.34044 MMP8 matrix metallopeptidase 8 0.000303 11.65928
28.47696 FAM46C family with sequence similarity 46, member C 0.000554 9.987735
24.60934 AA467197 expressed sequence AA467197 0.002566 6.686838
26.36377 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 0.000703 9.392834
25.1563 ITLN1 intelectin 1 (galactofuranose binding) 0.000212 12.76592
22.2565 SLC4A1 solute carrier family 4 (anion exchanger), member 1 7.07E-05 16.85385
21.6894 GM5483 predicted gene 5483 0.005589 5.410939
21.06786 FPR2 formyl peptide receptor 2 3.81E-05 19.69363
17.9257 SLC38A5 solute carrier family 38, member 5 0.001709 7.449092
16.68893 IGJ immunoglobulin joining chain 0.001035 8.496598
14.69588 CHI3L1 chitinase 3-like 1 0.001346 7.931548
14.35971 ZDHHC22 zinc finger, DHHC-type containing 22 0.00094 8.710488
14.1952 GM6522 chitinase 3-like 3 pseudogene 0.005608 5.406029
13.01874 RSAD2 radical S-adenosyl methionine domain containing 2 0.000576 9.889326
12.571 CTSE cathepsin E 0.000807 9.062293
12.33174 FCER1A Fc receptor, IgE, high affinity I, alpha polypeptide 0.009578 4.649321
12.24198 SCRG1 scrapie responsive gene 1 0.003213 6.294758
11.55962 STFA2L1 stefin A2 like 1 0.003603 6.102583
11.47234 ERMAP erythroblast membrane-associated protein 0.00182 7.326602
11.39002 ADAM8 a disintegrin and metallopeptidase domain 8 0.004594 5.711323
11.23685 PDZK1IP1 PDZK1 interacting protein 1 9.89E-05 15.48478
10.93351 VPREB3 pre-B lymphocyte gene 3 0.003101 6.355228
10.88412 PLA2G7 phospholipase A2, group VII (platelet-activating factoracetylhydrolase, plasma) 0.005259 5.502926
10.65692 PF4 platelet factor 4 0.002139 7.019331
10.63031 CTLA2A cytotoxic T lymphocyte-associated protein 2 alpha 0.000526 10.11961
9.953441 SIRPB1A signal-regulatory protein beta 1A 0.004855 5.625248
9.59762 FPR1 formyl peptide receptor 1 0.001424 7.815444
9.510684 RPS24 ribosomal protein S24 0.009377 4.677611
9.190772 NUF2 NUF2, NDC80 kinetochore complex component,homolog (S. cerevisiae) 0.000183 13.25005
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8.585921 F2R coagulation factor II (thrombin) receptor 0.004637 5.696916
8.176762 EPOR erythropoietin receptor 0.003268 6.265991
8.142974 ADD2 adducin 2 (beta) 0.005439 5.451817
8.100505 ART4 ADP-ribosyltransferase 4 0.006744 5.135146
8.050571 FHDC1 FH2 domain containing 1 0.001097 8.367229
7.960679 LILRB3 leukocyte immunoglobulin-like receptor, subfamily B(with TM and ITIM domains), member 3 0.002715 6.58647
7.875625 S100A6 S100 calcium binding protein A6 (calcyclin) 0.00116 8.245976
7.709034 TUG1 taurine upregulated gene 1 0.009717 4.630084
7.67796 IFITM6 interferon induced transmembrane protein 6 0.000406 10.81775
7.646765 ANKRD22 ankyrin repeat domain 22 0.009668 4.636809
7.634908 MGLL monoglyceride lipase 0.005811 5.352971
7.275156 GM14548 predicted gene 14548 0.007643 4.95762
6.933328 FGR Gardner-Rasheed feline sarcoma viral (Fgr) oncogenehomolog 0.000691 9.433297
6.856131 EPB4.9 erythrocyte protein band 4.9 0.000262 12.10256
6.85518 LTB lymphotoxin B 0.000977 8.622916
6.815796 PIRA7 paired-Ig-like receptor A7 0.008112 4.874806
6.787061 MS4A1 membrane-spanning 4-domains, subfamily A, member1 0.008867 4.752922
6.661626 SIRPB1A signal-regulatory protein beta 1A 0.003237 6.282154
6.552838 BST1 bone marrow stromal cell antigen 1 0.002795 6.535483
6.288875 ITLN1 intelectin 1 (galactofuranose binding) 0.004301 5.815522
6.235769 TSPAN33 tetraspanin 33 0.000852 8.936726
6.223626 GM11428 predicted gene 11428 0.00131 7.988815
6.188198 CES2G carboxylesterase 2G 0.006538 5.179828
6.134249 SLC14A1 solute carrier family 14 (urea transporter), member 1 0.00052 10.15174
6.115285 GYPA glycophorin A 0.000548 10.01633
6.10157 LY6D lymphocyte antigen 6 complex, locus D 0.001674 7.489839
5.771065 GM10693 predicted pseudogene 10693 0.002977 6.425451
5.731663 APOL8 apolipoprotein L 8 0.00311 6.350174
5.704967 LILRA6 leukocyte immunoglobulin-like receptor, subfamily A(with TM domain), member 6 0.007009 5.079888
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5.577841 LILRA6 leukocyte immunoglobulin-like receptor, subfamily A(with TM domain), member 6 0.001467 7.754438
5.527655 PEX11C peroxisomal biogenesis factor 11 gamma 0.00651 5.18603
5.445753 ISG20 interferon-stimulated protein 0.000431 10.65207
5.346245 SLC6A9 solute carrier family 6 (neurotransmitter transporter,glycine), member 9 0.000293 11.75981
5.306081 KEL Kell blood group 0.000527 10.11501
5.200905 NR3C1 nuclear receptor subfamily 3, group C, member 1 0.007717 4.944135
4.976604 OLFR312 olfactory receptor 312 0.007077 5.066086
4.945319 NUF2 NUF2, NDC80 kinetochore complex component,homolog (S. cerevisiae) 0.000451 10.52732
4.811501 PDZK1IP1 PDZK1 interacting protein 1 0.007654 4.955631
4.726137 GM10872 predicted gene 10872 0.003688 6.064157
4.537062 GM6792 predicted gene 6792 0.005667 5.390139
4.505204 SLC6A9 solute carrier family 6 (neurotransmitter transporter,glycine), member 9 0.000745 9.252588
4.449686 BUTR1 butyrophilin related 1 0.001224 8.131262
4.371499 ANK1 ankyrin 1, erythroid 0.002371 6.829628
4.302823 GDPD2 glycerophosphodiester phosphodiesterase domaincontaining 2 0.005765 5.364622
4.280243 GM13152 predicted gene 13152 0.004684 5.681189
4.240546 IL28RA interleukin 28 receptor alpha 0.007963 4.900524
4.226138 LHX3 LIM homeobox protein 3 0.009458 4.666083
4.219845 ALOXE3 arachidonate lipoxygenase 3 0.004133 5.878972
4.21471 DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 0.006675 5.149905
4.153978 CEACAM10
carcinoembryonic antigen-related cell adhesion
molecule 10 0.003582 6.112173
4.139992 ABCG4 ATP-binding cassette, sub-family G (WHITE), member 4 0.004543 5.728862
4.131521 PIRA11 paired-Ig-like receptor A11 0.004306 5.813411
4.102952 CTLA2B cytotoxic T lymphocyte-associated protein 2 beta 0.001084 8.394606
4.089062 GATA1 GATA binding protein 1 0.00051 10.20381
4.025715 ROBO3 roundabout homolog 3 (Drosophila) 0.009763 4.623886
3.964432 ZFPM1 zinc finger protein, multitype 1 0.005106 5.547805
3.937079 ITLN1 intelectin 1 (galactofuranose binding) 0.000565 9.935122
3.892899 ZFPM1 zinc finger protein, multitype 1 0.005468 5.443795
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3.887415 OLFR141 olfactory receptor 141 0.007145 5.052507
3.85886 GFI1B growth factor independent 1B 0.003611 6.099124
3.847685 ABCG4 ATP-binding cassette, sub-family G (WHITE), member 4 0.007938 4.904821
3.825118 IL1RL1 interleukin 1 receptor-like 1 0.003996 5.933315
3.814264 GM5196 chromobox homolog 3 pseudogene 0.000875 8.875132
3.769203 GM14325 predicted gene 14325 0.002415 6.795574
3.686704 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 0.000891 8.834269
3.668078 RHBDL1 rhomboid, veinlet-like 1 (Drosophila) 0.003584 6.111452
3.657873 RAB37 RAB37, member of RAS oncogene family 0.004393 5.7819
3.605121 SLC26A3 solute carrier family 26, member 3 0.008435 4.821096
3.582563 MCF2L mcf.2 transforming sequence-like 0.002204 6.963535
3.563904 SOWAHA sosondowah ankyrin repeat domain family member A 0.009244 4.696747
3.557407 CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 0.000745 9.252409
3.544677 RAB37 RAB37, member of RAS oncogene family 0.006401 5.210577
3.52069 ZFP931 zinc finger protein 931 0.003989 5.936077
3.488917 JHDM1D jumonji C domain-containing histone demethylase 1homolog D (S. cerevisiae) 0.001638 7.533139
3.455098 TGM2 transglutaminase 2, C polypeptide 0.006133 5.273187
3.454203 IFI27L2A interferon, alpha-inducible protein 27 like 2A 0.002659 6.623242
3.417496 S1PR1 sphingosine-1-phosphate receptor 1 0.0067 5.144599
3.366178 VANGL1 vang-like 1 (van gogh, Drosophila) 0.007853 4.919775
3.339354 GM14308 predicted gene 14308 0.004606 5.707319
3.299323 CBX3 chromobox homolog 3 (Drosophila HP1 gamma) 0.004037 5.916708
3.270372 CRISPLD2 cysteine-rich secretory protein LCCL domain containing2 0.007736 4.940638
3.268583 GM14391 predicted gene 14391 0.002439 6.777796
3.261638 GM14393 predicted gene 14393 0.002685 6.605611
3.255634 DYNLT1C dynein light chain Tctex-type 1C 0.004405 5.777552
3.251284 BLVRB biliverdin reductase B (flavin reductase (NADPH)) 0.001543 7.652174
3.208248 CD2 CD2 antigen 0.003035 6.392073
3.168414 CCL6 chemokine (C-C motif) ligand 6 0.004434 5.767308
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3.123637 CXCR2 chemokine (C-X-C motif) receptor 2 0.001238 8.107056
3.094544 MORF4L2 mortality factor 4 like 2 0.001393 7.860706
3.05565 SYCN syncollin 0.009643 4.640287
3.051958 EIF4A2 eukaryotic translation initiation factor 4A2 0.002634 6.64011
3.031052 EPB4.2 erythrocyte protein band 4.2 0.001773 7.377047
3.030024 RPS6KA2 ribosomal protein S6 kinase, polypeptide 2 0.004352 5.796808
3.025964 GM14411 predicted gene 14411 0.005173 5.528067
3.006443 CELF6 CUGBP, Elav-like family member 6 0.007861 4.918383
-3.16358 DTX3 deltex 3 homolog (Drosophila) 0.008567 -4.79988
-3.23963 WDR72 WD repeat domain 72 0.001943 -7.20008
-3.34374 MAFF v-maf musculoaponeurotic fibrosarcoma oncogenefamily, protein F (avian) 0.009851 -4.612
-3.36245 TNS4 tensin 4 0.001719 -7.43767
-3.43232 ITGA5 integrin alpha 5 (fibronectin receptor alpha) 0.008099 -4.87707
-3.54184 PLEKHJ1 pleckstrin homology domain containing, family Jmember 1 0.006987 -5.08441
-3.67918 PIK3IP1 phosphoinositide-3-kinase interacting protein 1 0.009348 -4.68184
-3.97775 TOX4 TOX high mobility group box family member 4 0.009536 -4.65523
-4.53167 APOA2 apolipoprotein A-II 0.001706 -7.45248
-5.57718 KRTAP5-4 keratin associated protein 5-4 0.000589 -9.83038
-5.95546 DUSP23 dual specificity phosphatase 23 0.001725 -7.43057
-26.5995 IQSEC3 IQ motif and Sec7 domain 3 0.002505 -6.72976
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7.4 LSK Low-density array results
Table 7.3 Gene expression results from low-density array of DARC KO and FYB(ES)TG
LSK cells. Significance calculated by upaired two way Student t test.
Gene WT DARC KO FYB(ES)TG
Mean
Fold
Change
Standard
Deviation
Mean
Fold
Change
Standard
Deviation
t-
test
Mean Fold
Change
Standard
Deviation
t-test
18S 1 0.76 0.89 0.63 n 0.79 0.21 n
ALAS2 1 5.26 0.80 5.08 n 0.73 4.58 n
CD19 1 2.86 1.53 3.44 n 1.24 1.47 n
CD2 1 2.63 2.51 0.97 n 2.60 1.86 n
C/EBPΑ 1 0.86 0.76 0.78 n 0.78 0.58 n
C/EBPΔ 1 0.74 0.52 0.36 n 0.23 1.29 *
C/EBPΕ 1 1.75 2.35 2.21 n 1.58 1.95 n
CSF3R 1 0.40 1.08 0.28 n 1.21 0.16 n
CXCR2 1 1.38 1.35 1.20 n 1.08 1.60 n
CXCR4 1 1.23 2.30 0.59 * 3.54 0.62 *
FLT3 1 0.25 1.06 0.42 n 0.82 0.41 n
FZD4 1 0.56 1.45 0.92 n 2.03 1.37 n
GAPDH 1 0.18 1.04 0.20 n 1.02 0.08 n
GATA1 1 0.76 1.50 0.95 n 1.50 0.76 n
GATA2 1 0.36 1.02 0.25 n 1.27 0.61 n
HBB-B1 1 5.08 0.82 4.50 n 0.77 5.96 n
HLF 1 0.28 1.12 0.35 n 1.27 0.06 *
HPRT 1 0.23 0.96 0.23 n 0.95 0.11 n
IFITM6 1 2.22 1.29 2.96 n 0.77 3.87 n
ITGAM 1 1.33 0.88 0.83 n 0.67 0.79 n
KLF4 1 1.07 0.76 0.86 n 1.08 1.17 n
LMO2 1 0.29 0.96 0.16 n 1.05 0.16 n
LTF 1 3.01 1.03 4.14 n 0.85 3.14 n
MMP8 1 3.05 1.37 3.37 n 0.84 3.24 n
NGP 1 3.06 1.05 5.00 n 0.64 3.31 n
RETNLG 1 3.93 1.11 3.37 n 0.86 2.27 n
RHD 1 2.77 0.95 2.14 n 1.05 3.30 n
S100A9 1 2.51 2.90 2.98 n 1.04 2.63 n
SLFN4 1 5.00 1.50 3.94 n 1.76 2.72 n
SPIB 1 1.39 2.04 1.83 n 1.84 2.26 n
STAT6 1 0.76 0.85 0.40 n 0.76 0.24 n
VCAM1 1 0.54 1.07 1.24 n 0.41 1.55 *
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7.5 GMP Low-density array results
Table 7.4 Gene expression results from low-density array of DARC KO and FYB(ES)TG
GMP cells. Significance calculated by upaired two way Student t test.
Gene WT DARC KO FYB(ES)TG
Mean
Fold
Change
Standard
Deviation
Mean
Fold
Change
Standard
Deviation
t-test Mean
Fold
Change
Standard
Deviation
t-test
18S 1 0.30 1.59 0.70 ns 1.27 0.26 ns
ALAS2 1 1.39 3.34 1.59 ns 8.72 2.10 ns
CD19 1 0.64 9.13 1.14 ** 12.53 1.48 *
CD2 1 0.94 3.54 0.45 * 6.79 2.05 ns
C/EBPΑ 1 0.40 1.76 1.32 ns 1.74 0.68 ns
C/EBPΔ 1 0.44 1.31 0.30 ns 1.32 0.70 ns
C/EBPΕ 1 0.21 0.92 0.79 ns 0.83 0.62 ns
CSF3R 1 0.24 1.07 0.47 ns 1.02 0.45 ns
CXCR2 1 0.38 1.14 0.49 ns 1.06 0.69 ns
CXCR4 1 1.06 2.19 1.42 ns 2.51 1.23 ns
FLT3 1 0.49 0.83 0.62 ns 1.04 0.80 ns
FZD4 1 0.12 1.25 0.39 ns 1.66 0.31 *
GAPDH 1 0.14 1.03 0.10 ns 0.99 0.09 ns
GATA1 1 0.76 2.88 1.24 ns 2.86 0.56 *
GATA2 1 0.52 2.27 1.17 ns 2.63 0.31 **
HBB-B1 1 1.71 3.25 1.64 ns 5.55 2.02 *
HLF 1 0.38 1.36 0.77 ns 1.28 0.20 ns
HPRT 1 0.20 1.03 0.13 ns 1.04 0.07 ns
IFITM6 1 0.38 1.79 0.69 ns 2.37 0.53 *
ITGAM 1 0.37 1.24 0.47 ns 1.16 0.23 ns
KLF4 1 0.76 1.88 0.67 ns 1.96 0.45 ns
LMO2 1 0.13 1.11 0.26 ns 1.13 0.25 ns
LTF 1 0.90 3.30 1.43 ns 6.76 2.33 ns
MMP8 1 0.24 2.37 1.03 ns 2.24 0.28 *
NGP 1 0.42 4.00 1.26 ns 2.81 1.41 ns
RETNLG 1 0.82 3.39 1.41 ns 5.60 2.13 ns
RHD 1 1.22 3.99 1.92 ns 8.56 2.01 ns
S100A9 1 1.09 5.04 1.20 * 4.72 2.25 ns
SLFN4 1 0.92 2.09 1.19 ns 6.06 2.20 ns
SPIB 1 1.06 2.57 1.03 ns 6.95 2.03 ns
STAT6 1 0.04 0.78 2.37 ns 1.25 0.32 ns
VCAM1 1 0.80 4.20 1.74 ns 0.55 0.46 *
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7.6 Complete multiplex chemokine and cytokine results – serum
Table 7.5 Results of all analytes from multiplex chemokine and cytokine assay of
serum from WT, DARC KO and FYB(ES)TG mice.
Sig, significance, calculated by Mann Whitney test
Analyte WT DARC KO FYB(ES)TG
Mean
Pg/mg
Range
Pg/mg
Mean
Pg/mg
Range
Pg/mg
Sig Mean
Pg/mg
Range
Pg/mg
Sig
G-CSF 138.62 61.84-262.71 254.80
207.32-
336.42
* 414.83
226.90-
569.39
***
GM-CSF 0 0 0 0 ns 0 0 ns
M-CSF 0 0 0 0 ns 0 0 ns
IFN-GAMMA 0 0 0 0 ns 0 0 ns
IL-1ALPHA 552.05 61.69-2086 133.55 78.05-277.85 ns 134.77 65.41-348.61 ns
IL-1BETA 0 0 0 0 ns 0 0 ns
IL-2 0 0 0 0 ns 0 0 ns
IL-3 0 0 0 0 ns 0 0 ns
IL-4 0 0 0 0 ns 0 0 ns
IL-5 0 0 0 0 ns 0 0 ns
IL-6 0 0 0 0 ns 0 0 ns
IL-9 92.10 0-258.87 62.32 37.18-107.56 ns 54.11 0-82.05 ns
IL-10 0 0 0 0 ns 0 0 ns
IL-12P40 0 0 0 0 ns 0 0 ns
IL-12P70 0 0 0 0 ns 0 0 ns
IL-13 49.12 0-144.53 29.42 0-79.99 ns 37.88 0-73.20 ns
IL-15 0 0 0 0 ns 0 0 ns
IL-17 0 0 0 0 ns 0 0 ns
LIF 0 0 0 0 ns 0 0 ns
CXCL1 51.13 27.45-68.58 12.05 0-42.93 * 7.89 0-33.30 *
CXCL2 0 0 0 0 ns 0 0 ns
CXCL5 6255.19
4568.77-
7701.04
7770.51
5540.02-
9310.13
ns
5758.88
2126.58-
7120.32
ns
CXCL9 71.15 50.84-110.74 82.13 56.88-159.97 ns 75.17 49.81-113.87 ns
CXCL10 67.69 51.20-76.97 52.27 34.06-73.60 ns 52.46 44.83-62.42 ns
CCL2 0 0 0 0 ns 0 0 ns
CCL3 0 0 0 0 ns 0 0 ns
CCL4 0 0 0 0 ns 0 0 ns
CCL5 6.60 0-14.83 7.32 2.97-11.20 ns 8.05 5.88-10.65 ns
CCL11 137.62 70.51-
182.25
111.61 88.01-
157.55
ns 173.88 150.15-
227.74
*
VEGF 0 0 0 0 ns 0 0 ns
TNF-ALPHA 0 0 0 0 ns 0 0 ns
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7.7 Complete multiplex chemokine and cytokine results – bone marrow
supernatant
Table 7.6 Results of all analytes from multiplex chemokine and cytokine assay of bone
marrow supernatant from WT, DARC KO and FYB(ES)TG mice.
Sig, significance, calculated by Mann Whitney test
Analyte WT DARC KO FYB(ES)TG
Mean
pg/mg
Range
pg/mg
Mean
pg/mg
Range
pg/mg
Sig Mean
pg/mg
Range
pg/mg
Sig
G-CSF 2.41 0.60-5.67 2.22 0.64-4.26 ns 6.31 1.02-55.38 ns
GM-CSF 11.94 0-28.12 13.44 0-36.52 ns 23.72 0-65.85 *
M-CSF 7.3 0-21.98 5.67 0.06-15.56 ns 14.53 0-65.19 ns
IFN-GAMMA 57.02 0-286.40 28.01 0-151.72 ns 59.98 0-271.35 ns
IL-1ALPHA 104.64 0-347.15 59.60 4.35-271.84 ns 123.05 8.88-354.56 ns
IL-1BETA 0 0 0 0 ns 0 0 ns
IL-2 0 0 0 0 ns 0 0 ns
IL-3 0 0 0 0 ns 0 0 ns
IL-4 0 0 0 0 ns 0 0 ns
IL-5 0 0 0 0 ns 0 0 ns
IL-6 19.31 0-32.54 6.95 0-33.71 ns 19.17 0-84.51 ns
IL-9 0 0 0 0 ns 0 0 ns
IL-10 0 0 0 0 ns 0 0 ns
IL-12P40 0 0 0 0 ns 0 0 ns
IL-12P70 0 0 0 0 ns 0 0 ns
IL-13 140.65 0-209.32 139.55 37.14-306.91 ns 212.21 26.72-429.08 *
IL-15 0 0 0 0 ns 0 0 ns
IL-17 0 0 0 0 ns 0 0 ns
LIF 0 0 0 0 ns 0 0 ns
CXCL1 18.76 2.5-73.34 7.87 1.49-23.59 * 17.31 2.94-59.98 ns
CXCL2 65.72 0-121.75 66.12 0-136.61 ns 76.04 0-203.91 *
CXCL5 88.32 43.89-182.96 72.21 36.85-117.42 ns 90.19 34.76-163.37 ns
CXCL9 214.01
107.23-
428.56
309.26
128.58-
473.73
* 326.81
179.48-
643.76
**
CXCL10 125.27 68.21-208.65 145.04 79.95-230.65 ns 155.22 79.59-320.24
CCL2 11.28 0-23.79 12.14 0-25.59 ns 24.10 0-91.36 *
CCL3 12.76 1.32-26.41 9.48 0-36.67 ns 26.03 2.99-78.92 *
CCL4 16.21 1.72-25.44 13.56 0-32.92 ns 22.95 4.08-55.96 ns
CCL5 15.82 5.22-45.93 12.55 4.64-29.17 ns 20.79 6.14-74.41 ns
CCL11 23.22 6.5-34.99 32.69 10.50-69.73 * 86.12 23.08-169.67 *****
VEGF 0 0 0 0 ns 0 0 ns
TNF-ALPHA 0 0 0 0 ns 0 0 ns
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7.8 LSK-selected mixed competitive chimeras
The experiment was conducted as per scheme in Figure 4.33. Owing to major
variation in the CD45.2 populations the validity of this data is unclear, but it is
included here for reference purposes.
Results in Figure 7.1a & b demonstrate no significant difference spleen size in animals
between groups, and bone marrow cell count, respectively.
Peripheral leukocyte counts were not different between the two groups, although
neutrophil counts were lower in the WT-KO group, both in absolute terms and as a
proportion of all leukocytes, Figure 7.2. Haemoglobin and platelet counts were not
significantly different between the two groups, Figure 7.2.
a b
Figure 7.1. Fundamental parameters of mixed LSK-selected competitive chimeras (a) Spleen size classified by
CD45.2 competitor, and (b), cell counts in bone marrow femurs. n=5 per group
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a b
*
c d
*
WT KO
H
b
g/
dL
e
Figure 7.2 Complete blood count of mixed LSK-selected competitive chimeras. Total white cell count (a),
neutrophil count (b), neutrophil proportions of white cell counts (c), haemoglobin (d) and platelet count (e), from
automated analyser. WT-WT n=5, WT-KO n=4
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Bone marrow erythroid proportions were not different between the two groups, and
in the WT-KO group, DARC negative erythropoiesis accounted on average for
approximately 40% of the total erythropoiesis, Figure 7.3.
Although neutrophil numbers were lower in WT-KO, Figure 7.4, relative to
CD45.1xCD45.2, myeloid cells including in particular Gr-1Hi cells proliferated faster in
CD45.2 DARC KO bone marrow fraction. Overall CD45.2 proportions between WT
and KO were not different relative to CD45.1xCD45.2, largely due to significant
variation between mice, with some animals harbouring <5% CD45.2 DARC KO
peripheral blood CD45+ cells, and other in excess of 20%. Reasons for this are
unclear, but could possibly represent uneven mixing pre-injection, or clumping of LSK
cells
a b
Figure 7.3 Erythroid cells analysis of bone marrow of mixed LSK-selected competitive chimeras. Erythroid cells as
a proportions of all cells in bone marrow, (a). Proportion of DARC-positive erythropoiesis in bone marrow (b).
n=5 per group
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Similarly in the bone marrow CD45.2 DARC KO proportions relative to CD45.2 WT
were increased, although the large variance between individual animals meant these
results were not significantly different, and also in total cell populations, Figure 7.5a,
b. However overall, there was a relatively higher CD45.2 DARC KO component
compared to CD45.2 WT (Figure 7.5c).
a b
* * * ** *
c
**
**
Figure 7.4 Analysis of blood leukocyte populations of mixed LSK-selected competitive chimeras. See Figure 4.28
for representative gating of blood populations examined in mixing chimeras.
(a) CD45.1xCD45.2+ cells were assigned a ratio of 1 (i.e. 100%) within each mouse, and the proportion of
CD45.2 cells (WT or KO) were computed. Shown are the relative contributions of CD45.2 WT or KO to
CD45.1xCD45.2 competitors for each of the main blood leukocyte populations. (b) Proportions of leukocyte
populations in blood, for CD45.2 WT or KO. c) Competitor proportions (CD45.2 WT or KO) relative to
CD45.1xCD45.2, averaged over 5 WT or 4KO samples. n=5 per group
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Examination of the bone marrow progenitors revealed no significant differences in
progenitor profiles, particularly for GMP and LSK. However, these data should be
interpreted with caution since there was large variance, and visually the GMP
populations appeared reduced in CD45.2 DARC KO, although the difference from
CD45.2 WT was modest. This would imply that HSC and progenitor cells have
possibly been exposed to a wild-type DARC environment for sufficient period to
a b
c
**
** *
Figure 7.5 Analysis of bone marrow leukocyte populations of mixed LSK-selected competitive chimeras. (a)
Relative contributions of CD45.2 compared to CD45.1xCD45.2 in the bone marrow. (b) Proportions of principle
bone marrow populations. (c) Overall CD45.2 contributions within the bone marrow relative to CD45.1xCD45.2.
n=5 per group.
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modify some of the maturation profiles in the DARC KO haematopoietic component
(Figure 7.6).
a
b
Figure 7.6 Bone marrow lineage-negative populations (LSK and myeloid progenitors) of LSK selected chimeras.
Representative gating, (a). Live cells were gated for CD45 expression, and then haematopoietic lineage-negativity.
There after subgates examining myeloid progenitors and their sub-populations (GMP: CD34+, CD16/CD32+, CMP
CD34+, CD16/CD32low, MEP CD34- CD16/CD32-). b) CD45.1xCD45.2+ cells were assigned a ratio of 1 (i.e. 100%)
within each mouse, and the proportion of CD45.2 cells (WT or KO) were computed. Shown are the relative
contributions of CD45.2 WT or KO to CD45.1xCD45.2 competitors for each of the main blood leukocyte
populations. Data from two animals from the WT-WT group was excluded as CD45.2 chimerism was <5% and
hence HSPC data is not considered reliable owing to low cell numbers. n=3-5 per group.
CD45.1
1.13%
CD45.1xCD45.2
78.3%
CD45.2
13.4%
LSK
2.89%
MP
38.4%
LSK
3.11%
MP
35.3%
10
0
10
1
10
2
10
3
10
4
CD45.2
10
0
10
1
10
2
10
3
10
4
C
D
45
.1 Lin-neg
2.53%
0 20K 40K 60K
Forward Scatter
10
0
10
1
10
2
10
3
10
4
Li
ne
ag
e
10
0
10
1
10
2
10
3
10
4
Sca1
10
0
10
1
10
2
10
3
10
4
cK
it
CMP
23.8%
GMP
44.9%
MEP
27.0%
10
0
10
1
10
2
10
3
10
4
CD34
10
0
10
1
10
2
10
3
10
4
C
D
16
/C
D
32
Lin-neg
1.82%
0 20K 40K 60K
Forward Scatter
10
0
10
1
10
2
10
3
10
4
Li
ne
ag
e
10
0
10
1
10
2
10
3
10
4
Sca1
10
0
10
1
10
2
10
3
10
4
cK
it
CMP
40.6%
GMP
35.1%
MEP
21.0%
10
0
10
1
10
2
10
3
10
4
CD34
10
0
10
1
10
2
10
3
10
4
C
D
16
/C
D
32
CD45.2 WT
CD45.2 KO
294
Similarly, there was no significant difference in LSK sub-populations between the two
study groups (Figure 7.7). However, maturation profiles were significantly different
from normal WT mice, with reduced numbers of MPP in both CD45.2 WT and CD45.2
DARC KO. Reasons for this are not clear.
Transplanted HSC establish localised areas of haematopoiesis which is comprised of
progenitors from that HSC, forming islands of maturing transplanted cells arising
from single HSC. This might partly explain the retention of the reduced-GMP
maturation profile in whole bone marrow and LSK-mixed chimeras, since chemokine
availability might be locally reduced in, for example, a DARC KO haematopoietic
island.
Repetition of this experiment with modifications, such a FACS sorting LSK cells and
mixing immediately with competitor cells, and using higher LSK cell numbers per
irradiated mouse, may help clarify findings.
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a
b
*
Figure 7.7 Bone marrow LSK sub-populations of LSK selected chimeras, representative gating (a), at 16 weeks
following transplantation of 500 LSK cells, either CD45.2 WT or CD45.2 DARC KO mixed with 106
CD45.1xCD45.2 competitor into lethally irradiated CD45.1 hosts. Live cells were gated for CD45 expression, and
then haematopoietic lineage-negativity. There after subgates examining LSK compartment. b) CD45.1xCD45.2+
cells were assigned a ratio of 1 within each mouse, and the proportion of CD45.2 cells (WT or KO) were
computed. Shown are the relative contributions of CD45.2 WT or KO to CD45.1xCD45.2 competitors. Data from
two animals from the WT-WT group was excluded as CD45.2 chimerism was <5% and hence HSPC data is not
considered reliable owing to low cell numbers. n=3-5 per group.
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